0001355250false--06-30FY202262000.001100000000000108745930.00010.0001180000001080156414630.000100.00011000000000000002300000.03710003710001486000800067799350.35P4Y5M12D34592300116786000.22000500000172987100001438000200000.02700000783500220530500000050170004983000100170003838000000114500000000The 20-year limitation was eliminated for losses incurred after January 1, 2018, giving the taxpayer the ability to carry forward losses indefinitely. However, NOL carry forward arising after January 1, 2018, will now be limited to 80% of taxable income. The $105.8 million available at June 30, 2022 includes $51.0 million of post 2017 NOLs without expiration dates and $54.8 million of pre-2018 NOLs expiring from 2024 to 203710580000000013552502021-07-012022-06-300001355250ipix:SeriesBTwoPreferredStockMember2021-07-012022-06-300001355250ipix:SeriesBTwoPreferredStockMember2020-07-012021-06-300001355250ipix:ExerciseOfwentyTwentySeriesB5ConvertiblePreferredStockWarrantsOneMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2021-06-300001355250ipix:ExerciseOfwentyTwentySeriesConvertiblePreferredStockWarrantsMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2020-12-012020-12-090001355250ipix:TwentyTwentySeriesB5ConvertiblePreferredStockMemberipix:SeriesBConvertiblePreferredStockMember2021-02-012021-02-080001355250ipix:ConversionOfwentyTwentySeriesB5ConvertiblePreferredStockcommonstockMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2021-07-012022-06-300001355250ipix:ExerciseOfwentyTwentySeriesB5ConvertiblePreferredStockWarrantsOneMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2020-12-052021-06-300001355250ipix:ExerciseOfwentyTwentySeriesConvertiblePreferredStockWarrantsMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2021-07-012022-06-300001355250ipix:TwentyTwentySeriesB5ConvertiblePreferredStockWarrantsOneMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2021-07-012022-06-300001355250ipix:TwentyTwentySeriesB5ConvertiblePreferredStockWarrantsMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2021-07-012022-06-300001355250ipix:ExerciseOfwentyTwentySeriesConvertiblePreferredStockWarrantsMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2020-12-052021-06-300001355250ipix:ConversionOfwentyTwentySeriesB5ConvertiblePreferredStockcommonstockMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2020-12-052021-06-300001355250ipix:ConversionOfwentyTwentySeriesB5ConvertiblePreferredStockcommonstockMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2021-02-012021-02-080001355250ipix:TwentyThousandTwentyAgreementMemberipix:AspireCapitalMemberipix:ClassACommonStockMember2021-06-300001355250ipix:TwentyThousandTwentyAgreementMemberipix:AspireCapitalMemberipix:ClassACommonStockMember2022-06-300001355250ipix:TwentyThousandTwentyAgreementMemberipix:AspireCapitalMemberipix:ClassACommonStockMember2021-07-012022-06-300001355250ipix:MrEhrlichMemberus-gaap:CommonClassBMember2020-12-290001355250ipix:MrEhrlichMemberus-gaap:CommonClassBMember2020-12-012020-12-290001355250ipix:MrEhrlichMemberus-gaap:CommonClassAMember2021-07-012022-06-300001355250ipix:MrEhrlichMemberus-gaap:CommonClassAMember2020-12-012020-12-280001355250ipix:OctoberTwoTwoThousandTwentyMemberipix:EhrlichMemberus-gaap:CommonClassBMember2021-02-012021-02-080001355250ipix:ConversionOfwentyTwentySeriesB5ConvertiblePreferredStockcommonstockMemberipix:SeriesBConvertiblePreferredStockwarrantsMember2021-06-300001355250ipix:TwentyTwentySeriesB5ConvertiblePreferredStockOneMemberipix:SeriesBConvertiblePreferredStockMember2022-06-300001355250ipix:TwentyTwentySeriesB5ConvertiblePreferredStockOneMemberipix:SeriesBConvertiblePreferredStockMember2021-02-012021-02-080001355250ipix:TwentyTwentySeriesB5ConvertiblePreferredStockOneMemberipix:SeriesBConvertiblePreferredStockMember2020-12-012020-12-040001355250us-gaap:CommonClassBMember2020-12-052021-06-300001355250us-gaap:CommonClassBMember2020-12-012020-12-280001355250ipix:MrEhrlichMemberus-gaap:CommonClassBMember2021-07-012022-06-300001355250ipix:OctoberTwoTwoThousandTwentyMemberipix:EhrlichMemberus-gaap:CommonClassBMember2022-06-300001355250ipix:OctoberTwoTwoThousandTwentyMemberipix:EhrlichMemberus-gaap:CommonClassBMember2021-07-012022-06-300001355250ipix:OctoberTwoTwoThousandTwentyMemberipix:EhrlichMemberus-gaap:CommonClassBMember2020-12-012020-12-280001355250ipix:OctoberTwoTwoThousandTwentyMemberipix:EhrlichMemberus-gaap:CommonClassBMember2020-09-102020-10-020001355250us-gaap:CommonClassBMember2020-09-012020-09-080001355250us-gaap:CommonClassAMember2020-12-280001355250ipix:MrEhrlichMemberus-gaap:CommonClassBMember2020-09-080001355250ipix:MrEhrlichMemberus-gaap:CommonClassBMember2020-12-280001355250us-gaap:CommonClassBMember2020-12-280001355250ipix:OctoberTwoTwoThousandTwentyMemberipix:EhrlichMemberus-gaap:CommonClassBMember2020-10-020001355250ipix:TwentyThousandTwentyAgreementMemberipix:AspireCapitalMemberipix:ClassACommonStockMember2020-07-310001355250ipix:MrEhrlichMemberus-gaap:CommonClassBMember2020-12-012020-12-280001355250ipix:JuneThirtyTwoThousandSixteenMemberipix:TwoThaousandSixteenEquityIncentivePlanMember2021-07-012022-06-300001355250ipix:FebruaryTwentyThreeTwoThousandTwentyMemberipix:TwoThousandSixteenEquityIncentivePlanMember2021-07-012022-06-300001355250ipix:OneConsultantMemberipix:JanuaryOneTwoThousandTwentyTwoMember2022-06-300001355250ipix:TwentyThreeFrbruaryTwoThousandtwentyMember2022-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberOneTwoThousandEighteenteenMember2020-07-012021-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberOneTwoThousandEighteenteenMember2021-07-012022-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberOneTwoThousandNineteenMember2020-07-012021-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberElevenTwoThousandTwentyMember2020-07-012021-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberOneTwoThousandNineteenMember2021-07-012022-06-300001355250ipix:TwentyThreeFrbruaryTwoThousandtwentyMember2021-07-012022-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberElevenTwoThousandTwentyMember2021-07-012022-06-300001355250ipix:MsJaneHarnessMemberipix:OnOctoberTenTwoThousandTwentyOneMember2021-07-012022-06-300001355250ipix:SixConsultantMemberipix:MayEighteenTwoThousandTwentyMember2020-07-012021-06-300001355250ipix:FiveConsultantMemberipix:JulyTwentythreeTwoThousandTwentyMember2021-07-012022-06-300001355250ipix:FourConsultantMemberipix:FebruaryOneTwentyThousandTwentyOneContractsMember2020-07-012021-06-300001355250ipix:FourConsultantMemberipix:FebruaryOneTwentyThousandTwentyOneContractsMember2021-07-012022-06-300001355250ipix:ThreeConsultantMemberipix:JulyOneTwoThousandTwentyOneMember2021-07-012022-06-300001355250ipix:TwoConsultantMemberipix:JulyThirtyTwoThousandTwentyOneMember2021-07-012022-06-300001355250ipix:MrEhrlichMemberipix:OnOctoberTenTwoThousandTwentyOneMember2021-07-012022-06-300001355250ipix:SixConsultantMemberipix:MayEighteenTwoThousandTwentyMember2021-07-012022-06-300001355250ipix:FiveConsultantMemberipix:JulyTwentythreeTwoThousandTwentyMember2020-07-012021-06-300001355250ipix:OneConsultantMemberipix:JanuaryOneTwoThousandTwentyTwoMember2021-07-012022-06-300001355250ipix:SixConsultantMemberipix:MayEighteenTwoThousandTwentyMember2022-06-300001355250ipix:FiveConsultantMemberipix:JulyTwentythreeTwoThousandTwentyMember2022-06-300001355250ipix:FourConsultantMemberipix:FebruaryOneTwentyThousandTwentyOneContractsMember2022-06-300001355250ipix:ThreeConsultantMemberipix:JulyOneTwoThousandTwentyOneMember2022-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberOneTwoThousandEighteenteenMember2022-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberOneTwoThousandNineteenMember2022-06-300001355250ipix:MsJaneHarnessMemberipix:OnSeptemberElevenTwoThousandTwentyMember2022-06-300001355250ipix:MsJaneHarnessMemberipix:OnOctoberTenTwoThousandTwentyOneMember2022-06-300001355250ipix:MrEhrlichMemberipix:OnOctoberTenTwoThousandTwentyOneMember2022-06-300001355250ipix:TwoConsultantMemberipix:JulyThirtyTwoThousandTwentyOneMember2022-06-300001355250ipix:YearEndingJuneThirtyTwoThousandTwentyFourMember2021-07-012022-06-300001355250ipix:YearEndingJuneThirtyTwoThousandTwentyThreeMember2021-07-012022-06-300001355250ipix:RestrictedStocksMember2022-06-300001355250ipix:RestrictedStocksMember2020-07-012021-06-300001355250ipix:RestrictedStocksMember2021-07-012022-06-300001355250ipix:RestrictedStocksMember2021-06-300001355250ipix:RestrictedStocksMember2020-06-300001355250us-gaap:StockOptionMember2021-06-300001355250us-gaap:StockOptionMember2020-06-300001355250us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012022-06-300001355250us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012021-06-300001355250us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012022-06-300001355250us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012021-06-300001355250us-gaap:StockOptionMember2020-07-012021-06-300001355250us-gaap:StockOptionMember2021-07-012022-06-300001355250srt:MaximumMemberus-gaap:StockOptionMember2020-07-012021-06-300001355250srt:MinimumMemberus-gaap:StockOptionMember2020-07-012021-06-300001355250srt:MaximumMemberus-gaap:StockOptionMember2021-07-012022-06-300001355250srt:MinimumMemberus-gaap:StockOptionMember2021-07-012022-06-300001355250ipix:PaycheckProtectionProgramMember2021-04-012021-04-190001355250ipix:PaycheckProtectionProgramMember2020-05-012020-05-100001355250ipix:PaycheckProtectionProgramMember2021-07-012022-06-300001355250ipix:EhrlichPromissoryNoteCMembersrt:MaximumMember2012-05-080001355250ipix:EhrlichPromissoryNoteCMembersrt:MinimumMember2012-05-080001355250ipix:EhrlichPromissoryNoteCMemberipix:OriginatedInTwoThousandTenMember2022-06-300001355250ipix:MrEhrlichMember2021-06-300001355250ipix:MrEhrlichMember2022-06-300001355250us-gaap:CommonClassBMemberipix:EhrlichMemberipix:ExerciseOptionMember2019-01-290001355250us-gaap:CommonClassBMemberipix:EhrlichMemberipix:ExerciseOptionMember2020-03-300001355250us-gaap:CommonClassBMemberipix:EhrlichMemberipix:ExerciseOptionMember2020-08-300001355250ipix:EhrlichPromissoryNoteCMember2012-04-062012-05-070001355250ipix:EhrlichPromissoryNoteCMember2012-05-080001355250ipix:EhrlichPromissoryNoteCMember2012-05-070001355250ipix:DecemberTwentyNineTwoThousandTenMemberipix:MrEhrlichMember2021-07-012022-06-300001355250ipix:DecemberTwentyNineTwoThousandTenMemberipix:MrEhrlichMember2022-06-300001355250ipix:ClinicalStudiesMember2021-06-300001355250ipix:ClinicalStudiesMember2022-06-300001355250ipix:DrKrishnaMenonMember2022-06-3000013552502019-12-3100013552502019-07-012019-09-300001355250ipix:LicenseAgreementMember2022-05-030001355250ipix:LicenseAgreementMember2019-07-180001355250srt:MaximumMemberipix:IntangibleAssetsMemberus-gaap:PatentsMember2021-07-012022-06-300001355250srt:MinimumMemberipix:IntangibleAssetsMemberus-gaap:PatentsMember2021-07-012022-06-300001355250ipix:PatentsThreeMember2021-07-012022-06-300001355250ipix:PatentsThreeMember2021-06-300001355250ipix:PatentsThreeMember2022-06-300001355250ipix:PatentsTwoMember2021-07-012022-06-300001355250ipix:PatentsTwoMember2021-06-300001355250ipix:PatentsTwoMember2022-06-300001355250ipix:BTBeaMedicalTechnologiesLimitedBTLMemberipix:PurchaseAgreementMember2022-06-012022-06-0900013552502022-06-102022-06-300001355250ipix:BTBeaMedicalTechnologiesLimitedBTLMember2022-06-300001355250ipix:TreasuryStocksMember2021-06-300001355250ipix:TreasuryStocksMember2022-06-300001355250us-gaap:CommonClassBMember2020-07-012021-06-300001355250us-gaap:CommonClassBMember2021-07-012022-06-300001355250us-gaap:CommonClassAMember2020-07-012021-06-300001355250us-gaap:CommonClassAMember2021-07-012022-06-300001355250us-gaap:RetainedEarningsMember2022-06-300001355250us-gaap:AdditionalPaidInCapitalMember2022-06-300001355250us-gaap:TreasuryStockMember2022-06-300001355250ipix:CommonsClassBMember2022-06-300001355250ipix:CommonsClassAMember2022-06-300001355250ipix:CommonsClassAMember2021-07-012022-06-300001355250us-gaap:TreasuryStockMember2021-07-012022-06-300001355250us-gaap:RetainedEarningsMember2021-07-012022-06-300001355250us-gaap:AdditionalPaidInCapitalMember2021-07-012022-06-300001355250ipix:CommonsClassBMember2021-07-012022-06-300001355250us-gaap:RetainedEarningsMember2021-06-300001355250us-gaap:AdditionalPaidInCapitalMember2021-06-300001355250us-gaap:TreasuryStockMember2021-06-300001355250ipix:CommonsClassBMember2021-06-300001355250ipix:CommonsClassAMember2021-06-300001355250us-gaap:RetainedEarningsMember2020-07-012021-06-300001355250us-gaap:AdditionalPaidInCapitalMember2020-07-012021-06-300001355250us-gaap:TreasuryStockMember2020-07-012021-06-300001355250ipix:CommonsClassBMember2020-07-012021-06-300001355250ipix:CommonsClassAMember2020-07-012021-06-3000013552502020-06-300001355250us-gaap:RetainedEarningsMember2020-06-300001355250us-gaap:AdditionalPaidInCapitalMember2020-06-300001355250us-gaap:TreasuryStockMember2020-06-300001355250ipix:CommonsClassBMember2020-06-300001355250ipix:CommonsClassAMember2020-06-3000013552502020-07-012021-06-300001355250us-gaap:CommonClassAMember2021-06-300001355250us-gaap:CommonClassAMember2022-06-300001355250us-gaap:CommonClassBMember2021-06-300001355250us-gaap:CommonClassBMember2022-06-3000013552502021-06-3000013552502022-06-3000013552502022-09-2200013552502021-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒	ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED JUNE 30, ~~2021~~2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ~~_________~~________ TO __________

Commission File Number: 001-37357

INNOVATION PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Nevada		30-0565645
(State or other jurisdiction of incorporation or organization)		(I.R.S. Empl.Ident. No.)
(State or other jurisdiction ofincorporation or organization)		(I.R.S. Empl.Ident. No.)

301 Edgewater Place - Suite 100

Wakefield, MA 01880

(Address of principal executive offices, Zip Code)

(978) 921-4125

(Registrant’s telephone number, including area code)

Securities registered under Section 12(b) of the Exchange Act: none

Securities registered under Section 12(g) of the Exchange Act: common stock, Class A, par value $0.0001 per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-~~Accelerated~~accelerated Filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates on December 31, ~~2020~~2021 was $6322,~~972~~052,~~816~~667 (~~355~~441,~~404~~053,~~535~~335 shares), based on the closing price of the registrant’s common stock of $0.1805.

The number of shares outstanding of each of the issuer’s classes of common equity, as of September 22, ~~2021~~2022 is as follows:

Class of Securities		Shares Outstanding
Common Stock Class A, $0.0001 par value		~~437~~488,~~096~~225,~~222~~673
Common Stock Class B, $0.0001 par value		15,641,463

INNOVATION PHARMACEUTICALS INC.

FORM 10-K

For the Fiscal Year Ended June 30, ~~2021~~2022

TABLE OF CONTENTS

		PAGE NO
PART I
ITEM 1	BUSINESS	86
ITEM 1A	RISK FACTORS	2315
ITEM 1B	UNRESOLVED STAFF COMMENTS	4632
ITEM 2	PROPERTIES	4632
ITEM 3	LEGAL PROCEEDINGS	4632
ITEM 4	MINE SAFETY DISCLOSURES	4632
PART II
ITEM 5	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	4733
ITEM 6	~~SELECTED FINANCIAL DATA~~[RESERVED]	4733
ITEM 7	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	4833
ITEM 7A	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	5640
ITEM 8	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	5741
ITEM 9	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	5842
ITEM 9A	CONTROLS AND PROCEDURES	5842
ITEM 9B	OTHER INFORMATION	5843
PART III
ITEM 10	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	5944
ITEM 11	EXECUTIVE COMPENSATION	6448
ITEM 12	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	6751
ITEM 13	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	6852
ITEM 14	PRINCIPAL ACCOUNTANT FEES AND SERVICES	6953
PART IV
ITEM 15	EXHIBITS AND FINANCIAL STATEMENTS	7054
ITEM 16	FORM 10-K SUMMARY	7155
SIGNATURES		7256

Table of Contents

PART I

PRELIMINARY NOTES

References in this report to “Innovation Pharmaceuticals,” “Company,” “we,” “us,” and “our” refer to Innovation Pharmaceuticals Inc., unless the context requires otherwise. References herein to our common stock refer to our Class A common stock, par value $0.0001 per share, unless the context requires otherwise. The Company’s common stock is traded under the stock symbol “IPIX” on the OTCQB.

Our fiscal year ends on June 30. When we refer to a fiscal year or quarter, we are referring to the year in which the fiscal year ends and the quarters during that fiscal year. Therefore, fiscal ~~2021~~2022 refers to the fiscal year ended June 30, ~~2021~~2022.

GLOSSARY OF TERMS

Set forth below are definitions of certain technical terms used in this report that are commonly used in the pharmaceutical and biotechnology industries.

ABSSSI: Acute Bacterial Skin and Skin Structure Infection.

Apoptosis: A type of cell death in which a series of molecular steps in a cell lead to its death. This is one method the body uses to get rid of unneeded or abnormal cells. The process of apoptosis may be blocked in cancer cells. Also called programmed cell death.

BSL: Biological Safety Levels or Biosafety Levels (BSLs) are a series of biocontainment precautions applied to activities that take place in biological labs, in ascending order of containment based on the degree of the health-related risk associated with the work being conducted. They are safeguards designed to protect laboratory personnel, as well as the surrounding environment and community. These levels, which are ranked from one to four, are selected based on the agents or organisms that are being researched or worked on in any given laboratory setting. For example, a basic lab setting specializing in the research of nonlethal agents that pose a minimal potential threat to lab workers and the environment are generally considered BSL-1—the lowest biosafety lab level. A specialized research laboratory that deals with potentially deadly infectious agents like Ebola would be designated as BSL-4—the highest and most stringent level. The research to date on Brilacidin’s antiviral properties against the Coronavirus have mostly been researched at BSL-3 labs.

COVID-19 Variants: Numerous genetic viral mutations have emerged during the COVID-19 pandemic, giving rise to variants (new strains) of the original SARS-CoV-2 virus. A U.S. government Interagency Group (SIG) has created a three-tiered variant classification system—Variant of Interest, Variant of Concern or Variant of High Consequence. Currently, a number of variants have been identified as Variants of Interest, including: B.1.427, B.1.429, B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa), and B.1.617.3. The B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and P.1 (Gamma) variants of the original SARS-CoV-2 strain have been identified as Variants of Concern. Laboratory studies, as well as real-world data, show variants can reduce the efficacy of COVID-19 treatments and vaccines.

Covid-19 Breakthrough Infections: When a previously vaccinated individual contracts the virus resulting in infection. A breakthrough infection is specifically defined by the Centers for Disease Control and Prevention as the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person ≥14 days after receipt of all recommended doses of an FDA-authorized COVID-19 vaccine.

3 Table of Contents

Coronavirus, SARS, SARS-CoV-2, COVID-19: Coronavirus Disease-2019 (COVID-19) is the disease caused by SARS-CoV-2, which is a new strain of coronavirus. SARS-CoV-2 is a positive sense, single-strand enveloped RNA virus. The Coronavirus name is derived from the Latin corona, meaning crown. The viral envelope under electron microscopy appears crown-like due to small bulbar projections formed by the viral spike (S) peplomers. SARS is the acronym for Severe Acute Respiratory Syndrome.

Cytotoxicity: The quality of being toxic to cells.

Defensin mimetics: Small compounds that mimic the structure and function of defensins, also known as host defense proteins.

EMA: The European Medicines Agency.

Emergency Use Authorization: An Emergency Use Authorization (EUA) is a mechanism to facilitate the availability and use of medical countermeasures during public health emergencies, such as the current COVID-19 pandemic.

FDA: The U.S. Food and Drug Administration.

HNC: Head and Neck Cancer. Head and neck cancer is a term used to define cancer that develops in the mouth, throat, nose, salivary glands, oral cancers or other areas of the head and neck. Most of these cancers are squamous cell carcinomas, or cancers that begin in the lining of the mouth, nose and throat.

IBD: Inflammatory Bowel Disease. An umbrella term for chronic, hard-to-treat conditions of the Gastrointestinal tract, with ulcerative colitis, and Crohn’s disease being common examples of extensive forms of the disease and ulcerative proctitis / proctosigmoiditis being more limited in distribution.

IND: Investigational New Drug. A substance that has been tested in the laboratory and has been approved by the FDA for testing in people.

In Vitro: Refers to the technique of performing a given experiment in a test tube, or, generally, in a controlled environment outside a living organism.

In Vivo: Refers to that which takes place inside an organism. In science, in vivo refers to experimentation done in or on the living tissue of a whole, living organism as opposed to a partial or dead one. Animal testing and clinical trials are forms of in vivo research.

NDA: A New Drug Application with the FDA.

OM: Oral Mucositis. Oral mucositis is a common complication of cancer chemotherapy/ chemoradiation or radiation therapy. Oral mucositis causes the mucosal lining of the mouth to atrophy and break down, forming ulcers.

~~P21~~Small ~~(also~~Molecule ~~known as protein 21)~~Drug: ~~The~~A ~~expression~~medicinal ofdrug ~~this~~compound ~~gene~~having ~~is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to~~ a ~~variety~~low ofmolecular ~~stress stimuli~~weight. ~~Used as a biomarker to detect change in p53.~~

~~P53~~3 ~~(also~~Table ~~known as protein 53): A tumor suppressor gene that is mutated in many human cancers and results in the loss~~ of ~~a cell’s ability to check for DNA damage.~~ Contents

RBL: In the U.S., there are twelve Regional Biocontainment Laboratories (RBLs), and two National Biocontainment Laboratories (NBLs), which provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.

Small Molecule Drug: A medicinal drug compound having a molecular weight of less than 1,000 Daltons, and typically up to 500 Daltons.

4 Table of Contents

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. These forward-looking statements include, but are not limited to, any statements regarding our future financial performance, results of operations or sufficiency of capital resources to fund our operating requirements; statements relating to potential licensing, partnering or similar arrangements concerning our drug compounds; statements concerning our future drug development plans and projected timelines for the initiation and completion of preclinical and clinical trials; the potential for the results of ongoing preclinical or clinical trials; other statements regarding our future product development and regulatory strategies, including with respect to specific indications ~~such as, among others, COVID-19~~; and any other statements which are other than statements of historical fact. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include, but are not limited to, our ability to continue as a going concern and our capital needs; our ability to fund and successfully progress internal research and development efforts; our ability to create effective, commercially-viable drugs; our ability to effectively and timely conduct clinical trials; our ability to ultimately distribute our drug candidates; our ability to achieve certain future regulatory, development and commercialization milestones under our license agreement with Alfasigma S.p.A.; ~~the development of treatments or vaccines relating to the COVID-19 pandemic by other entities;~~ and compliance with regulatory requirements, as well as other factors described elsewhere in this report and our other reports filed with the Securities and Exchange Commission (the “SEC”). Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Forward-looking statements speak only as of the date on which they are made. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business. Readers are cautioned not to put undue reliance on forward-looking statements.

For further information about these and other risks, uncertainties and factors, please review the disclosure included in this report under “Part I, Item 1A, Risk Factors.”

SUMMARY RISK FACTORS

The following is a summary of the risks and uncertainties that could cause the Company’s business, financial condition or operating results to be harmed. Prospective investors should carefully consider all of the information in this report and, in particular, the disclosure included in this report under “Part I, Item 1A, Risk Factors,” before deciding whether to invest in the Company’s common stock.

5 Table of Contents

Risks Related to Our Business

· There are doubts about our ability to continue as a going concern. · We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds. · Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic. · Newly emerging SARS-CoV-2 variants could reduce the effectiveness of Brilacidin as a potential COVID-19 treatment. · There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States. · We have no products approved for commercial sale to generate revenue. · In our existing or any future potential collaborations or partnerships, we will likely not be able to control all aspects of the development and commercialization of our compounds. · We depend on license agreements for the development and commercialization of certain compounds. · We have limited experience in drug and formulation development and may not be able to successfully develop any drugs. · Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control and we are subject to regulatory authority permissions and approvals, most importantly the FDA. · We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials. · Success in early clinical trials may not be predictive or indicative of results in current ongoing clinical trials or potential future clinical trials. · We are subject to risks inherent in conducting clinical trials. · Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues. · We must comply with significant and complex government regulations. · We or third-party manufacturers we rely on may encounter failures or difficulties in manufacturing or formulating clinical development and commercial supplies of drugs. · We can provide no assurance that our drug candidates will obtain regulatory approval or that the results of clinical studies will be favorable. · Even if we obtain regulatory approvals, our marketed drug candidates will be subject to ongoing regulation. · All of our Polymedix drug product candidates are licensed from or based upon licenses from the University of Pennsylvania. · We or our third-party manufacturers may fail to comply with manufacturing regulations. · Controls we or our third-party service providers have in place to ensure compliance with laws may not be effective to ensure compliance with all applicable laws and regulations. · The Company is exposed to product liability, clinical and preclinical liability risks which could place a substantial financial burden upon the Company should it be sued. · Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information. · We may be unable to obtain or protect intellectual property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others.

64 Table of Contents

· Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control and we are subject to regulatory authority permissions and approvals, most importantly the FDA. · We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials. · Success in early clinical trials may not be predictive or indicative of results in current ongoing clinical trials or potential future clinical trials. · We are subject to risks inherent in conducting clinical trials. · Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues. · We must comply with significant and complex government regulations. · We or third-party manufacturers we rely on may encounter failures or difficulties in manufacturing or formulating clinical development and commercial supplies of drugs. · We can provide no assurance that our drug candidates will obtain regulatory approval or that the results of clinical studies will be favorable. · Even if we obtain regulatory approvals, our marketed drug candidates will be subject to ongoing regulation. · All of our Polymedix drug product candidates are licensed from or based upon licenses from the University of Pennsylvania. · We or our third-party manufacturers may fail to comply with manufacturing regulations. · Controls we or our third-party service providers have in place to ensure compliance with laws may not be effective to ensure compliance with all applicable laws and regulations. · The Company is exposed to product liability, clinical and preclinical liability risks which could place a substantial financial burden upon the Company should it be sued. · Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information. · We may be unable to obtain or protect intellectual property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others. · Our potential collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk. · We may not be able to attract and retain highly skilled personnel or consultants. · We depend upon our senior management and their loss or unavailability could put us at a competitive disadvantage. · The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition.

Risks Related to the Securities Markets and Investments in Our Class A Common Stock

· ~~The sale of our Class A Common Stock to Aspire Capital may cause substantial dilution to our existing stockholders. ·~~ In addition to potential dilution associated with future fundraising transactions, we currently have significant numbers of securities outstanding that are exercisable for our common stock. · Because our common stock is quoted on the OTC, your ability to sell your shares in the secondary trading market may be limited. · Because our Class A Common Stock is considered “penny stock” you may have difficulty selling them in the secondary trading market. · Our stock price may be volatile and your investment in our Class A Common Stock could suffer a decline in value. · ~~Short sellers of our stock may be manipulative and may drive down the market price of our common stock. ·~~ Our directors and executive officers own or control a sufficient number of shares of our common stock to control our Company. · We do not intend to pay any cash dividends in the foreseeable future. · We may issue additional equity shares to fund the Company’s operational requirements which would dilute your share ownership.

75 Table of Contents

ITEM 1. BUSINESS

OVERVIEW OF OUR BUSINESS

Overview

Innovation Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing innovative therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company’s ~~owns~~lead ~~the~~drug ~~rights~~candidate to Brilacidin, ~~our~~is ~~lead drug~~ in a ~~new~~ class of compounds called defensin-mimetics, small compounds that mimic the structure and ~~Kevetrin~~function of defensins, also known as host defense peptides. The Company’s efforts are primarily focused on advancement of Brilacidin in Oral Mucositis and in infectious diseases. Ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. The Company also acquired an interest in BT BeaMedical Technologies Ltd. (~~thioureidobutyronitrile~~formerly known as Squalus Medical Ltd.), ~~our~~a ~~anti-cancer~~private ~~compound~~company developing a novel image guided surgical laser platform. Management is focused on other avenues of business development, including, but not limited to, joint ventures, mergers and acquisitions, strategic investments, and licensing agreements, for the purpose of diversifying corporate assets, although there can be no assurances that any agreement will be consummated in the future.

Recent Developments

As of the date of this filing, Brilacidin is being studied by ~~the~~independent ~~Company,~~researchers asfunded ~~well~~by asUS ~~other~~Government ~~independent researchers~~grants, as a potential broad-spectrum antiviral therapeutic for the treatment of viruses. ~~including~~We anticipate these studies to continue as long as researchers remain positive about the ~~novel~~antiviral ~~coronavirus~~properties ~~(SARS-CoV-2),~~and ~~which~~therapeutic ispotential ~~responsible~~of ~~for~~Brilacidin ~~COVID-19.~~and government funding is available.

InOn ~~December~~June ~~2020~~15, 2022, the ~~U.S.~~Company ~~Food~~announced ~~and~~acquiring ~~Drug~~a ~~Administration~~stake ~~(FDA)~~in ~~approved~~BT ~~the~~BeaMedical ~~Company’s~~Technologies ~~Investigational~~Ltd. ~~New~~(formerly ~~Drug~~known ~~(IND)~~as ~~application~~Squalus toMedical ~~proceed~~Ltd.), ~~with~~a ~~initiation~~private ofcompany developing a ~~randomized,~~novel ~~placebo-controlled~~image ~~Phase~~guided 2surgical ~~clinical~~laser ~~trial~~platform offor ~~Brilacidin~~treating inpreviously ~~moderate-to-severe~~inoperable ~~hospitalized~~cases ~~patients~~of ~~with~~epilepsy ~~COVID-19.~~and ~~Similar~~for ~~regulatory~~enabling ~~approval~~new ~~was~~treatment ~~obtained~~options ~~from~~for ~~the~~cancer ~~Russian~~cases ~~Ministry~~in ofmultiple ~~Health~~key specialties.

InOn ~~January~~June ~~2021~~23, 2022, the ~~FDA~~Company ~~designated~~reported asBrilacidin ainhibited ~~Fast~~the ~~Track~~Omicron, ~~development~~Delta, ~~program~~Gamma ~~the~~and ~~investigation~~Alpha variants of ~~Brilacidin~~SARS-CoV-2 ~~for~~based on in vitro testing conducted by NIH-sponsored and Rutgers University researchers. Results from the ~~treatment~~Brilacidin ~~for~~Phase 2 COVID-19 clinical trial and from Brilacidin in vitro testing in over 20 viruses were also reported as being prepared for publication.

InOn ~~February~~June ~~2021~~28, 2022, the ~~clinical~~Company ~~trial~~announced ofnew ~~Brilacidin~~antiviral ~~for~~research ~~treating~~on ~~hospitalized~~Brilacidin ~~patients~~in ~~with~~bunyaviruses ~~COVID-19~~and inalphaviruses ~~the~~was ~~United~~accepted ~~States~~for ~~and~~presentation ~~Russia~~at ~~began~~the ~~with~~2022 ~~patients~~Military ~~being~~Health ~~recruited~~System toResearch ~~the study~~Symposium.

On ~~February~~July 922, ~~2021~~2022, ~~antiviral~~the ~~results~~Company ~~demonstrating~~reported ~~Brilacidin’s~~additional ~~inhibition~~information ofbased ~~SARS-CoV-2~~on inprovider ~~cell~~and ~~culture~~payer ~~were~~analysis ~~published~~supporting in the ~~journal~~potential ~~Viruses~~commercialization of Brilacidin as a novel oral mucositis drug candidate.

InOn ~~April~~August ~~2021~~5, 2022, the ~~COVID-19~~Company ~~clinical~~announced ~~trial’s~~NIH-NIAID-affiliated ~~independent~~researchers ~~Data~~were ~~Monitoring~~to ~~Committee~~evaluate ~~(DMC)~~Brilacidin ~~completed~~for its ~~scheduled~~treatment ~~review~~potential ofagainst ~~interim~~the ~~safety~~monkeypox ~~data~~virus. ~~Upon~~Initial ~~reaching~~in 25vitro ~~percent~~testing ~~enrollment~~to ~~(30~~establish ~~subjects),~~potential ~~recruitment was paused and a pre~~proof-~~specified~~of-concept ~~unblinded~~is ~~safety~~to ~~data~~be ~~review and evaluation was~~ conducted byin ~~the~~poxviruses ~~DMC.~~related ~~The DMC recommended increasing the dosing regimen of Brilacidin from 3 days~~ to ~~5 days of treatment, as intended per the protocol, which the Company implemented~~monkeypox.

In ~~June~~September ~~2021~~2022, ~~100~~the ~~percent~~Company, after a review of its assets and opportunities, discontinued its Kevetrin program in oncology due to reduced patent life and the ~~planned~~added ~~number~~research and development costs for oral delivery of ~~patients~~the ~~(n=120)~~compound. ~~were~~The ~~randomized~~Company’s research and development efforts going forward will be focused on advancement of Brilacidin, which has shown therapeutic potential in ~~the~~treating ~~study~~multiple indications.

In July 2021, new in vitro data supporting Brilacidin’s broad-spectrum antiviral potential were presented by George Mason University/National Center for Biodefense and Infectious Disease researchers at the American Society of Virology’s Annual Meeting. Brilacidin showed inhibition in multiple human cell lines and in different strains of alphaviruses and bunyaviruses, building on earlier antiviral work in coronaviruses.

In July 2021, the independent DMC completed a second review of interim safety data from the Phase 2 clinical trial of Brilacidin in moderate-to-severe hospitalized patients with COVID-19. From their review, the DMC agreed to recommend the trial continue with no further modifications to the protocol.

On July 30, 2021, the last subject’s final visit occurred in the Company’s COVID-19 clinical trial.

8 Table of Contents

On August 2, 2021, the Company provided an update on ongoing Brilacidin antiviral laboratory research being conducted by different groups of scientists. Their research includes insights into Brilacidin’s antiviral mechanisms of action as well as in vitro data supporting Brilacidin’s inhibition of the Alpha and Gamma variants and different strains of human coronaviruses.

The Company has received individual patient Expanded Access (compassionate use) requests for Brilacidin to treat critically ill COVID-19 patients who are not responding to prior therapy. Expanded Access was implemented by the FDA and Congress to address physician applications for access to potentially lifesaving drugs, prior to FDA approval, for patients in their care when available treatment options have failed. Following receipt of such requests, the Company has supplied Brilacidin to relevant hospitals for individual patient use, with the FDA granting the treating physician permission for the emergency administration of Brilacidin.

The study results as of the date of this Form 10-K remain blinded. The Company and vendors are currently engaged in the process of completing the necessary tasks for the unblinding of the Brilacidin COVID-19 clinical trial and obtaining study results.

Business Development and Licensing

The Company is actively engaged in business development and licensing initiatives with ~~multiple~~ specialty and global pharmaceutical companies. The Company may also seek to enter into agreements with other third-party entities for research, development, and commercialization of other types of technologies or products. The goal of these efforts is to diversify and add value to the Company’s assets. From time to time, the Company may be party to various indications of interest and term sheets and participate in preliminary discussions and negotiations regarding potential licensing or partnership arrangements. It remains the Company’s primary objective to complete licensing deals, territorial and/or global, to provide access to non-dilutive capital to advance clinical assets forward in the most expeditious and cost-effective manner. The Company can make no assurance that partnerships will occur, but is committed toward executing on these potential alliance and partnership opportunities.

In July 2019, the Company entered into a license agreement with Alfasigma S.p.A. (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize rectally administered Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis (“UP/UPS”). The license agreement provides Alfasigma with a right of first refusal for Brilacidin for the treatment of more extensive forms of inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s disease, as well as a right of first negotiation for Brilacidin in other gastrointestinal indications. In January 2021, Alfasigma notified the Company that the Phase 1 study for the treatment of UP/UPS using Brilacidin in a proprietary Alfasigma formulation successfully completed dosing per protocol; an extra treatment cohort was subsequently added by amendment and commenced in 2Q 2021. In April 2021, the Company was notified that a Phase 2 multinational clinical trial for UP/UPS is planned to commence during the fourth quarter of 2021, and Alfasigma has ordered Brilacidin drug substance from the Company for use in this study. Due to a delay at the manufacturing vendor, delivery of drug substance to Alfasigma has moved out (mid 4Q2021), and the subsequent drug product manufacturing time will likely push any clinical trial start into 2022. The Company is eligible to receive $24 million in upfront and milestone payments, and a 6 ~~percent~~Table ~~royalty (net sales) upon the successful marketing~~ of ~~Brilacidin for UP/UPS.~~ Contents

In July 2019, the Company entered into a license agreement with Alfasigma S.p.A. (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize rectally administered Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis (“UP/UPS”). The license agreement provides Alfasigma with a right of first refusal for Brilacidin for the treatment of more extensive forms of inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s disease, as well as a right of first negotiation for Brilacidin in other gastrointestinal indications. Phase 1 studies in healthy volunteers using Brilacidin in a proprietary Alfasigma formulation have successfully completed, and Alfasigma has notified the Company that Phase 2 multinational clinical trial planning/regulatory submissions have commenced; Brilacidin drug substance has been manufactured under direction of the Company for delivery to Alfasigma for use in this study. The Company is eligible to receive $24 million in upfront and milestone payments, and a 6 percent royalty (net sales) upon the successful marketing of Brilacidin for UP/UPS.

On July 22, 2020, the Company and Fox Chase Chemical Diversity Center, Inc. (“FCCDC”) amended an earlier collaborative research agreement related to antifungal drug discovery work to which the Company had rights. In exchange for a six (6) percent fee tied to all potential future proceeds, the Company granted FCCDC all discovery, intellectual property and commercialization rights related to its share of their joint antifungal drug program.

9Development ~~Table of Contents~~Programs

Active Clinical Development Programs

Compound	Target/Indication	Clinical Status
Brilacidin	Oral Mucositis (OM)	Phase 2 Study (completed) Phase 3 planned, contingent upon sufficient funding
	Inflammatory Bowel Disease (IBD)	Phase 2 UP/UPS Proof of Concept Study (completed) Phase 1 Safety/toleration/PK of oral dosage form (completed)
	ABSSSI (Acute Bacterial Skin and Skin Structure Infection)	Phase 2 (completed)

Compound	Target/Indication	Clinical Status
Brilacidin	Oral Mucositis (OM)	Phase 2 Study (completed) Phase 3 in preparation
	Inflammatory Bowel Disease (IBD)	Phase 2 UP/UPS Proof of Concept Study (completed) Phase 1 Safety/toleration/PK of oral dosage form (completed) Phase 2 UC Safety/toleration/PK and Proof of Concept in preparation
	ABSSSI (Acute Bacterial Skin and Skin Structure Infection)	Phase 2 (completed)
	COVID-19	Phase 2 Study
Kevetrin	Ovarian Cancer	Phase 2 Study (completed)

We have no product sales to date and we will not receive any product revenue until we receive approval from the FDA or equivalent foreign regulatory agencies to begin marketing a pharmaceutical product. Milestone payments from our licensee are also dependent on clinical/regulatory milestones. We are actively engaged in business development for partnering Brilacidin. Developing pharmaceutical products, however, is a lengthy and very expensive process and there can be no assurance that we will complete such development or commercialize such pharmaceutical products for several years, if ever. Advancement of our Brilacidin clinical programs is dependent on securing sufficient working capital.

WeThe ~~have~~Company nodevotes ~~product~~most ~~sales~~of toits ~~date~~efforts and weresources ~~will~~on ~~not~~Brilacidin. ~~receive~~We ~~any~~expect ~~product revenue until we receive approval from the FDA or equivalent foreign regulatory agencies~~ to ~~begin~~concentrate ~~marketing~~on ~~a pharmaceutical~~ product. ~~Milestone~~development ~~payments~~and ~~from~~engage ~~our~~in ~~licensee~~a ~~are~~limited ~~also~~way ~~dependent on clinical/regulatory milestones. We are actively engaged~~ in ~~business~~product ~~development for partnering our drugs. Developing pharmaceutical products~~discovery, ~~however,~~avoiding isthe asignificant ~~lengthy~~investment ~~and~~of ~~very~~time ~~expensive process~~ and ~~there~~financial ~~can~~resources ~~be no assurance~~ that weis ~~will~~generally ~~complete~~required ~~such~~for ~~development~~a orpromising ~~commercialize~~compound ~~such~~to ~~pharmaceutical~~be ~~products~~identified ~~for~~and ~~several~~brought ~~years,~~into ifclinical ~~ever~~trials.

~~The~~Set ~~Company~~forth ~~devotes~~below ~~most of its efforts and resources on Brilacidin, which~~ is inan ~~clinical~~overview ~~development.~~of ~~We anticipate using~~ our ~~expertise to manage and perform what we believe are the~~ most ~~critical~~recent ~~aspects~~research ~~of the product development process, which include: (i) design~~ and ~~oversight of clinical trials; (ii)~~ development ~~and~~efforts ~~execution~~on ofBrilacidin ~~strategies~~through ~~for~~ the ~~protection~~date ~~and maintenance~~ of ~~intellectual~~this ~~property~~Annual ~~rights;~~Report ~~and (iii) interactions with regulatory authorities, domestically and internationally. We expect to concentrate~~ on ~~product~~Form development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.10-K:

Set forth below is an overview of our most recent research and development efforts on Brilacidin and Kevetrin through the date of this Annual Report on Form 10-K:

Brilacidin

COVID-19 ~~— Due to the global COVID-19 pandemic, the Company was approached by a number of organizations to research Brilacidin against the novel coronavirus~~ (~~COVID~~SARS-~~19). Material Transfer Agreements were signed with two academic institutions that operate Biosafety Level 3 Laboratories (BSL~~CoV-32)., ~~Brilacidin~~Additional ~~drug substance (Brilacidin tetrahydrochloride) was provided for antiviral research.~~Viruses

~~The~~In ~~research~~December ~~data~~2020, ~~demonstrated~~the ~~that~~U.S. ~~Brilacidin~~Food ~~exerts~~and ~~potent~~Drug ~~inhibition~~Administrations (FDA) approved the Company’s Investigational New Drug (IND) application to proceed with initiation of ~~SARS~~a randomized, placebo-~~CoV~~controlled Phase 2 clinical trial (NCT04784897) of Brilacidin in moderate-to-severe hospitalized patients with COVID-19. Similar regulatory approval was obtained from the Russian Ministry of Health. This Phase 2 ~~and~~clinical ~~thus~~trial ~~supported~~of intravenously-administered Brilacidin as(3- aand ~~promising~~5-day dosing) for COVID-19 ~~drug~~conducted ~~candidate~~at sites in the United States and Russia has since completed (n=120). While the trial’s primary endpoint of time to sustained recovery through Day 29 was not met, patients who started study treatment within fewer than 7 days of onset of COVID-19 symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group versus pooled placebo, p=0.03). Other beneficial treatment effects based on the trial’s primary endpoint of sustained recovery were also observed in subgroups of patients with the highest (upper quartile) baseline values for key COVID-19 biomarkers. On two secondary endpoints, more patients treated with Brilacidin (5-dose group) achieved clinical ~~studies~~improvement by 10 days as measured by National Emergency Warning Score 2 (NEWS2) criteria, and the mean change from baseline in NEWS2 was greater for Brilacidin treatment groups at all assessment timepoints. ~~Also~~Additionally, under compassionate use of ~~note~~Brilacidin in critical cases of COVID-19, where Brilacidin was administered more frequently and over a longer duration than in ~~these~~the ~~research~~Phase ~~studies~~2 ~~demonstrated~~trial, ~~excellent~~investigators ~~synergistic~~reported ~~antiviral~~positive ~~activity~~changes ~~when~~to ~~combined~~subject status. Pursing a biomarker-driven approach, increasing Brilacidin dosing, targeting different patient populations, testing Brilacidin in combination with ~~Remdesivir~~other drugs (e.g., aremdesivir, ~~broad~~given synergistic in vitro data) -~~spectrum~~- ~~antiviral~~all ~~medication~~are areas under consideration for potential future Brilacidin COVID-19 clinical trials pending obtaining government, partnership-based or other financial support. Antiviral data on Brilacidin in non-SARS-CoV-2 viruses has been generated and presented at scientific conferences. Results from the Brilacidin COVID-19 clinical trial, as well as findings from in vitro testing of Brilacidin in multiple viruses, are being prepared for publication.

~~Research~~7 ~~Highlights:~~Table of Contents

☐IBD, ~~Brilacidin~~Ulcerative ~~potently~~Proctitis/Proctosigmoiditis ~~inhibits~~(UP/UPS) ~~SARS~~study -~~CoV~~ A Phase 2a trial has previously been completed by the Company, comprised of three sequential cohorts, with progressive dose escalation by cohort: cohort A (6 patients) -2 in50 anmg, ~~ACE2~~cohort ~~positive~~B ~~human~~(6 ~~lung~~patients) ~~cell~~- ~~line~~100 mg, and cohort C (5 patients) - 200 mg, respectively. ☐Treatment with Brilacidin ~~achieved~~by adaily ~~high~~enema ~~Selectivity~~administration ~~Index~~was performed for 42 days. The primary efficacy endpoint of ~~426~~clinical remission (~~CC50=241μM/IC50=0~~accounting for stool frequency, rectal bleeding and endoscopy findings subscores) was met by the majority of patients across the cohorts.~~565μM~~ Brilacidin was generally well-tolerated. Patient quality of life (as assessed by the short inflammatory bowel disease questionnaire, or SIBDQ) showed notable improvements. ☐Limited systemic exposure to Brilacidin’s ~~main~~was ~~mechanism~~demonstrated ~~appears~~as tomeasured ~~disrupt~~by ~~viral~~plasma ~~integrity~~Brilacidin concentrations. In July 2019, the Company entered into a license agreement with Alfasigma, granting Alfasigma the worldwide right to develop, manufacture and ~~impact~~commercialize ~~viral~~rectally ~~entry~~administered Brilacidin for UP/UPS. ☐Phase 1 studies in healthy volunteers using Brilacidin in a proprietary Alfasigma formulation have successfully completed, and ~~remdesivir~~Alfasigma ~~exhibit~~has ~~excellent~~notified ~~synergistic~~the ~~activity~~Company ~~against~~that ~~SARS-CoV-~~Phase 2 multinational clinical trial planning/regulatory submissions have commenced; Brilacidin drug substance has been manufactured under direction of the Company for delivery to Alfasigma for use in this study.

10IBD, ~~Table~~Ulcerative Colitis (UC) - Brilacidin has also been developed as a treatment in more extensive forms of ~~Contents~~IBD. Development of a delayed release oral formulation has been in progress, with development work expanding into immediate release formulations due to unexpected findings encountered. Such findings appear due to the inherent physiochemical properties of the compound, and those of polymers used to achieve delayed release. An immediate release, multi-particulate, capsule formulation has been developed, although further work has since been halted due to instability of that formulation being identified. Hence, further advancement in the indication of ulcerative colitis requires conduct of additional formulation development work prior to Phase 1 testing of that oral formulation. Completion of formulation/analytical development work, clinical trial supply manufacturing, and subsequent progression into clinical trials, are pending securing sufficient drug supply and working capital.

Oral Mucositis (OM) study - In a ~~broader context~~randomized, ~~demonstration~~double-blind Phase 2 study of Brilacidin’s ~~direct~~for ~~antiviral~~the ~~activity~~prevention ~~against~~and control of OM in patients receiving chemoradiation for treatment of Head and Neck Cancer (HNC), Brilacidin (administered three times daily as an oral rinse) markedly reduced the ~~SARS~~rate of severe OM (WHO Grade ≥ 3), delayed onset of severe OM and decreased duration of severe OM. The Company and the FDA have completed an End-~~CoV~~of-Phase 2 ~~virus~~meeting ~~supports~~concerning the ~~drug’s~~continuing ~~unique~~development of Brilacidin oral rinse to decrease the incidence of severe OM in HNC patients receiving chemoradiation. Both parties agreed to an acceptable Brilacidin Phase 3- development pathway, including studying Brilacidin oral rinse effects on severe OM when cisplatin, the preferred chemotherapy regimen in-1 ~~therapeutic~~HNC ~~potential—antiviral~~care, ~~anti~~is administered in higher concentrations (80-~~inflammatory~~100 mg/m2) every 21 days, ~~antimicrobial—to~~and ~~treat~~at ~~COVID~~lower concentrations (30-1940 ~~and~~mg/m2) ~~its~~administered ~~associated~~weekly ~~complications~~as part of the chemoradiation regimen.

AAn ~~Phase~~optimized 2oral ~~clinical~~rinse ~~trial~~formulation ~~of intravenously-administered Brilacidin for COVID-19~~ has ~~achieved~~been ~~full~~developed, ~~enrollment~~and ~~(n=120)~~ongoing instability ~~sites~~testing inwill ~~the~~be ~~United~~completed ~~States~~by ~~and~~January, ~~Russa~~2023.. ~~The~~Further ~~Company~~advancement isin ~~now~~the ~~preparing~~indication ~~for study unblinding, statistical analysis and reporting~~ of ~~data.~~oral ~~The~~mucositis ~~study~~requires isadditional adrug ~~randomized,~~formulation/analytical ~~double-blind~~work, ~~placebo-controlled,~~followed ~~multi-center~~by ~~study~~clinical ~~to evaluate the efficacy and safety of Brilacidin in COVID-19 hospitalized patients. The~~ trial’s ~~primary~~supply ~~endpoint~~manufacturing isprior ~~time~~ to ~~sustained~~progressing ~~recovery~~to ~~through~~Phase ~~Day~~3 ~~29, using a~~ clinical ~~status~~trials. ~~ordinal~~Given ~~scale~~the ~~based~~low onprice ~~that~~per ~~used~~share ~~in the series~~ of ~~National~~our ~~Institute~~common ofstock ~~Allergy~~ and ~~Infectious~~the ~~Diseases~~many ~~(NIAID)~~multiple ~~Adaptive~~million ~~COVID-19~~dollar ~~Treatment~~costs ~~Trials~~associated ~~(ACTTs).~~with ~~Additional~~a ~~endpoints~~Phase ~~include:~~3 ~~in-hospital outcomes (e.g.~~program, ~~duration~~at ofthis ~~hospitalization,~~ time toclinical ~~discharge),~~trial ~~all-cause~~supply ~~mortality,~~manufacturing ~~measurement of disease biomarkers (e.g., CRP, ferritin)~~ and ~~inflammation-related~~Phase ~~biomarkers~~3 ~~(e.g.,~~clinical ~~IL-1β,~~trial ~~IL-6,~~conduct ~~IL-10,~~are ~~total IL-18~~delayed, ~~TNF-α),~~with ~~changes~~such toactivities ~~SARS-CoV-2~~pending ~~viral~~securing ~~load,~~sufficient asworking ~~well~~capital asand/or ~~other key measures~~partnership.

ABSSSI - In ~~April~~February ~~2021~~2016, the ~~clinical~~Company ~~trial’s~~submitted ~~independent~~a ~~DMC~~Special ~~completed~~Protocol ~~its~~Assessment ~~scheduled~~(SPA) ~~review~~request, along with a final protocol, to the FDA, for a Phase 3 clinical trial of ~~interim~~Brilacidin ~~safety~~for ~~data.~~the ~~Upon~~treatment ~~reaching~~of 25Acute ~~percent~~Bacterial ~~enrollment~~Skin ~~(30~~and ~~subjects~~Skin Structure Infection (ABSSSI), ~~recruitment~~caused ~~was~~by ~~paused~~gram-positive ~~and~~bacteria, aincluding ~~pre~~methicillin-~~specified~~resistant ~~unblinded~~Staphylococcus ~~safety~~aureus ~~data~~(MRSA). ~~review~~We received from the FDA comments and ~~evaluation~~considerations ~~was~~for ~~conducted~~incorporation byinto ~~the~~our ~~DMC~~study design. ~~The~~Management ~~DMC~~decided ~~recommended~~to ~~increasing~~delay ~~the~~its ~~dosing~~response ~~regimen~~to ofthe ~~Brilacidin~~FDA ~~from~~due 3to ~~days~~the tolow 5price ~~days~~per share of ~~treatment,~~our ascommon ~~intended~~stock ~~per~~and the ~~protocol,~~many ~~which~~multiple ~~the~~million ~~Company~~dollar ~~implemented~~costs associated with a Phase 3 program. InOur ~~July~~strategy, ~~2021~~for now, ~~the~~is ~~independent~~to ~~DMC~~achieve ~~completed~~success awith ~~second~~other ~~review~~trials ofand ~~interim~~attract ~~safety~~partnering ~~data;~~opportunities ~~based~~that onmay ~~their~~provide ~~review~~significant upfront payments and milestone payments, ~~the~~which ~~DMC~~can ~~agreed~~then be used to ~~recommend~~fund the ~~trial~~ABSSSI ~~continue~~program. ~~with~~We nosee ABSSSI as the appropriate gateway indication in infectious diseases, enabling potential further ~~modifications~~studies toof ~~the~~Brilacidin’s ~~protocol~~use for implant coating and biofilm infections.

~~The~~Expenditures ~~Company~~on ~~is collaborating with a Regional Biocontainment Laboratory researcher investigating further research opportunities with~~ Brilacidin aswere aapproximately ~~treatment~~$3.3 ~~for~~million ~~the SARS-CoV-2 virus, other Human Coronaviruses (H-CoVs),~~ and ~~other types of viruses~~$5.0 ~~Further,~~million ~~grant~~during ~~applications~~the ~~for~~years ~~federally-funded~~ended ~~research~~June ~~are pending~~30, 2022 and ~~further~~2021, ~~grant applications are planned~~respectively.

IBD, Ulcerative Proctitis/Proctosigmoiditis (UP/UPS) study —A Phase 2a trial has previously been completed by the Company, comprised of three sequential cohorts, with progressive dose escalation by cohort—cohort A (6 patients) - 50 mg, cohort B (6 patients) - 100 mg, and cohort C (5 patients) - 200 mg, respectively. Treatment with Brilacidin by daily enema administration was performed for 42 days. The primary efficacy endpoint of clinical remission (accounting for stool frequency, rectal bleeding and endoscopy findings subscores) was met by the majority of patients across the cohorts. Brilacidin was generally well-tolerated. Patient quality of life (as assessed by the short inflammatory bowel disease questionnaire, or SIBDQ) showed notable improvements. Limited systemic exposure to Brilacidin was demonstrated as measured by plasma Brilacidin concentrations. In July 2019, the Company entered into a license agreement with Alfasigma, granting Alfasigma the worldwide right to develop, manufacture and commercialize rectally administered Brilacidin for UP/UPS. In January 2021, Alfasigma notified the Company that the Phase 1 study for the treatment of UP/UPS using Brilacidin in a proprietary Alfasigma formulation successfully completed dosing per protocol; an extra treatment cohort was subsequently added by amendment and commenced in 2Q 2021. In April 2021, the Company was notified that a Phase 2 multinational clinical trial for UP/UPS is planned to commence 4Q 2021, and Alfasigma has ordered Brilacidin from the Company for use in this study. Due to a delay at the manufacturing vendor, delivery of drug substance to Alfasigma has moved out (mid 4Q2021), and the subsequent drug product manufacturing time will likely push any clinical trial start into 2022.

11 Table of Contents

See Note 7. Exclusive License Agreement of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.

IBD, Ulcerative Colitis (UC) — Brilacidin is also being developed as a treatment in more extensive forms of IBD.

Development of a delayed release oral formulation has been in progress, with development work expanding into immediate release formulations due to unexpected findings encountered. Such findings appear due to the inherent physiochemical properties of the compound, and those of polymers used to achieve delayed release. An immediate release, multi-particulate capsule formulation has been developed and a ‘research and development’ batch has progressed to stability testing at the manufacturing vendor. Further work is ongoing, in preparation for manufacture of clinical trial supplies.

Based on these recent findings, the development plan for ulcerative colitis has been adapted with inclusion of Phase 1 testing of the immediate release oral formulation. Clinical trials will be able to progress pending completion of clinical trial supply manufacturing (currently scheduled for January 2022) and securing sufficient working capital.

Oral Mucositis (OM) study — In a randomized, double-blind Phase 2 study of Brilacidin for the prevention and control of OM in patients receiving chemoradiation for treatment of Head and Neck Cancer (HNC), Brilacidin markedly reduced the rate of severe OM (WHO Grade ≥ 3), delayed onset of severe OM and decreased duration of severe OM. The Company made available on its website a comparative data table (based on public information) showing Brilacidin compares favorably to other compounds in development for preventing and treating severe OM. The Company and the FDA have completed an End-of-Phase 2 meeting concerning the continuing development of Brilacidin oral rinse to decrease the incidence of severe OM in HNC patients receiving chemoradiation. Both parties agreed to an acceptable Brilacidin Phase 3 development pathway, including studying Brilacidin oral rinse effects on severe OM when cisplatin, the preferred chemotherapy regimen in HNC care, is administered in higher concentrations (80-100 mg/m2) every 21 days, and at lower concentrations (30-40 mg/m2) administered weekly as part of the chemoradiation regimen.

Development of an optimized oral rinse formulation is in progress, with potential to progress to Phase 3 clinical trials in 2022, pending completion of drug formulation work and securing sufficient drug supply and working capital.

ABSSSI — In February 2016, the Company submitted a Special Protocol Assessment (SPA) request, along with a final protocol, to the FDA, for a Phase 3 clinical trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). We received from the FDA comments and considerations for incorporation into our study design. Management decided to delay its response to the FDA due to the low price per share of our common stock and the many multiple million dollar costs associated with a Phase 3 program. Our strategy, for now, is to achieve success with other trials and attract partnering opportunities that may provide significant upfront payments and milestone payments, which can then be used to fund the ABSSSI program. We see ABSSSI as the appropriate gateway indication in infectious diseases, enabling potential further studies of Brilacidin’s use for implant coating and biofilm infections.

Expenditures on Brilacidin were approximately $5.0 million and $1.2 million during the years ended June 30, 2021 and 2020, respectively.

12 Table of Contents

For Brilacidin overall, we see significant potential in treatment of COVID-19 (by the IV route), and in treatment of Oral Mucositis (by oral rinse) and IBD (by oral capsule or tablet). The available clinical data also suggest that other inflammatory conditions including various dermatology disorders and conditions may, likewise, be treated locally and efficaciously with Brilacidin.

Kevetrin

The Company has completed a Phase 2a trial of Kevetrin in treating late-stage ovarian cancer. The main objective of the trial focused on confirming the modulation by Kevetrin of p53 pathways in tumors, as well as monitoring the response of tumors to the treatment. The study was successful in demonstrating modulation of p53 directly in ovarian cancer tumor tissue in patients. Pharmacokinetic data collected on Kevetrin during the Phase 1 clinical trial demonstrated that the compound has a short half-life of approximately two hours. This short half-life makes it a compelling candidate for an oral drug delivery treatment for the main purpose of allowing simple daily, or multiple-times daily administrations within or outside the hospital setting. Compared to injectable or intravenous treatments, oral therapy is the preferred drug delivery method of patients. Preliminary laboratory studies are encouraging and support the potential of developing an oral formulation, but there are no assurances made or implied that the Company will be successful in completing development of an oral formulation. Toxicology studies for the oral formulation of Kevetrin are approximately half completed, with the remainder of this work to be completed when the Company secures additional financial resources. Presently we are focusing our resources on Brilacidin, our other lead candidate.

Expenditures on Kevetrin were insignificant during the years ended June 30, 2021 and 2020.

We have no product sales to date and we will not receive any product revenue until we receive approval from the FDA or equivalent foreign regulatory agencies to begin marketing a pharmaceutical product. Developing pharmaceutical products, however, is a lengthy and very expensive process and there can be no assurance that we will complete such development or commercialize such for several years, if ever.

Table of Contents

BT BEAMEDICAL TECHNOLOGIES LTD. (FORMERLY KNOWN AS SQUALUS MEDICAL LTD.)

On June 9, 2022, the Company entered into a Series A Preferred Share Purchase Agreement (the “Purchase Agreement”) with BT BeaMedical Technologies Ltd. (formerly known as Squalus Medical Ltd.) (“BeaMedical”), the inventing company and developer of a novel laser-based thermal ablation technology designed for treatment of previously inoperable cases of epilepsy and for improvement of outcomes and enablement of new treatment options for oncology procedures, including those treating brain, prostate, liver, breast and lung cancers.

The new fiber optic technology with an advanced laser console and computerized intelligent control is being designed to allow a match between the structure of tumors and epileptic focal points and the energy delivery, while protecting vital functional areas against thermal damage. The console integrates advanced imaging modalities, and guides the physician, making sure the treatment is adjusted to the specific patient needs with real time energy control.

BeaMedical is pursuing the FDA 510(k) pathway for marketing clearance in the U.S. and the corresponding process for a CE Mark in Europe.

Pursuant to the Purchase Agreement, the Company purchased 55,556 shares of BeaMedical’s Series A Redeemable Preferred Shares (the “Series A Shares”) and a warrant to purchase 27,778 Series A Shares for aggregate consideration of $4,000,000, or approximately $72.00 per Series A Share. Following the closing under the Purchase Agreement, the Company owns approximately 35.7% of BeaMedical’s issued and outstanding equity securities and approximately 41.6% of BeaMedical’s equity securities on a fully diluted basis. The Company also entered into customary investor rights and indemnification agreements with BeaMedical.

INTELLECTUAL PROPERTY

~~Patents~~As of June 30, 2022, we had 8 issued patents, and 1 pending patent application relating to Brilacidin, in the United States and other countries. Our issued patents expire between 2024 and 2036. We rely on a combination of patents and trade secrets, as well as confidentiality and non-use agreements to protect our intellectual property. Our patent strategy is designed to facilitate commercialization of our current and future product candidates, and create barriers to entry.

~~Set~~Patent ~~forth~~Write ~~below is a description of our patents owned and co-owned, including the current status and jurisdictions in which a patent has been issued or a patent application has been filed.~~Off

~~Categories:~~During the fiscal years ended June 30, 2022 and 2021, the Company has written off the patent costs relating to Kevetrin of approximately $141,000 and $0, respectively and included these in general and administrative expenses.

1. Brilacidin, and related compounds 2. Arylamide and Salicylamide compounds 3. Anti-microbial compounds (including anti- Gram negative compounds) 4. Kevetrin and related compounds

13 Table of Contents

Patent Title	Status	Description
Arylamide Compounds And Compositions And Uses Thereof	United States: issued 11/24/15 and 01/01/19; Europe: issued 03/04/15; Japan: issued 05/15/15; Australia: issued 11/28/13; China: issued 10/01/14; Canada: issued 8/9/16; India: issued 10/23/17 Pending: United States (Other claims) Patents Expire: 2027	Category 1 Brilacidin compound, compositions, and methods of treating bacterial ophthalmic infections
Synthetic Mimetics Of Host Defense And Uses Thereof	United States: issued 10/02/12; Taiwan: issued 04/01/15 Patents Expire: 2029 and 2030	Category 1 Brilacidin enantiomer, compositions and formulations, and methods of preparation of enantiomer; Methods of preparation of Brilacidin
Host Defense Protein (HDP) Mimetics For Prophylaxis And/Or Treatment Of Inflammatory Diseases of the Gastrointestinal Tract	Pending – United States, Patent Cooperation Treaty (PCT) – National phase entered in Australia. Europe and Japan– Granted Patents Expire: 2036	Category 1 Treatment Of Inflammatory Diseases of the Gastrointestinal Tract
Compounds For Use In Treatment Of Mucositis	United States: issued 08/12/14, 10/13/15, 10/4/16, 10/24/17, 02/19/19, and 3/31/20; Europe: issued 10/11/17; Japan: issued 11/06/15; Taiwan: issued 2/11/16; China: issued 04/20/16; Australia: issued 10/6/16; Israel: issued 7/31/18; South Korea: issued 8/14/19; Canada: issued 6/16/20. Pending: Russia, Patents Expire: 2032	Category 1 Methods of treating mucositis with Brilacidin and related compounds, and compositions of Brilacidin and palifermin

Cyclic Compounds And Methods Of Making And Using The Same	United States: issued 10/18/16 Patent Expires: 2032	Category 3 Cyclic compounds, compositions, methods of inhibiting the growth of a bacteria, and method of treating a mammal having a bacterial infection
Facially Amphiphilic Polymers As Anti-infective Agents	United States: issued 02/06/07; 11/18/14 Latest Patent Expires: 2028	Category 1 & 3 - Brilacidin and related compounds; anti-microbial surfactants and related compounds
Facially Amphiphilic Polyaryl And Polyarylalkynyl Polymers And Oligomers And Uses Thereof	United States: issued 07/17/12; 05/06/14 Latest Patent Expires: United States (2028)	Category 1 & 3
Facially Amphiphilic Polymers And Oligomers And Uses Thereof	United States: issued 08/07/12; 06/04/13; 01/26/16 Australia: issued 9/22/16 Canada: issued 05/20/14 India: issued 11/10/16 Japan: issued 03/11/16 South Korea: issued 03/04/13 Taiwan: issued 05/21/15 Latest Patent Expires: foreign (2024); United States (2027)	Category 1 & 2
Nitrile Derivatives and their Pharmaceutical Use and Compositions	United States patent issued 12/25/2012 United States patent issued 5/17/16 United States patent issued 4/4/17 Patent Cooperation Treaty (PCT) - filed National Phase entered Other patents allowed or issued: Canada, Europe, Eurasian Patent Convention granted for Russia, Israel, Japan, Korea (2 divisional applications), Mexico Other Applications filed arising from PCT: Australia, India, South Korea, Singapore, Thailand Other applications filed independent of PCT: Argentina, Venezuela Patents expire: 2030	Category 4 - Kevetrin and related compounds

In 2021, the Company filed a non-provisional patent application with the U.S. Patent and Trademark Office in support of Brilacidin’s use as an antiviral treatment including the SARS-CoV-2 virus.

We rely on a combination of patents and trade secrets, as well as confidentiality and non-use agreements to protect our intellectual property. Our patent strategy is designed to facilitate commercialization of our current and future product candidates, and create barriers to entry.

Payments Related to Assignment of Compounds

The Company acquired all rights, title, and interest to Kevetrin from Dr. Krishna Menon, a former director and executive officer of the Company. The Company previously had similar rights to seven other pharmaceutical compounds, KM 277, KM 278, KM 362, KM 3174, KM 732, and KM-391, but the Company abandoned the rights to those compounds. The Company has agreed to pay the assignors 5% of net sales of Kevetrin in countries where composition of matter patents have been issued, divided 2% to Dr. Menon, 2% to an unaffiliated third party, and 1% to Leo Ehrlich, our CEO, and 3% of net sales in other countries.

15 Table of Contents

In September 2013, the Company acquired substantially all of the assets of Polymedix Inc, and Polymedix Pharmaceuticals, Inc. (together, “Polymedix”), including Polymedix’s rights to Brilacidin under a patent license agreement with the Trustees of the University of Pennsylvania (“Penn”). Under the terms of the patent license agreement, the Company will pay to Penn a royalty on gross sales of the compounds licensed thereunder ranging from 0.5% to 3.0%, plus certain other payments as provided therein. In addition, the Company will pay Penn 10% of all consideration received from sublicensees.

MANUFACTURING

The Company does not intend to establish manufacturing capabilities or facilities ~~to produce its drug product candidates (compounds) in the near or mid-term~~. The Company believes it can contract or partner with third parties for ~~the~~ manufacturing ~~of its investigational compounds~~ at sites registered with the FDA and contract with third-party scientists for pharmaco-kinetic, pharmaco-dynamic and toxicology studies. Such studies generally must be completed prior to filing an investigational new drug (IND) application with the FDA, and an IND is necessary to begin ~~the~~ human safety and efficacy trials ~~of its compounds~~ (Phase 1, 2 and 3).

GOVERNMENT REGULATION

Our operations and activities are subject to extensive regulation by numerous government authorities in the United States and other countries. In the United States, drugs are subject to rigorous regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (FDCA) and other federal and state statutes and regulations govern the testing, development, manufacture, quality control, distribution, safety, effectiveness, labeling, storage, record keeping, reporting, approval, advertising and promotion, and import and export of our investigational products. Failure to comply with FDA requirements may result in enforcement action, including warning letters, fines, civil or criminal penalties, suspension or delays in clinical development, recall or seizure of products, partial or total suspension of production or withdrawal of a product from the market. Although the discussion below focuses on regulation in the United States, which is our primary initial focus, we anticipate seeking approval to market our products in other countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences.

Table of Contents

Development and Approval

Product development and the product approval process are very expensive and time consuming, and we cannot be certain that the FDA will grant approval for any of our drug product candidates on a timely basis, if at all. Under the FDCA, the FDA must approve any new drug before it can be sold in the United States. The general process for obtaining FDA approval of a drug is as follows:

Preclinical Testing

Before we can test a drug candidate in humans, we must develop extensive preclinical data, generally derived from laboratory evaluations of product chemistry and formulation, as well as toxicological and pharmacological studies in animals, to generate data to support the drug’s quality and potential safety and benefits. Certain animal studies must be performed in compliance with the FDA’s Good Laboratory Practice, or GLP, regulations and the U.S. Department of Agriculture’s Animal Welfare Act. ~~Presently we have Brilacidin in antiviral studies testing against SARS-CoV-2.~~

We submit this preclinical data and other information to the FDA in an IND. Human clinical trials cannot commence until an IND application is submitted and becomes effective. Based on the data and information contained in the IND, the FDA must determine whether there is an adequate basis for testing the drug candidate in initial clinical studies in human volunteers. Unless the FDA raises concerns, the IND becomes effective 30 days following its receipt by the FDA.

16 Table of Contents

Clinical Trials

Once the IND goes into effect, we study an investigational drug in human clinical trials to determine if the drug is safe and effective for a particular use. Clinical trials involve the administration of the drug to healthy human volunteers or to patients under the supervision of a qualified investigator. The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA’s bioresearch monitoring regulations and Good Clinical Practice, or GCP, requirements, which establish standards for conducting, recording data from, and reporting the results of clinical trials, and are intended to assure that the data and reported results are credible and accurate, and that the rights, safety, and well-being of study participants are protected. Clinical trials must be conducted under protocols that detail the study objectives, parameters for monitoring safety, and the efficacy criteria, if any, to be evaluated. FDA reviews each protocol that is submitted to the IND. In addition, each clinical trial must be reviewed and approved by, and conducted under the auspices of, an Institutional Review Board, or IRB, for each institution conducting the clinical trial. Companies sponsoring the clinical trials, investigators, and IRBs also must comply with regulations and guidelines for obtaining informed consent from the study subjects, complying with the protocol and investigational plan, adequately monitoring the clinical trial, and timely reporting adverse events. Foreign studies conducted under an IND must meet the same requirements that apply to studies being conducted in the U.S. Data from a foreign study not conducted under an IND may be submitted in support of an NDA if the study was conducted in accordance with GCP and, if necessary, the FDA is able to validate the data through an on-site inspection, if the agency deems such inspection necessary.

In general, clinical trials involve three separate phases that often overlap, can take many years to complete, and are very expensive. These three phases are as follows:

Phase 1. The investigational drug is given to a small number of human subjects to test for safety, dose tolerance, pharmacokinetics, metabolism, distribution and excretion. In most disease states Phase 1 studies are performed in healthy volunteers. In cancer, Phase 1 studies generally are performed in cancer patients.

Phase 2. The investigational drug is given to a limited patient population to determine the initial effect of the drug in treating the disease, the best dose of the drug, and the possible side effects and safety risks of the drug. Phase 2 trials typically are controlled studies.

Phase 3. If Phase 2 clinical trials of a compound yield promising data regarding safety and effectiveness, the compound may be advanced to Phase 3 clinical trials to confirm those results. Phase 3 clinical trials typically are long-term, involve a significantly larger population of patients, are conducted at numerous sites in different geographic regions, and are carefully designed to provide reliable and conclusive data regarding the safety and benefits of a drug and to form the basis for labeling. It is not uncommon for a drug that appears promising in Phase 2 clinical trials to fail in the more rigorous and reliable Phase 3 clinical trials.

Table of Contents

At any point in this process, the development of a drug could be stopped for a number of reasons, including safety concerns and lack of treatment benefit. We cannot be certain that any clinical trials that we are currently conducting, or any that we conduct in the future, will be completed successfully or within any specified time period. We may choose, or the FDA or an IRB may require us, to delay or suspend our clinical trials at any time if, for example, it appears that the patients are being exposed to an unacceptable health risk or if the drug candidate does not appear to have sufficient treatment benefit. Success in early-stage clinical trials does not assure success in later-stage clinical trials, and data obtained from clinical activities are not always conclusive and may be subject to alternative interpretations that could delay, limit or prevent further development and regulatory approval.

17 Table of Contents

FDA Approval Process

If we believe that the data from the Phase 3 clinical trials show an adequate level of safety and effectiveness, we will file a new drug application (NDA) with the FDA seeking approval to sell the drug for a particular use. When an NDA is submitted, the FDA conducts a preliminary review to determine whether the application is sufficiently complete to be accepted for filing. If it is not, the FDA may refuse to file the application and request additional information, in which case the application must be resubmitted with the supplemental information, and review of the application is delayed.

Upon accepting the NDA for filing, the FDA will review the NDA and may hold a public hearing where an independent advisory committee of expert advisors considers key questions regarding the drug. This advisory committee makes a recommendation to the FDA, which is not binding on the FDA, but is generally followed.

Under the Pediatric Research Equity Act, certain applications for approval must include an assessment, generally based on clinical study data, of the safety and effectiveness of the subject drug in relevant pediatric populations. The FDA may waive or defer the requirement for a pediatric assessment, either at the company’s request or by the agency’s initiative. The FDA may determine that a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to ensure that the benefits of a new product outweigh its risks. A REMS may include various elements, ranging from a medication guide or patient package insert to limitations on who may prescribe or dispense the drug, depending on what the FDA considers necessary for the safe use of the drug.

Before approving an NDA, the FDA will inspect the facilities at which the product will be manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities for the drug, including those of companies who manufacture our drugs for us and including foreign establishments that may manufacture the product for sale in the U.S., comply with cGMP requirements (described below) and are adequate to assure consistent production of the product within required specifications.

If the FDA concludes that an NDA does not meet the regulatory standards for approval, the FDA typically issues a Complete Response letter communicating the agency’s decision not to approve the application and outlining the deficiencies in the submission. The Complete Response letter also may request further information, including additional preclinical or clinical data or improvements to manufacturing processes, procedures, or facilities. Even if such additional information and data are submitted, the FDA may decide that the NDA still does not meet the standards for approval.

The FDA may reject an application because, among other reasons, it believes that the drug is not safe enough, or effective enough, or because it does not believe that the data submitted are reliable or conclusive. FDA may interpret data differently than the sponsor. Obtaining regulatory approval often takes a number of years, involves the expenditure of substantial resources, and depends on a number of factors, including the nature of the disease or condition the drug is intended to address, the availability of alternative treatments, and the risks and benefits demonstrated in clinical trials.

If the FDA agrees that the ~~compound~~drug candidate has met the required level of safety and effectiveness for a particular use, it will approve the NDA, allowing the Company to sell the drug in the United States for that use. As a condition of approval, the FDA may impose restrictions that could affect the commercial success of a drug. For example, the FDA could require post-approval commitments, including completion within a specified time period of additional clinical studies, which often are referred to as “Phase 4” or “post-marketing” studies. The FDA also may limit the scope of the approved uses of the drug. Certain post-approval modifications to the drug product, such as changes in indications, labeling, or manufacturing processes or facilities, may require a sponsor to develop additional data or conduct additional preclinical or clinical trials, to be submitted in a new or supplemental NDA, which would require FDA approval.

1811 Table of Contents

Should our products be approved for marketing, we would also be subject to various other state and federal laws concerning the marketing and cost reimbursement of our products.

Major jurisdictions outside the United States, such as the European Union, Japan and Canada, have similarly rigorous regulatory processes. They may also require studies not required by the FDA, which can add to the cost and risk of development. Products approved by the FDA might not be approved in these other countries. After review by the health authorities, pricing and cost reimbursement are also subject to separate approvals in many of these countries.

Post-Approval Regulation

Even if regulatory approval is granted, a marketed drug product is subject to continuing comprehensive requirements under federal, state and foreign laws and regulations, including requirements and restrictions regarding adverse event reporting, recordkeeping, marketing, and compliance with current good manufacturing practices (cGMP). Adverse events reported after approval of a drug can result in additional restrictions on the use of a drug or requirements for additional post-marketing studies or clinical trials. The FDA or similar agencies in other countries may also require labeling changes to products at any time based on new safety information. If ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market, the FDA or similar agencies in other countries may at any time withdraw product approval or take actions that would suspend marketing or approval.

Good Manufacturing Practices. Companies engaged in manufacturing drug products or their components must comply with applicable cGMP requirements and product-specific regulations enforced by the FDA and other regulatory agencies. If, after approval, a company makes a material change in manufacturing equipment, location, or process (all of which are, to some degree, incorporated in the NDA), additional regulatory review and approval may be required. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval of a product. Failure to comply with applicable cGMP requirements and conditions of product approval may lead the FDA to seek sanctions, including fines, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA approval, seizure or recall of products, and criminal prosecution.

Advertising and Promotion. The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for advertising, promotion to physicians and patients, communications regarding unapproved uses, and industry-sponsored scientific and educational activities. Failure to comply with applicable FDA requirements and other restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the Department of Justice, the Office of the Inspector General of the Department of Health and Human Services, and state authorities, as well as civil and criminal fines and agreements that may materially restrict the manner in which a company promotes or distributes drug products.

Other Requirements. In addition, companies that manufacture or distribute drug products or that hold approved NDAs must comply with other regulatory requirements, including submitting annual reports, reporting information about adverse drug experiences, submitting establishment registrations and drug listings, and maintaining certain records.

19 Table of Contents

Orphan Drug Exclusivity

The Orphan Drug Act established incentives for the development of drugs intended to treat rare diseases or conditions, which generally are diseases or conditions affecting less than 200,000 individuals in the U.S. at the time of the request for orphan designation. If a sponsor demonstrates that a drug is intended to treat a rare disease or condition and meets other applicable requirements, the FDA grants orphan drug designation to the product for that use. ~~In November 2014, the FDA granted orphan drug designation to Kevetrin for use in the treatment of ovarian cancer.~~ The benefits of orphan drug designation include tax credits for clinical testing expenses and exemption from user fees. A drug candidate that is approved for the orphan drug designated use typically is granted seven years of orphan drug exclusivity. During that period, the FDA generally may not approve any other application for the same product for the same indication, although there are exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. There may be opportunities for the Company to pursue Orphan Drug designation for Brilacidin.

Pediatric Exclusivity

Section 505A of the FDCA provides for six months of additional exclusivity if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be safe and effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or Orange Book listed patent protection that cover the drug are extended by six months.

Table of Contents

Qualified Infectious Disease Product Exclusivity

The Generating Antibiotic Incentives Now (GAIN) Act amended the FDCA to encourage pharmaceutical companies to develop new antimicrobial drugs to treat serious and life-threatening infections. Among other measures, GAIN grants an additional five years of marketing exclusivity for new antibacterial or antifungal human drugs designated under the law as a “qualified infectious disease product” (QIDP). This five-year period of exclusivity is in addition to any existing regulatory exclusivity, including Hatch-Waxman, orphan drug, or pediatric exclusivity. In addition, QIDPs are eligible for fast-track designation and priority review to facilitate expedited development and review processes with the FDA. Our investigational drug Brilacidin has been granted QIDP designation as a potential new treatment for ABSSSI. There may be additional opportunities for the Company to pursue QIDP designation for Brilacidin.

Fast Track Designation and Priority Review

~~Certain of our product candidates~~Brilacidin, ~~such as Brilacidin~~ for the indications of SARS-CoV-2 and Oral Mucositis, ~~and~~has ~~Kevetrin for the indication of ovarian cancer, have~~ been awarded Fast Track designation. The Fast Track program is intended to expedite or facilitate the process for reviewing new drugs that demonstrate the potential to address unmet medical needs involving serious or life-threatening diseases or conditions. If a drug receives Fast Track designation, the FDA may consider reviewing sections of the NDA on a rolling basis, rather than requiring the entire application to be submitted to begin the review. Products with Fast Track designation also may be eligible for more frequent meetings and correspondence with the FDA about the product’s development.

~~Certain of our product candidates, such as~~ Brilacidin, also may qualify for priority review. Priority review is available to a drug that treats a serious condition and that, if approved, would provide a significant improvement in safety or effectiveness. Priority review designation provides for a six-month review goal for an NDA, rather than the standard 10-month review timeframe.

20 Table of Contents

Other FDA programs intended to expedite development and review include accelerated approval, which allows the FDA to approve a drug on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, and Breakthrough Therapy designation, which is intended to expedite the development and review of drugs for serious or life-threatening conditions and where preliminary clinical evidence shows that the drug may have substantial improvement on at least one clinically significant endpoint over available therapy.

Even if a product qualifies for Fast Track designation or Breakthrough Therapy designation, the FDA may later decide that the product no longer meets the conditions for qualification and may rescind the designation. Moreover, none of these programs assures ultimate approval of an investigational product. FDA may determine that the product does not meet the standards for approval.

Expanded Access

Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Expanded access may be appropriate when all the following apply:

	·	Patient has a serious disease or condition, or whose life is immediately threatened by their disease or condition.

	·	There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.

	·	Patient enrollment in a clinical trial is not possible.

	·	Potential patient benefit justifies the potential risks of treatment.

	·	Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.

Investigational drugs, biologics or medical devices have not yet been approved or cleared by FDA and FDA has not found these products to be safe and effective for their specific use. Furthermore, the investigational medical product may, or may not, be effective in the treatment of the condition, and use of the product may cause unexpected serious side effects.

~~Coronavirus~~13 ~~Treatment~~Table ~~Acceleration~~of ~~Program~~ Contents

FDA has created a special emergency program for possible coronavirus therapies, the Coronavirus Treatment Acceleration Program (CTAP). The FDA website describes the program as one that “uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful.” Subject to FDA approval, the Company plans to utilize this program.

21 Table of Contents

PAYCHECK PROTECTION PROGRAM

~~During~~On ~~the~~May ~~years~~10, ~~ended~~2020 ~~June~~and 30April 19, 2021 ~~and 2020~~, the Company received loan proceeds in the amount of approximately $93,000 and $79,000, respectively, under the Paycheck Protection Program (“PPP”) and it was recorded under loan payable. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period.

~~The~~During ~~Company~~the ~~applied~~years ~~for~~ended June 30, 2022, the ~~forgiveness~~Company obtained the approval of the ~~first~~forgiveness ~~loan~~of ~~and~~the ~~such~~above ~~application~~mentioned istwo inloans, ~~process.~~and ~~The~~the Company ~~intends~~recorded tothe ~~apply~~total ~~for~~loan forgiveness of ~~the~~$172,000 ~~second~~under ~~PPP~~other ~~loan as well~~income.

COMPETITION

Competition in the pharmaceutical and biotechnology industries is intense. ~~The~~and ~~drugs~~upon ~~that~~any wesuccessful ~~are~~drug ~~developing~~approval we will have to compete with existing therapies. In addition, a large number of companies are pursuing the development of pharmaceuticals that target the same diseases and conditions that we are targeting. Many pharmaceutical or biotechnology companies have products on the market and are actively engaged in the research and development of products that are competitive with our potential products. Many of these companies and institutions, either alone or together with their collaborative partners, have substantially greater financial, manufacturing, sales, distribution and technical resources and more experience in research and development, clinical trials and regulatory matters, than we do. In addition, our competitors may succeed in developing technologies and drugs that are more effective, better tolerated or less costly than any which are being developed by us or which would render our technology or potential drugs obsolete or noncompetitive.

With respect to ~~Kevetrin~~Brilacidin, our ~~lead~~drug ~~compound for cancer~~candidate, there are many drugs approved to treat ~~cancers~~illnesses and ~~many~~infections ~~more~~ in the ~~publicly~~therapeutic ~~disclosed~~areas ~~development~~we ~~pipeline.~~are ~~The same is true for our other compound in clinical development~~targeting, ~~Brilacidin.~~including ~~There are many drugs approved to treat various forms of~~ inflammatory bowel ~~diseases~~disease, ABSSSI and ~~ABSSSI~~COVID-19, and many more in the publicly disclosed development pipeline. There is no drug yet approved for preventing severe oral mucositis in head and neck cancer patients.

Several pharmaceutical companies have received FDA approval or an Emergency Use Authorization (EUA) for their COVID-19 treatments and vaccines, which are currently being distributed in the U.S., and abroad. While the widespread distribution of such treatments and vaccines have helped mitigate the pandemic, both in reducing the number of severely infected patients and providing relief to those infected, the virus continues to evolve. Mutations, in the form of variants, are showing signs of overcoming current COVID-19 treatments and vaccines, leading to rising case numbers and more breakthrough infections. ~~In this broader context of the pandemic, the Company anticipates a continued need for novel antiviral therapeutics.~~

The key competitive factors affecting the success of ~~all of~~ our ~~product~~drug ~~candidates~~candidate, if approved, ~~are~~is likely to be ~~their~~its efficacy, safety, convenience and price, the effectiveness of alternative products, the level of competition and the availability of coverage and adequate reimbursement from government and other third-party payors.

22Our ~~Table~~commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products or therapies that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product that we may develop. Our competitors also may obtain FDA, European Medicines Agency (EMA), or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of ~~Contents~~generic products.

Our ~~commercial~~success ~~opportunity~~depends ~~could~~on ~~be reduced or eliminated if~~ our ~~competitors~~ability ~~develop~~to ~~and~~identify ~~commercialize~~types ~~products~~of orthese ~~therapies~~respective ~~that~~diseases ~~are~~where safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA, European Medicines Agency (EMA), or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our ~~competitors~~drug ~~establishing~~has aan ~~strong~~advantage ~~market~~over ~~position~~existing ~~before~~therapies weand ~~are~~those ~~able to enter the market. In addition, our ability to compete may be affected~~ in ~~many cases by insurers or other third-party payors seeking to encourage~~ the ~~use~~publicly ofdisclosed ~~generic~~development ~~products~~pipeline.

Our success depends on our ability to identify types of these respective diseases where our drugs have an advantage over existing therapies and those in the publicly disclosed development pipeline.

EMPLOYEES

As of June 30, ~~2021~~2022, the Company had 4 employees. The Company also conducts its operations using contractors and consultants.

Table of Contents

CORPORATE INFORMATION

Innovation Pharmaceuticals Inc. was incorporated on August 1, 2005 in the State of Nevada. The Company has as its corporate headquarters 301 Edgewater Place - Suite 100, Wakefield, MA 01880, a facility that maintains our virtual offices, and if needed, the use of physical offices, meeting rooms, and business support services on a fee for use basis. All our employees and consultants work remotely. The Company’s telephone number is (978) 921-4125. The Company maintains an internet website at www.IPharmInc.com. The Company makes available, free of charge, through the Investors section of its website, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information on the Company’s website is not, and shall not be deemed to be, a part hereof or incorporated into this or any of our other filings with the SEC.

ITEM 1A. RISK FACTORS

Investing in the Company’s common stock involves a high degree of risk. Prospective investors should carefully consider the risks described below, together with all of the other information included or referred to in this Annual Report on Form 10-K, before purchasing shares of the Company’s common stock. There are numerous and varied risks, known and unknown, that may prevent the Company from achieving its goals. The risks described below are not the only ones the Company will face. If any of these risks actually occur, the Company’s business, financial condition or results of operation may be materially adversely affected. In such case, the trading price of the Company’s common stock could decline and investors in the Company’s common stock could lose all or part of their investment.

Risks Related to Our Business

There are doubts about our ability to continue as a going concern.

We have generated revenue of $18,000 and $0 for the fiscal years ended June 30, 2022 and 2021, respectively and have an accumulated deficit of $122.2 million through June 30, 2022. These factors raise substantial doubt about our ability to continue as a going concern.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources, such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations, or to raise capital from external sources would force us to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on our existing stockholders.

We seek to overcome the circumstances that impact our ability to remain a going concern through a combination of the growth of revenues, with interim cash flow deficiencies being addressed through additional equity and debt financing. We anticipate raising additional funds through public or private financing, strategic relationships or other arrangements in the near future to support our business operations; however, we may not have commitments from third parties for a sufficient amount of additional capital. We cannot be certain that any such financing will be available on acceptable terms, or at all, and our failure to raise capital when needed could limit our ability to continue operations. Our ability to obtain additional funding will determine the Company’s ability to continue as a going concern. Failure to secure additional financing in a timely manner and on favorable terms would have a material adverse effect on our financial performance, results of operations and stock price and require us to curtail or cease operations, sell off our assets, seek protection from our creditors through bankruptcy proceedings, or otherwise. Furthermore, additional equity financing may be dilutive to the holders of our common stock, and debt financing, if available, may involve restrictive covenants, and strategic relationships, if necessary, to raise additional funds, and may require that we relinquish valuable rights.

We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has a history of losses, primarily due to being a mid-stage developmental pharmaceutical company. The Company intends on financing its future development activities largely from a variety of sources, including ~~applying for government grants and contracts for~~ the ~~development of Brilacidin for the treatment of COVID-19, the~~ sale of equity securities and seeking relationships with partners to help fund future clinical trial costs. However, there is no assurance these plans will be realized and that any additional financing will be available to us on satisfactory terms and conditions, if at all. In the event that we are unable to raise additional funds, we may be required to delay, reduce or severely curtail our operations or otherwise impede our ongoing efforts to develop our drug candidates, which could have a material adverse effect on our business, operating results, financial condition and long-term prospects.

2315 Table of Contents

We currently have an approximate $~~11.~~3.2 million cash balance ~~in the bank~~ as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $104.2 million in the upcoming fiscal year ending June 30, ~~2022~~2023 to operate our business in accordance with our business plans and budgets.

If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us.

Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, it may be necessary to significantly reduce our current rate of spending through reductions in staff and delaying, scaling back or stopping certain research and development programs, including costly Phase 2 and Phase 3 clinical trials, and our business, operating results, financial condition and prospects could be materially and adversely affected and we may be unable to continue our operations. ~~As of the date of this report, we have already delayed incurring additional expenses for Kevetrin and completing bridging toxicology work for oral dosing.~~ In the event that we cannot obtain acceptable financing, we would be unable to complete preclinical development projects, and further clinical trials for Brilacidin ~~and Kevetrin~~. This will delay:

•· research and development programs; •· preclinical studies and clinical trials; •· material characterization studies; •· regulatory processes; •· drug substance and drug product manufacturing; and •· establishment of our own laboratory or a search for third party marketing partners to market our products for us.

The amount of capital we may require will depend on many factors, including the:

•· progress, timing and scope of our research and development programs; •· progress, timing and scope of our preclinical studies and clinical trials; •· time and cost necessary to obtain regulatory approvals; •· time and cost necessary to establish our own marketing capabilities or to seek marketing partners; •· time and cost necessary to respond to technological and market developments; •· changes made or new developments in our existing collaborative, licensing and other commercial relationships; and •· new collaborative, licensing and other commercial relationships that we may establish.

24 Table of Contents

Our fixed expenses, such as contractual commitments, may increase in the future, as we may:

•· enter into leases for new facilities and capital equipment; and •· enter into additional licenses and collaborative agreements.

Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.

In December 2019, a novel strain of coronavirus, since named SARS-CoV-2, causing COVID-19 disease, was reported in China. Since then, COVID-19 has spread globally, including throughout the United States. The spread of COVID-19 has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a “pandemic,” or a worldwide spread of a new disease, on March 11, 2020. Many countries around the world, including the United States, have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus, and have closed non-essential businesses.

As16 ~~local~~Table jurisdictions continue to put restrictions in place, our ability to plan and enroll patients in our planned clinical trials, manufacture our product candidates and pursue collaborations, may also be limited. Such events may result in a period of ~~business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.~~Contents

~~The~~As ~~continued~~local ~~spread~~jurisdictions ofcontinue ~~COVID-19~~to ~~globally~~put ~~could~~restrictions ~~also~~in ~~adversely affect our planned clinical trial operations~~place, ~~including~~ our ability to ~~initiate~~plan ~~the trials on the expected timelines~~ and ~~recruit~~enroll ~~and retain~~ patients ~~and~~in ~~principal~~clinical ~~investigators~~trials, ~~and~~manufacture ~~site~~our ~~staff~~product ~~who,~~candidates asand ~~healthcare~~pursue ~~providers~~collaborations, may ~~have~~also ~~heightened~~be ~~exposure to COVID-19 if an outbreak occurs in their geography~~limited. ~~Further,~~Such ~~the~~events ~~COVID-19~~may ~~outbreak could~~ result in ~~delays~~a inperiod ~~our clinical trials due to prioritization~~ of ~~hospital~~business ~~resources~~and ~~toward~~manufacturing ~~the outbreak~~disruption, ~~restrictions~~and in ~~travel,~~reduced ~~potential unwillingness of patients to enroll in trials at this time~~operations, orany ~~the inability~~ of ~~patients~~which tocould ~~comply~~materially ~~with~~affect clinical trial protocols as quarantines or travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our ~~preclinical studies and clinical trials~~business, ~~and~~financial ~~the~~condition ~~outbreak may affect their ability to devote sufficient time~~ and ~~resources~~results toof ~~our programs or to travel to sites to perform work for us~~operations.

The continued spread of COVID-19 globally could also adversely affect our future clinical trial operations, including our ability to initiate the trials on the expected timelines and recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Further, COVID-19 could result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of patients to enroll in trials at this time, or the inability of patients to comply with clinical trial protocols as quarantines or travel restrictions impede patient movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us.

Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.

The global outbreak of COVID-19 continues to ~~rapidly~~ evolve. The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, the effectiveness of actions taken in the United States and other countries to contain and treat the disease and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 is highly uncertain and cannot be predicted with confidence.

25 Table of Contents

Newly emerging SARS-CoV-2 variants could reduce the effectiveness of Brilacidin as a potential COVID-19 treatment.

Multiple variants of the virus that causes COVID-19 have been documented in the United States and globally during this pandemic. While Brilacidin is showing an ability in vitro to be resistant to SARS-CoV-2 mutations, the compound might not continue to do so based on the potential emergence of new variants in the future.

There can be no assurance that the product we are developing for COVID-19 would be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. If we do not apply for such an authorization or, if we do apply and no authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and instead, will be required to pursue the new drug licensure process in order to sell our product, which is lengthy and expensive.

We may seek an Emergency Use Authorization, or EUA, from the FDA or similar authorization from regulatory authorities outside of the United States, such as conditional marketing authorization from the EMA. If we apply for an EUA and it is granted, an EUA will authorize us to market and sell our COVID-19 treatment under certain conditions of authorization as long as the public health emergency exists. The FDA expects that companies which receive an EUA for COVID-19 treatments will proceed to licensure of their products under a full New Drug Application (NDA). The FDA may issue an EUA during a Public Health Emergency if the agency determines that the potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. There is no guarantee that we will apply for an EUA or other similar authorization or, if we do apply, that we will be able to obtain such authorization. If an EUA or other authorization is granted, we will rely on the FDA or other applicable regulatory authority policies and guidance governing treatments authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. An EUA authorizing the marketing and sale of our product will terminate upon expiration of the Public Health Emergency, which is a determination made by the Secretary of Health and Human Services. The FDA may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of authorization. If we apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our COVID-19 treatment, which could adversely impact our business, financial condition and results of operations.

We have no products approved for commercial sale to generate revenue, however we signed an Exclusive License Agreement in 2019.

We currently have no products approved for commercial sale. On July 18, 2019, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS).

26 Table of Contents

Our ability to generate revenue depends heavily on:

•· successful demonstration in clinical trials that our drug ~~candidates~~candidate, Brilacidin, ~~and~~is ~~Kevetrin are~~ safe and effective; •· our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; •· the successful commercialization of our product candidates; and •· market acceptance of our products.

If we and/or our licensee do not successfully develop and commercialize ~~at least one of our compounds~~Brilacidin, we will not achieve revenues or profitability in the foreseeable future, if at all. If we are unable to generate revenues or achieve profitability, we may be unable to continue our operations.

In our existing or any future potential collaborations or partnerships, we will likely not be able to control all aspects of the development and commercialization of our ~~compounds~~drug candidate (compound). This lack of control could subject us to additional risks that could harm our business.

Collaborations or license agreements involving our ~~compounds~~compound, including our current license agreement with Alfasigma S.p.A. and any future collaboration or partnering arrangement with other pharmaceutical companies, are subject to numerous risks, which may include:

•· partners have significant discretion in determining the efforts and resources that they will apply to collaborations; • partners may not pursue development and commercialization of our compounds or may elect not to continue or renew development or commercialization programs based on clinical study results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities; • partners may delay clinical studies, provide insufficient funding for a clinical study program, stop a clinical study, abandon a product candidate, repeat or conduct new clinical studies, or require a new formulation of a product candidate for clinical testing; • partners could independently develop, or develop with third parties, products that compete directly or indirectly with our compounds; • a partner with marketing, manufacturing, and distribution rights to one or more compounds may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; • we could grant exclusive rights to our partners that would prevent us from collaborating with others; • partners may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; • partners may not aggressively or adequately pursue litigation concerning our compounds or may settle such litigation on unfavorable terms, as they may have different economic interests than ours, and such decisions could negatively impact any royalties we may receive under our license agreements; • disputes may arise between us and a partner that causes the delay or termination of the research, development, or commercialization of our current or future compounds or that results in costly litigation or arbitration that diverts management attention and resources; • agreements may be terminated, possibly at-will, without penalty, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable compounds; • partners may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property; and • a partner’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

2717 Table of Contents

	·	partners may not pursue development and commercialization of our compound or may elect not to continue or renew development or commercialization programs based on clinical study results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;

	·	partners may delay clinical studies, provide insufficient funding for a clinical study program, stop a clinical study, abandon a product candidate, repeat or conduct new clinical studies, or require a new formulation of a product candidate for clinical testing;

	·	partners could independently develop, or develop with third parties, products that compete directly or indirectly with our compound;

	·	a partner with marketing, manufacturing, and distribution rights to one or more compound may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;

	·	we could grant exclusive rights to our partners that would prevent us from collaborating with others;

	·	partners may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;

	·	partners may not aggressively or adequately pursue litigation concerning our compound or may settle such litigation on unfavorable terms, as they may have different economic interests than ours, and such decisions could negatively impact any royalties we may receive under our license agreements;

	·	disputes may arise between us and a partner that causes the delay or termination of the research, development, or commercialization of our current or future compounds or that results in costly litigation or arbitration that diverts management attention and resources;

	·	agreements may be terminated, possibly at-will, without penalty, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable compound;

	·	partners may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property; and

	·	a partner’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

We depend on license agreements for the development and commercialization of certain compounds.

On July 18, 2019, we entered into a license agreement with Alfasigma, under which we granted Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS). Pursuant to the terms of the license agreement, Alfasigma is obligated to use commercially reasonable efforts (as defined in the license agreement) to develop, manufacture and commercialize Brilacidin for UP/UPS, and to achieve specified developmental milestones.

Under the terms of the license agreement, Alfasigma will make payments of up to $24.0 million to the Company based upon the achievement of certain milestones. In addition, Alfasigma will pay a royalty to the Company equal to six percent of net sales of Brilacidin for UP/UPS, subject to adjustment as provided in the license agreement.

The right to potential future payments under the license agreement represents a significant portion of the value of the license agreement to us. We cannot be certain that we will receive any future payments under the license agreement, which would adversely affect the trading price of our common stock and our business prospects.

Additionally, if Alfasigma were to breach or terminate the license agreement, we may not be able to obtain, or may be delayed in obtaining, marketing approvals for Brilacidin for UP/UPS and will not be able to, or may be delayed in our efforts to, successfully commercialize Brilacidin for UP/UPS. We may not be able to seek and obtain a viable, alternative collaborator to partner for the development and commercialization of the licensed products on similar terms or at all.

Table of Contents

In addition, on July 22, 2020, the Company granted to Fox Chase Chemical Diversity Center, Inc. (“FCCDC”) all discovery, intellectual property and commercialization rights related to its share of their joint antifungal drug program in exchange for a six percent fee tied to all potential future proceeds. Acquisitions of royalties from development-stage biopharmaceutical product candidates are subject to a number of uncertainties, and there can be no assurance that the FDA, the EMA or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products.

We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.

We have limited experience in drug and formulation development and may not be able to successfully develop any drugs or drug formulations necessary to achieve a drug’s potential as seen in preclinical research and early clinical studies. Our ability to achieve revenues and profitability in our business will depend, among other things, on our ability to:

•· develop products internally or obtain rights to them from others on favorable terms; •· complete laboratory testing and human clinical studies; •· obtain and maintain necessary intellectual property rights to our products; •· successfully fulfill regulatory requirements to obtain requisite marketing approvals from governmental agencies; •· enter into arrangements with third parties to manufacture our products on our behalf; and •· enter into arrangements with third parties to provide sales and marketing functions.

28We ~~Table~~have limited experience conducting clinical trials and obtaining regulatory approvals, and we may not be successful in some or all of ~~Contents~~these activities. We have not previously conducted a Phase 3 or later stage clinical trial such as the Phase 3 clinical trials planned (contingent upon sufficient funding) for our drug candidate Brilacidin.

We have limited experience conducting clinical trials and obtaining regulatory approvals, and we may not be successful in some or all of these activities. We have not previously conducted a Phase 3 or later stage clinical trial such as the Phase 3 clinical trials planned for our most advanced drug candidate. We expect to spend significant amounts to recruit and retain highly quality personnel with clinical development experience.

We have no experience as a company in the sales, marketing and distribution of pharmaceutical products and do not currently have a sales and marketing organization. To the extent we are unable to, or determine not to develop these resources internally, we may be forced to rely on third parties for these capabilities, which could subject us to costs and to delays that are outside our control. If we are unable to establish adequate capabilities independently or with others, we may be unable to generate product revenues for certain candidates. If we are unable to achieve revenues and profitability, then we will be forced to cease operations, which could cause you to lose all of your investment.

Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. ~~Many~~Our ~~of our~~ drug ~~candidates~~candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.

The drug discovery and development process is highly uncertain and we have not developed, and may never develop, a drug candidate that ultimately leads to a commercially viable drug. Our drug ~~candidates~~candidate, ~~are~~Brilacidin, is in early and mid-stages of development, and ~~our most advanced drug candidate~~ has only completed Phase 2 testing. Further development and extensive testing will be required to determine their technical feasibility and commercial viability.

Conducting clinical trials is a complex, time-consuming and expensive process that requires an appropriate number of trial sites and patients to support the product label claims being sought. The length of time, number of trial sites and number of patients required for clinical trials vary substantially according to their type, complexity, novelty and the drug candidate’s intended use, and we may spend several years completing certain trials. The time within which we can complete our clinical trials depends in large part on the ability to enroll eligible patients who meet the enrollment criteria and who are in proximity to the trial sites. We face competition with other clinical trials for eligible patients. As a result, there may be limited availability of eligible patients, which can result in increased development costs, delays in regulatory approvals and associated delays in drug candidates reaching the market. We experienced these issues in our psoriasis and oral mucositis clinical trials.

Table of Contents

At any time, we, the FDA (or foreign regulatory authority) or an institutional review board (“IRB”), may temporarily or permanently stop a clinical trial, for a variety of reasons. We may experience numerous unforeseen events during, or as a result of, the clinical development process that could delay or prevent our drug candidates from being approved, including:

29· ~~Table~~failure to achieve clinical trial results that indicate a candidate is effective in treating a specified condition or illness in humans; · presence of ~~Contents~~harmful side effects; · determination by the FDA that the submitted data do not satisfy the criteria for approval; · lack of commercial viability of the drug; · failure to acquire, on reasonable terms, intellectual property rights necessary for commercialization; and · existence of alternative therapeutics that are more effective.

•As ~~failure~~our drug candidate advances to ~~achieve~~later stage clinical ~~trial~~trials, ~~results~~it ~~that~~is ~~indicate~~customary athat ~~candidate~~various isaspects ~~effective~~of inthe ~~treating~~development aprogram, ~~specified~~such ~~condition~~as ormanufacturing, ~~illness~~formulation inand ~~humans;~~other •processes, ~~presence~~and methods of ~~harmful~~administration, ~~side~~may ~~effects;~~be •altered ~~determination~~to byoptimize the ~~FDA~~candidates ~~that~~and ~~the~~processes ~~submitted~~for ~~data~~scale-up donecessary ~~not~~for ~~satisfy~~later ~~the~~stage ~~criteria~~clinical ~~for~~trials and potential approval; •and ~~lack~~commercialization. These changes may not produce the intended optimization, including production of ~~commercial~~drug ~~viability~~substance and drug product of a quality and in a quantity sufficient for Phase 3 clinical stage development or for commercialization, which may cause delays in the ~~drug;~~initiation •or ~~failure~~completion of clinical trials and greater costs. We may also need to ~~acquire,~~conduct on“bridging ~~reasonable~~studies” ~~terms,~~to ~~intellectual~~demonstrate ~~property~~comparability ~~rights~~between ~~necessary~~newly manufactured drug substance and/or drug product for commercialization; relative to previously manufactured drug substance and/or •drug ~~existence~~product for clinical trials. Demonstrating comparability may require us to incur additional costs or delay initiation or completion of ~~alternative~~clinical ~~therapeutics~~trials ~~that~~and, ~~are~~if ~~more~~unsuccessful, ~~effective~~could require us to complete additional preclinical studies or clinical trials.

AsIf ~~our~~we ~~product~~fail ~~candidates advance~~ to ~~later~~adequately ~~stage~~manage ~~clinical trials, it is customary that various aspects of~~ the ~~development~~increasing ~~program~~number, ~~such~~size ~~as manufacturing, formulation~~ and ~~other~~complexity ~~processes, and methods~~ of ~~administration~~clinical trials, ~~may be altered to optimize~~ the ~~candidates and processes for scale-up necessary for later stage~~ clinical trials and ~~potential~~corresponding ~~approval~~regulatory ~~and~~approvals ~~commercialization.~~may ~~These~~be ~~changes~~delayed ~~may~~or ~~not~~we ~~produce~~or ~~the~~our ~~intended~~partners ~~optimization,~~may ~~including~~fail ~~production~~to ofgain ~~drug~~approval ~~substance~~for ~~and~~our drug ~~product~~candidates ofaltogether. aEven ~~quality~~if ~~and~~we insuccessfully aconduct ~~quantity sufficient for Phase 3~~ clinical ~~stage development or for commercialization~~trials, ~~which~~we may ~~cause~~not ~~delays~~obtain infavorable ~~the initiation or completion of~~ clinical ~~trials~~trial results and ~~greater costs. We~~ may ~~also~~not ~~need~~be toable ~~conduct “bridging studies”~~ to ~~demonstrate~~obtain ~~comparability~~regulatory ~~between~~approval ~~newly~~on ~~manufactured~~this ~~drug~~basis. ~~substance~~If ~~and/or~~we ~~drug~~are ~~product~~unable ~~for~~to ~~commercialization~~market ~~relative~~and tosell ~~previously~~our ~~manufactured~~ drug ~~substance~~candidate ~~and/~~or ~~drug~~are ~~product~~unable ~~for~~to ~~clinical~~obtain ~~trials.~~approvals ~~Demonstrating~~in ~~comparability~~the ~~may~~time ~~require~~frame usneeded to ~~incur~~execute ~~additional~~our ~~costs~~product orstrategies, ~~delay~~our ~~initiation~~business orand ~~completion~~results of ~~clinical~~operations ~~trials~~would ~~and,~~be ifmaterially ~~unsuccessful,~~adversely ~~could require us to complete additional preclinical studies or clinical trials~~affected.

WeOur ~~learned~~success ~~during~~will depend on our ~~completed~~ability ~~Kevetrin~~to ~~Phase~~achieve 1scientific ~~study~~and ~~that,~~technological ~~when~~advances ~~administered~~and ~~IV,~~to ~~Kevetrin~~translate ~~was~~such ~~almost~~advances ~~completely~~into ~~cleared~~reliable, ~~from~~commercially ~~the~~competitive ~~systemic~~drugs ~~circulation~~on ~~within~~a 24timely ~~hours~~basis. ~~Therefore~~The length of time required to complete clinical studies, ~~little~~submit ~~drug~~an ~~remains~~application for ~~any~~marketing ~~substantial~~approval, ~~period~~and ofobtain ~~time~~approval ~~afterwards.~~can ~~Having~~vary ~~the~~considerably ~~patient~~from ~~receive~~one ~~multiple~~product IVto ~~infusions~~another, ~~per~~and ~~week~~may isbe a difficult ~~course~~to ofpredict ~~treatment~~or control. ~~Therefore,~~Drugs anthat ~~oral~~we ~~formulation~~may develop are not likely to be commercially available for ~~Kevetrin~~several isyears, ~~needed~~if ever. ~~There~~The isproposed nodevelopment ~~assurance~~schedules wefor ~~will~~our drug candidate may be ~~successful~~affected by a variety of factors, including technological difficulties, proprietary technology of others, and changes in ~~developing~~government anregulation, ~~oral~~many ~~formulation~~of which will not be within our control.

WeAny ~~used~~delay ~~Brilacidin~~ in athe ~~water base~~development, ~~administered~~introduction byor ~~enema,~~marketing inof our ~~Phase~~drug 2candidate ~~UP/UPS~~could ~~study.~~result ~~However,~~either in such a ~~commercial~~drug ~~product~~being ~~for~~marketed ~~IBD~~at ~~ulcerative~~a ~~colitis~~time ~~will~~when ~~need~~their acost ~~different~~and ~~formulation~~performance ~~(e.g.~~characteristics ~~Brilacidin~~would not be competitive in ~~capsule~~the marketplace or ~~tablet).~~in ~~Formulation~~the ~~development~~shortening isof intheir ~~progress~~commercial lives. ~~There~~In islight noof ~~assurance~~the long-term nature of our projects, the unproven technology involved and the other factors described elsewhere in “Risk Factors”, we ~~will~~may not be ~~successful~~able into ~~developing~~complete ~~new~~successfully ~~formulations~~the ~~for~~development ~~possible~~or ~~commercialization~~marketing of our drug candidate.

IfWe ~~we fail to adequately manage the increasing number, size and complexity of clinical trials, the clinical trials and corresponding regulatory approvals~~ may ~~be delayed or we or our partners may~~ fail to ~~gain approval for our drug candidates altogether. Even if we~~ successfully ~~conduct~~develop ~~clinical trials, we may not obtain favorable clinical trial results~~ and ~~may~~commercialize ~~not be able to obtain regulatory approval on this basis. If we are unable to market and sell~~ our drug ~~candidates~~candidate orfor ~~are~~multiple ~~unable to obtain approvals in the time frame needed to execute our product strategies~~reasons, ~~our~~including ~~business~~because ~~and~~it: ~~results of operations would be materially adversely affected.~~

~~Our~~· ~~success~~is ~~will~~found ~~depend on our ability~~ to ~~achieve~~be ~~scientific~~unsafe ~~and~~or ~~technological~~ineffective ~~advances~~in ~~and~~clinical totrials; ~~translate~~· ~~such~~does ~~advances~~not ~~into~~receive ~~reliable,~~necessary ~~commercially~~approval ~~competitive~~from ~~drugs~~the onFDA aor ~~timely~~foreign ~~basis.~~regulatory ~~The~~agencies; ~~length~~· ofhas ~~time~~manufacturing ~~required~~production ~~to complete clinical studies~~problems, ~~submit an application for marketing approval~~costs, ~~and~~pricing ~~obtain~~or ~~approval~~reimbursement ~~can vary considerably from one product to another~~issues, ~~and may be difficult to predict~~ or ~~control.~~other ~~Drugs~~factors that wemake ~~may~~the ~~develop~~product ~~are~~ not ~~likely~~economical; to· beis ~~commercially~~hampered ~~available~~by ~~for~~the ~~several~~proprietary ~~years,~~rights ifof ~~ever.~~others ~~The~~and ~~proposed~~their ~~development~~competing ~~schedules~~products ~~for~~and ~~our~~technologies; ~~drug~~· ~~candidates~~fails ~~may~~to beconform ~~affected~~to by a ~~variety~~changing standard of ~~factors,~~care ~~including~~for ~~technological~~the ~~difficulties,~~diseases ~~proprietary~~it ~~technology~~seeks ofto ~~others,~~treat; ~~and~~or ~~changes~~· inis ~~government~~less ~~regulation,~~effective ~~many~~or ofmore ~~which~~expensive ~~will~~than ~~not~~current beor ~~within~~alternative ~~our~~treatment ~~control~~methods.

~~Any~~20 ~~delay~~Table ~~in the development, introduction or marketing~~ of our drug candidates could result either in such drugs being marketed at a time when their cost and performance characteristics would not be competitive in the marketplace or in the shortening of their commercial lives. In light of the long-term nature of our projects, the unproven technology involved and the other factors described elsewhere in “Risk Factors”, we may not be able to complete successfully the development or marketing of any of our drug candidates. Contents

30Drug ~~Table~~development failure can occur at any stage of ~~Contents~~clinical trials and as a result of many factors and there can be no assurance that we will reach any clinical targets. Promising results in preclinical development or early clinical trials may not be predictive of results obtained in later clinical trials. Many pharmaceutical companies have experienced significant setbacks in advanced clinical trials, even after obtaining promising results in earlier preclinical studies and clinical trials. Clinical results are susceptible to varying interpretations that may delay, limit, or prevent regulatory approvals.

WeEven ~~may~~if ~~fail~~we complete our clinical trials, we do not know what the long-term effects of exposure to ~~successfully~~our ~~develop~~drug candidate will be. Furthermore, our drug candidate may be used in combination with other treatments and ~~commercialize~~there can be no assurance that such use will not lead to unique safety issues. Failure to complete clinical trials or to prove that our drug ~~candidates~~candidate ~~for~~is ~~multiple~~safe ~~reasons~~and effective would have a material adverse effect on our ability to generate revenue and could require us to reduce the scope of or discontinue our operations, ~~including~~which ~~because~~could ~~they:~~cause you to lose all of your investment.

•At ~~are~~any ~~found~~time, towe bemay ~~unsafe~~decide orto ~~ineffective~~discontinue inthe ~~clinical~~development ~~trials;~~of, •or doto not ~~receive~~commercialize, ~~necessary~~a ~~approval~~drug ~~from~~candidate, ~~the~~such ~~FDA~~as orour ~~foreign~~decision ~~regulatory~~in ~~agencies;~~December •2018 ~~have~~to ~~manufacturing~~discontinue ~~production~~the ~~problems,~~Prurisol ~~costs~~psoriasis program, ~~pricing~~and orour ~~reimbursement~~decision ~~issues,~~in orSeptember ~~other~~2022 ~~factors~~to ~~that~~discontinue ~~make~~ the ~~product~~Kevetrin ~~not~~oncology ~~economical;~~program. •If ~~are~~we ~~hampered~~terminate bya ~~the~~program ~~proprietary~~in ~~rights~~which ofwe ~~others~~have ~~and~~invested ~~their~~significant ~~competing~~resources, ~~products~~we ~~and~~will ~~technologies;~~not •receive ~~fail~~any toreturn ~~conform~~on toour ainvestment ~~changing~~and ~~standard~~we ofwill ~~care~~have ~~for~~missed the ~~diseases~~opportunity ~~they seek~~ to ~~treat;~~allocate orthose •resources ~~are~~to ~~less~~potentially ~~effective or~~ more ~~expensive~~productive ~~than current or alternative treatment methods~~uses.

Drug development failure can occur at any stage of clinical trials and as a result of many factors and there can be no assurance that we will reach our anticipated clinical targets. Promising results in preclinical development or early clinical trials may not be predictive of results obtained in later clinical trials. Many pharmaceutical companies have experienced significant setbacks in advanced clinical trials, even after obtaining promising results in earlier preclinical studies and clinical trials. Clinical results are susceptible to varying interpretations that may delay, limit, or prevent regulatory approvals.

Even if we complete our clinical trials, we do not know what the long-term effects of exposure to our drug candidates will be. Furthermore, our drug candidates may be used in combination with other treatments and there can be no assurance that such use will not lead to unique safety issues. Failure to complete clinical trials or to prove that our drug candidates are safe and effective would have a material adverse effect on our ability to generate revenue and could require us to reduce the scope of or discontinue our operations, which could cause you to lose all of your investment.

At any time, we may decide to discontinue the development of, or to not commercialize, a drug candidate, such as our decision in December 2018 to discontinue the Prurisol psoriasis program. If we terminate a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity to allocate those resources to potentially more productive uses.

We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials, which exposes us to risks which could have a materially adverse effect on our business.

We have limited experience in conducting and supervising clinical trials that must be performed to obtain data to submit in applications for approval by the FDA. Because we have limited experience in conducting or supervising clinical trials, we outsource a significant amount of the work relating to our clinical trials to third parties. We therefore have less control over the conduct of our clinical trials, the timing and completion of the trials, the required reporting of adverse events, and the management of data developed through the trials than would be the case if we were relying entirely upon our own staff. We are now awaiting our vendors to complete the data management review before unblinding our COVID-19 study. Had we had the staff and experience to do this in house, it is likely the process would be quicker and result in cost savings.

We also have more limited control over compliance with procedures and protocols used to complete clinical trials. If these contractors fail to meet applicable regulatory standards, the testing of our drugs would be adversely affected, causing a delay in our ability to engage in revenue-generating operations that could have a materially adverse effect on our business.

31 Table of Contents

Communicating with outside parties can also be challenging, potentially leading to mistakes, as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our trials. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization may lead us to seek to terminate the relationship and use an alternative service provider. However, making this change may be costly and may delay our trials and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct our trials in an acceptable manner and at an acceptable cost.

Success in early clinical trials may not be predictive or indicative of results in current ongoing clinical trials or potential future clinical trials. Likewise, preliminary data from clinical trials should be considered carefully and with caution since the final data may be materially different from the preliminary data, particularly as more patient data become available.

A number of new drugs and biologics have shown promising results in preclinical studies and initial clinical trials, but subsequently have failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals to initiate commercial sale. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Product candidates in later stages of clinical trials may fail to show the desired benefit-risk profile despite having progressed through preclinical studies and initial clinical trials. As a result, data from our preclinical studies and Phase 1 and Phase 2 clinical trials of our drug ~~candidates~~candidate, Brilacidin ~~and Kevetrin~~, as well as the results of the past or future internal data reviews, should not be relied upon as predictive or indicative of future clinical results. The results we have previously obtained, as well as any future results, may not predict the future therapeutic benefit of our drug ~~candidates~~candidate.

In addition, from time-to-time, preliminary or interim data from clinical trials or other research, such as relating to the Brilacidin Phase 2, open-label, UP/UPS Proof-of-Concept (PoC) clinical trial, the Brilacidin Phase 2 COVID-19 clinical trial, the ongoing research relating to Brilacidin as a potential therapeutic for the treatment of ~~the novel coronavirus (SARS-CoV-2)~~viruses, ~~which is responsible for COVID-19,~~ or potential future clinical trials, may be reported or announced by us or the clinical investigators and medical institutions with which we work. Such data are preliminary and the data from any final analysis may be materially different. Even if final safety and/or efficacy data are positive, significant additional clinical testing will be necessary to advance the future development of our drug ~~candidates~~candidate. Preliminary or interim results may also not be reproduced in any potential future clinical trials. Accordingly, preliminary or interim data should be considered carefully and with caution.

We21 ~~are~~Table ~~subject~~of to risks inherent in conducting clinical trials. Non-compliance with the FDA-approved good clinical practices by clinical investigators, clinical sites, or data management services could delay or prevent us from developing or commercializing our drug candidates, which could cause us to cease operations.Contents

~~Agreements~~We ~~with~~are ~~clinical~~subject ~~investigators~~to ~~and~~risks ~~medical~~inherent ~~institutions for clinical testing and with other third parties for data management services place substantial responsibilities on these parties, which could result~~ in ~~delays~~conducting ~~in, or termination of, our~~ clinical trials ~~if these parties fail to perform as expected~~. ~~For~~Non-compliance ~~example, if any of our clinical trial sites fail to comply~~ with the FDA-approved good clinical practices, weby ~~may be unable to use the data gathered at those sites. If these~~ clinical investigators, ~~medical~~clinical ~~institutions or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines~~sites, or ~~if the quality or accuracy of the clinical~~ data ~~they~~management ~~obtain~~services iscould ~~compromised~~delay ~~due~~or toprevent ~~their~~us ~~failure~~from todeveloping ~~adhere to our clinical protocols~~ or ~~for~~commercializing ~~other reasons,~~ our ~~clinical~~drug ~~trials may be extended~~candidate, ~~delayed~~which orcould ~~terminated,~~cause ~~and~~us ~~we may be unable~~ to ~~obtain~~cease ~~regulatory approval for or successfully commercialize our drug candidates~~operations.

32Agreements ~~Table~~with clinical investigators and medical institutions for clinical testing and with other third parties for data management services place substantial responsibilities on these parties, which could result in delays in, or termination of, ~~Contents~~our clinical trials if these parties fail to perform as expected. For example, if any of our clinical trial sites fail to comply with FDA-approved good clinical practices, we may be unable to use the data gathered at those sites. If these clinical investigators, medical institutions or other third parties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approval for or successfully commercialize our drug candidate.

We or regulators may suspend or terminate our clinical trials for a number of reasons. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the patients enrolled in our clinical trials. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the patients enrolled in our clinical trials. In addition, clinical trials may have independent monitoring boards composed of experts in the field. These boards may also have the authority to suspend or terminate clinical trials.

Our clinical trial operations are and will be subject to regulatory inspections at any time. If regulatory inspectors conclude that we or our clinical trial sites are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observations or warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deem our responses to be inadequate, or are dissatisfied with the corrective actions that we or our clinical trial sites have implemented, our clinical trials may be temporarily or permanently discontinued, we may be fined, we or our investigators may be precluded from conducting any ongoing or any future clinical trials, the government may refuse to approve our marketing applications or allow us to manufacture or market our drug ~~candidates~~candidate or we may be criminally prosecuted. If we are unable to complete clinical trials and have our products approved due to our failure to comply with regulatory requirements, we will be unable to commence revenue-generating operations, which could force us to cease operations.

Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.

Delays in the commencement or completion of clinical testing of our products or products could significantly affect our product development costs and our ability to generate revenue. We do not know whether the FDA will agree with the trial designs for ~~ongoing~~future ~~and planned~~ clinical trials or whether ~~planned~~future clinical trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to our ability to do the following:

•· provide sufficient safety, efficacy or other data regarding a drug candidate to support the commencement of a Phase 3 or other clinical trial; •· reach agreement on acceptable terms with prospective contract manufacturers, contract research organizations (CROs) and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different third parties; •· select CROs, trial sites and, where necessary, contract manufacturers that do not encounter any regulatory compliance problems; •· manufacture sufficient quantities of a product candidate for use in clinical trials; •· obtain IRB approval to conduct a clinical trial at a prospective site; •· recruit and enroll patients to participate in clinical trials, which can be impacted by many factors outside our or our contracted parties’ control, including competition from other clinical trial programs for the same or similar indications; and •· retain patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues.

3322 Table of Contents

Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us or our partner, the FDA, an IRB, a clinical trial site with respect to that site, or other regulatory authorities due to a number of factors, including:

•· failure to conduct the clinical trial in accordance with regulatory requirements, including GCP, or our protocol; •· inspection of the clinical trial operations, trial sites or manufacturing facility by the FDA or other regulatory authorities resulting in findings of non-compliance and the imposition of a clinical hold; •· unforeseen safety issues or results that do not demonstrate efficacy; and •· lack of adequate funding to continue the clinical trial.

Additionally, we may need to amend clinical trial protocols for a variety of reasons, including changes in regulatory requirements and guidance. Such amendments may require us to, for example, resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. We may decide to terminate a clinical study for commercial reasons including increased market availability of generic treatments. If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our product candidates may be harmed and our ability to generate product revenues will be delayed and/or reduced. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.

We must comply with significant and complex government regulations, compliance with which may delay or prevent the commercialization of our drug ~~candidates~~candidate, which could have a materially adverse effect on our business.

The Research and Development (R&D), manufacture and marketing of drug candidates are subject to regulation, primarily by the FDA in the United States, and by comparable authorities in other countries. These national agencies and other federal, state, local and foreign entities regulate, among other things, R&D activities (including testing in animals and in humans) and the testing, manufacturing, handling, labeling, storage, record keeping, approval, advertising and promotion of the products that we are developing. Noncompliance with applicable requirements can result in various adverse consequences, including approval delays or refusals to approve drug licenses or other applications, suspension or termination of clinical investigations, revocation of approvals previously granted, fines, criminal prosecution, recalls or seizures of products, injunctions against shipping drugs and total or partial suspension of production and/or refusal to allow a company to enter into governmental supply contracts.

The process of obtaining FDA approval for a drug has historically been costly and time consuming. Current FDA requirements for a new human drug or biological product to be marketed in the United States include: (i) the successful conclusion of pre-clinical laboratory and animal tests, if appropriate, to gain preliminary information on the product’s safety; (ii) filing with the FDA of an IND application to conduct human clinical trials for drugs or biologics; (iii) the successful completion of adequate and well-controlled human clinical investigations to establish the safety and efficacy of the product for its recommended use; and (iv) filing by a company and acceptance and approval by the FDA of a New Drug Application (“NDA”), for a drug product or a biological license application (“BLA”), for a biological product to allow commercial distribution of the drug or biologic. A delay in one or more of the procedural steps outlined above could be harmful to the Company in terms of getting our drug candidates through clinical testing and to market.

34 Table of Contents

The FDA reviews the results of the clinical trials and may order the temporary or permanent discontinuation of clinical trials at any time if it believes the drug candidate exposes clinical subjects to an unacceptable health risk. Investigational drugs used in clinical studies must be produced in compliance with cGMP rules pursuant to FDA regulations.

Sales outside the United States of products that we may develop will also be subject to additional regulatory requirements governing human clinical trials and marketing for drugs and biological products and devices. The requirements vary widely from country to country, but typically the registration and approval process takes several years and requires significant resources.

Table of Contents

We also are subject to the following risks and obligations, related to the approval of our products:

•· The FDA or foreign regulators may interpret data from pre-clinical testing and clinical trials in different ways than we interpret them. •· If regulatory approval of a product is granted, the approval may be limited to specific indications or limited with respect to its distribution. In addition, many foreign countries control pricing and coverage under their respective national social security systems. •· The FDA or foreign regulators may not approve our manufacturing processes or manufacturing facilities. •· The FDA or foreign regulators may change their approval policies or adopt new regulations. •· Even if regulatory approval for any of our product is obtained, the corresponding marketing license will be subject to continual review, and newly discovered or developed safety or effectiveness data may result in suspension or revocation of the marketing license. •· If regulatory approval of the product candidate is granted, the marketing of that product would be subject to adverse event reporting requirements and a general prohibition against promoting products for unapproved uses. •· In some foreign countries, we may be subject to official release requirements that require each batch of the product we produce to be officially released by regulatory authorities prior to its distribution by us. •· We will be subject to continual regulatory review and periodic inspection and approval of manufacturing modifications, including compliance with cGMP regulations.

If we do not have the requisite resources to comply with all applicable regulations, then we could be forced to cease operations, which could cause you to lose all of your investment.

We or third-party manufacturers we rely on may encounter failures or difficulties in manufacturing or formulating clinical development and commercial supplies of drugs, which could delay the clinical development or regulatory approval of our drug candidates, or their ultimate commercial production if approved.

Currently, third parties manufacture our drug candidates on our behalf. Third-party manufacturers may lack capacity to meet our needs, go out of business or fail to perform. In addition, supplies of raw materials needed for manufacturing or formulation of clinical supplies may not be available or in short supply. Furthermore, should we obtain FDA or EMA approval for any of our drug candidates, we expect to rely, at least to some extent, on third-party manufacturers for commercial production. Our dependence on others for the manufacture of our drug candidates may adversely affect our ability to develop and deliver such drug candidates on a timely and competitive basis.

35The ~~Table~~most recent manufacturing campaign activities for production of ~~Contents~~Brilacidin drug substance are ongoing; the process conducted at scale has encountered delays at the third party manufacturing facility with cost overruns. There is no assurance the drug substance from this campaign will meet specifications or be received timely.

WeAny ~~have~~performance ~~ordered~~failure ~~Brilacidin~~on ~~API~~the ~~(active~~part ~~pharmaceutical~~of ~~ingredient)~~a ~~for~~third-party ~~delivery~~manufacturer incould ~~January~~delay ~~2022~~clinical development, ~~for~~regulatory ~~use~~approval inor, ultimately, sales of our ~~planned~~drug ~~oral~~candidate. ~~mucositis~~Our ~~Phase~~third-party 3manufacturers ~~clinical~~may ~~study.~~encounter ~~There~~difficulties isinvolving noproduction yields, regulatory compliance, lot release, quality control and quality assurance, ~~the~~as ~~order~~well ~~will~~as shortages of qualified personnel. Approval of our drug candidate could be ~~manufactured~~delayed, limited or ~~received~~denied ~~timely~~if the FDA does not approve our or a third-party manufacturer’s processes or facilities. WeMoreover, ~~have~~the ~~encountered~~ability ~~prior~~to ~~delays~~adequately and ~~cost~~timely ~~overruns~~manufacture inand ~~ordering~~supply a drug candidate is dependent on the ~~production~~uninterrupted and efficient operation of ~~Brilacidin~~the ~~API.~~manufacturing facilities, which is impacted by many manufacturing variables including:

~~Any~~· ~~performance~~availability ~~failure on the part of a third-party manufacturer could delay clinical development, regulatory approval~~ or, ~~ultimately,~~contamination ~~sales~~ of ~~our~~raw ~~drug~~materials ~~candidates.~~and ~~Our~~components ~~third-party~~used ~~manufacturers~~in ~~may~~the ~~encounter~~manufacturing ~~difficulties involving production yields~~process, ~~regulatory~~particularly ~~compliance,~~those ~~lot~~for ~~release,~~which ~~quality~~we ~~control~~have ~~and~~no ~~quality~~other ~~assurance,~~source asor ~~well~~supplier; as· ~~shortages~~capacity of ~~qualified~~our ~~personnel.~~facilities ~~Approval~~or those of our ~~drug~~contract ~~candidates~~manufacturers; ~~could~~· befacility ~~delayed,~~contamination ~~limited~~by ormicroorganisms ~~denied if the FDA does not approve our~~ or aviruses ~~third-party manufacturer’s processes~~ or ~~facilities.~~cross Moreover, the ability to adequately and timely manufacture and supply drug candidates is dependent on the uninterrupted and efficient operation of the manufacturing facilities, which is impacted by many manufacturing variables including:contamination;

•24 ~~availability~~Table ~~or contamination~~ of raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier; • capacity of our facilities or those of our contract manufacturers; • facility contamination by microorganisms or viruses or cross contamination; • compliance with regulatory requirements, including Form 483 notices and Warning Letters; • changes in forecasts of future demand; • timing and actual number of production runs; • production success rates and bulk drug yields; and • timing and outcome of product quality testing.Contents

In· ~~addition,~~compliance ~~our~~with ~~third-party~~regulatory ~~manufacturers may encounter delays and problems in manufacturing our drug candidates or drugs for a variety of reasons~~requirements, including ~~accidents~~Form ~~during~~483 ~~operation,~~notices ~~failure~~and ofWarning ~~equipment,~~Letters; ~~delays~~· ~~in receiving materials, natural or other disasters, political or governmental~~ changes, ~~or other factors inherent~~ in ~~operating~~forecasts ~~complex~~of ~~manufacturing~~future ~~facilities.~~demand; ~~Supply~~· ~~chain~~timing ~~management is complex,~~ and ~~involves~~actual ~~sourcing from a~~ number of ~~different~~production ~~companies~~runs; ~~and~~· ~~foreign~~production ~~countries.~~success ~~Commercially~~rates ~~available starting materials, reagents~~ and ~~excipients~~bulk ~~may~~drug ~~become~~yields; ~~scarce or more expensive to procure,~~ and we· ~~may~~timing not be able to obtain favorable terms in agreements with contractors or subcontractors. Our third-party manufacturers may not be able to operate their respective manufacturing facilities in a cost-effective manner or in a time frame that is consistent with our expected future manufacturing needs. If we or our third-party manufacturers cease or interrupt production or if our third-party manufacturers and ~~other~~outcome ~~service~~of ~~providers~~product ~~fail~~quality to supply materials, products or services to us for any reason, such interruption could delay progress on our programs, or interrupt the commercial supply, with the potential for additional costs and lost revenuestesting. ~~If this were to occur, we may also need to seek alternative means to fulfill our manufacturing needs.~~

WeIn addition, our third-party manufacturers may ~~not~~encounter bedelays ~~able~~and toproblems ~~enter~~in ~~into~~manufacturing ~~agreements~~our drug candidate or drug for ~~the~~a ~~manufacture~~variety of ~~our~~reasons, ~~drug~~including ~~candidates~~accidents ~~with~~during ~~manufacturers~~operation, ~~whose~~failure ~~facilities~~of ~~and~~equipment, ~~procedures~~delays ~~comply~~in ~~with~~receiving ~~applicable~~materials, ~~law.~~natural ~~Manufacturers~~or ~~are~~other ~~subject~~disasters, topolitical ~~ongoing~~or ~~periodic~~governmental ~~unannounced~~changes, ~~inspection~~or byother ~~the~~factors ~~FDA~~inherent in operating complex manufacturing facilities. Supply chain management is complex, and ~~corresponding~~involves ~~state~~sourcing from a number of different companies and foreign ~~authorities~~countries. toCommercially ~~ensure~~available ~~strict~~starting ~~compliance~~materials, ~~with~~reagents ~~cGMP~~ and ~~other~~excipients ~~applicable~~may ~~government~~become ~~regulations~~scarce or more expensive to procure, and ~~corresponding~~we ~~foreign~~may ~~standards~~not be able to obtain favorable terms in agreements with contractors or subcontractors. WeOur dothird-party manufacturers may not ~~have~~be ~~control~~able ~~over~~to operate their respective manufacturing facilities in a ~~third~~cost-~~party~~effective ~~manufacturer’s~~manner ~~compliance~~or ~~with~~in ~~these~~a ~~regulations~~time ~~and~~frame ~~standards.~~that Ifis ~~one~~consistent ofwith our ~~manufacturers~~expected ~~fails~~future tomanufacturing ~~maintain~~needs. ~~compliance,~~If we or ~~they~~our ~~could~~third-party bemanufacturers ~~subject~~cease toor ~~enforcement,~~interrupt ~~the~~ production ofor if our ~~drug~~third-party ~~candidates~~manufacturers ~~could~~and beother ~~interrupted~~service orproviders ~~suspended~~fail to supply materials, ~~and/~~products or ~~our~~services ~~product~~to ~~could~~us befor ~~recalled~~any ~~or withdrawn~~reason, ~~among~~such ~~other~~interruption ~~consequences.~~could ~~Any~~delay ofprogress ~~these~~on ~~events~~our ~~could~~programs, ~~result~~or ininterrupt ~~delays~~the commercial supply, with the potential for additional costs and ~~potentially~~ lost revenues. If this were to occur, we may also need to seek alternative means to fulfill our manufacturing needs.

36We ~~Table~~may not be able to enter into agreements for the manufacture of ~~Contents~~our drug candidate with manufacturers whose facilities and procedures comply with applicable law. Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer’s compliance with these regulations and standards. If one of our manufacturers fails to maintain compliance, we or they could be subject to enforcement, the production of our drug candidates could be interrupted or suspended, and/or our product could be recalled or withdrawn, among other consequences. Any of these events could result in delays, additional costs and potentially lost revenues.

We can provide no assurance that our drug ~~candidates~~candidate will obtain regulatory approval or that the results of clinical studies will be favorable, and if we fail to obtain such approval or if clinical studies are not favorable, we could be forced to cease operations.

Our drug ~~candidates~~candidate Brilacidin ~~and Kevetrin~~ will require lengthy and costly studies in humans to obtain approval from the FDA before ~~they~~it can be marketed. We cannot predict with any certainty that the study results will be satisfactory to the FDA for approval to ultimately be granted. Preclinical and clinical trials may reveal that one or more products are ineffective or unsafe, in which event further development of such products could be seriously delayed or terminated.

Approval of a drug candidate as safe and effective for use in humans is never certain and regulatory agencies may delay or deny approval of drug candidates for commercialization. For example, even though our product candidate Brilacidin has received QIDP designation, such designation may not result in a faster development process, review, or approval than drugs considered for approval under conventional FDA procedures; nor does such designation assure ultimate approval by the FDA or related exclusivity benefits. Regulatory agencies also may delay or deny approval based on additional government regulation or administrative action, changes in regulatory policy during the period of clinical trials in humans and regulatory review, or the availability of alternative treatments.

Delays in obtaining, or failure to obtain, FDA or any other necessary regulatory approvals of any proposed drugs would have an adverse effect on the drug’s potential commercial success and on our business, prospects, financial condition and results of operations. In addition, it is possible that a proposed drug may be found to be ineffective or unsafe due to conditions or facts that arise after development has been completed and regulatory approvals have been obtained. In this event, we may be required to withdraw such drug from the market. To the extent that our success will depend on any regulatory approvals from government authorities outside of the United States that perform roles similar to that of the FDA, uncertainties similar to those stated above will also exist.

~~Even~~25 ifTable we obtain regulatory approvals, our marketed drug candidates will be subject to ongoing regulation. If we fail to comply with U.S. and foreign regulations, we could be subject to adverse consequences, including loss of ~~our approvals to market these drugs, and our business would be seriously harmed.~~ Contents

~~Following~~Even ~~any~~if ~~initial regulatory approval of any of our drug candidates,~~ we ~~will~~obtain ~~also~~regulatory ~~be subject to continuing regulation of the manufacture~~approvals, labeling, storage, recordkeeping, reporting, distribution, advertising, promotion, marketing, sale, import, and export of those drugs. Such regulation includes review of adverse experiences and the results of any clinical trials completed after our ~~drug~~marketed ~~candidates are made commercially available, including any post marketing requirements that were required as a condition of approval. The contract manufacturers that make any of our~~ drug ~~candidates~~candidate will ~~also~~ be subject to ~~periodic~~ongoing ~~review and inspection by the FDA~~regulation. If ~~our~~we ~~products, if approved, or the manufacturing facilities for our products~~ fail to comply with ~~applicable~~U.S. ~~regulatory~~and ~~requirements~~foreign regulations, awe ~~regulatory~~could ~~agency~~be ~~may~~subject ~~suspend any ongoing clinical trials; issue warning letters or untitled letters; suspend or withdraw regulatory approval; refuse~~ to ~~approve~~adverse ~~pending applications or supplements to applications; suspend or impose restrictions on operations; seize or detain products~~consequences, ~~prohibit~~including ~~the~~loss ~~export or import~~ of ~~products,~~our orapprovals ~~require us~~ to ~~initiate~~market athe ~~product recall; or seek other monetary or injunctive remedies~~drug, ~~or impose civil or criminal penalties. We do not have,~~ and ~~currently do not intend to develop, the ability to manufacture material for~~ our ~~clinical~~business ~~trials or on a commercial scale. Reliance on third-party manufacturers entails risks to which we~~ would ~~not~~ be ~~subject~~seriously ~~if we manufactured drugs ourselves, including reliance on the third-party manufacturer for regulatory compliance~~harmed.

37Following ~~Table~~any initial regulatory approval of ~~Contents~~our drug candidate, we will also be subject to continuing regulation of the manufacture, labeling, storage, recordkeeping, reporting, distribution, advertising, promotion, marketing, sale, import, and export of those drugs. Such regulation includes review of adverse experiences and the results of any clinical trials completed after our drug candidate is made commercially available, including any post marketing requirements that were required as a condition of approval. The contract manufacturers that make our drug candidate will also be subject to periodic review and inspection by the FDA. If our products, if approved, or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may suspend any ongoing clinical trials; issue warning letters or untitled letters; suspend or withdraw regulatory approval; refuse to approve pending applications or supplements to applications; suspend or impose restrictions on operations; seize or detain products, prohibit the export or import of products, or require us to initiate a product recall; or seek other monetary or injunctive remedies, or impose civil or criminal penalties. We do not have, and currently do not intend to develop, the ability to manufacture material for our clinical trials or on a commercial scale. Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the drug ourselves, including reliance on the third-party manufacturer for regulatory compliance.

Our drug promotion and advertising also would be subject to regulatory requirements and continuing FDA review. Our marketing of ~~these~~a ~~drugs~~drug also may be heavily scrutinized by the Department of Justice, the Department of Health and Human Services’ Office of Inspector General, state attorneys general, members of Congress and the public. Our promotional activities will be regulated not only by the FDCA and FDA regulations, but also by federal and state laws pertaining to health care “fraud and abuse,” such as:

•· the federal anti-kickback law prohibiting bribes, kickbacks or other remuneration for the order, purchase or recommendation of items or services reimbursed by federal health care programs; •· the federal False Claims Act, imposing criminal and civil penalties for knowingly presenting or causing to be presented claims to the federal government that are false or fraudulent; and •· the federal Physician Payment Sunshine Act, requiring pharmaceutical manufacturers to engage in extensive tracking of physician and teaching hospital payments, maintenance of a payments database and public reporting of the payment data.

Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of fraud and abuse laws can result in costly litigation, fines and/or imprisonment, exclusion from participation in federal health care programs, and burdensome reporting and compliance obligations.

Compliance with ongoing regulation consumes substantial financial and management resources and may expose us to the potential for other adverse circumstances. For example, approval for a drug may be conditioned on costly post-marketing follow-up studies. Based on these studies, if a regulatory authority does not believe that the drug demonstrates an appropriate benefit-risk profile to patients, it could limit the indications for which a drug may be sold or revoke the drug’s marketing approval. In addition, identification of certain side effects after a drug is on the market may result in the subsequent withdrawal of approval, reformulation of a drug, additional preclinical and clinical trials, changes in labeling or distribution. Alternatively, we may be required by the FDA to develop and implement a REMS to ensure the safe use of our products. REMS may include costly risk management measures such as enhanced safety surveillance, restricted distribution and use, patient education, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials and restrictions on direct-to-consumer advertising. Any of these events could delay or prevent us from generating revenue, or limit the revenue, from the commercialization of ~~these~~a ~~drugs~~drug and/or cause us to incur significant additional costs.

Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. If we are required to withdraw all or ~~more~~most of our ~~drugs~~drug from the market as a result of actions or inactions on our part or that of a third party, we may be unable to continue revenue-generating operations, which could cause you to lose all of your investment.

Table of Contents

All of our Polymedix drug product candidates are licensed from or based upon licenses from the University of Pennsylvania. Upon our purchase of the Polymedix Assets we assumed all contractual rights and obligations of the licenses. If any of these license agreements are terminated, our ability to advance our Polymedix product candidates or develop new product candidates will be materially adversely affected which could have a materially adverse effect on our business.

We now depend, and will continue to depend, on our Polymedix licenses and potentially on other licensing arrangements and/or strategic relationships with third parties for the research, development, manufacturing and commercialization of our Polymedix product candidates. If any of our licenses or relationships are terminated or breached, we may:

•· lose our rights to develop and market our Polymedix product candidates; •· lose patent and/or trade secret protection for our Polymedix product candidates; •· experience significant delays in the development or commercialization of our Polymedix product candidates; •· not be able to obtain any other licenses on acceptable terms, if at all; and/or •· incur liability for damages.

If we experience any of the foregoing, it could have a materially adverse effect on our business and could force us to cease operations which could cause you to lose all of your investment.

38 Table of Contents

We or our third-party manufacturers may fail to comply with manufacturing regulations.

All facilities and manufacturing processes used in the production of active pharmaceutical ingredient, or API, and drug products for clinical use in the U.S. must be operated in conformity with cGMP as established by the FDA. Similar requirements in other countries exist for manufacture of drug products for clinical use. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Before we can commercialize a drug, we must obtain regulatory approval of our cGMP manufacturing facility and process, if any, or the cGMP manufacturing facility and process of the third party or parties with whom we may outsource our manufacturing activities.

In connection with any application for commercial approval, and if any drug candidate is approved by the FDA or other regulatory agencies for commercial sale, a significant scale-up in manufacturing may require additional validation studies. If we are unable to successfully increase the manufacturing capacity for a drug candidate, the regulatory approval or commercial launch of that drug candidate may be delayed, or there may be a shortage of supply, which could limit our ability to develop or commercialize the drug.

Our manufacturing facilities, if any in the future, and the manufacturing facilities of our third-party manufacturers will be subject to inspection by the FDA and other state, local and foreign regulatory authorities, before and after product approval. We cannot guarantee that we, or any potential third-party manufacturer of our products, will be able to comply with the cGMP regulations or other applicable manufacturing regulations.

Failure on our or our third party manufacturers’ part to comply with applicable regulations and specific requirements or specifications of other countries could result in the termination of ongoing research, disqualification of data for submission to regulatory authorities, delays or denials of new product approvals, warning letters, fines, consent decrees restricting or suspending manufacturing operations, injunctions, civil penalties, recall or seizure of products and criminal prosecution. Any of these consequences could have a materially adverse effect on our business.

Controls we or our third-party service providers have in place to ensure compliance with laws may not be effective to ensure compliance with all applicable laws and regulations.

The development of our investigational products and our general operations are subject to extensive regulation in the U.S. and in foreign countries. Although we have developed and instituted controls to comply with applicable regulatory requirements, we cannot assure you that we, our employees, our consultants or our contractors will operate at all times in full compliance with all potentially applicable U.S. federal and state regulations and/or laws or all potentially applicable foreign law and/or regulations. Further, we have a limited ability to monitor and control the activities of third-party service providers, suppliers and manufacturers to ensure compliance by such parties with all applicable regulations and/or laws. We may be subject to direct liabilities or be required to indemnify such parties against certain liabilities arising out of any failure by them to comply with such regulations and/or laws. If we or our employees, consultants or contractors fail to comply with any of these regulations and/or laws a range of consequences could result, including, but not limited to, the termination of clinical trials, the failure to obtain approval of a product candidate, restrictions on our products or manufacturing processes, withdrawal of our products from the market, significant fines, exclusion from government healthcare programs or other sanctions or litigation that could adversely affect our results of operations.

3927 Table of Contents

The Company is exposed to product liability, clinical and preclinical liability risks which could place a substantial financial burden upon the Company should it be sued.

The Company could be exposed to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of pharmaceutical products. In addition, the use in the Company’s clinical trials of its investigational products and the potential subsequent sale of these products by the Company or its potential collaborators may cause the Company to bear some or all of the associated product liability risks. A successful liability claim or series of claims brought against the Company could have a material adverse effect on its business, financial condition and results of operations.

The Company has $5,000,000 per occurrence / $10,000,000 in aggregate in liability insurance for our clinical trials. The Company cannot assure that such insurance will provide adequate coverage against the Company’s potential liabilities. Claims or losses in excess of any product liability insurance coverage obtained by the Company could have a material adverse effect on our business, financial condition and results of operations.

Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information. Disclosure of our trade secrets or proprietary information could compromise any competitive advantage that we have, which could have a materially adverse effect on our business.

We depend upon confidentiality and non-use agreements with our officers, employees, consultants, and subcontractors to maintain the proprietary nature of the technology. These measures may not afford us sufficient or complete protection, and may not afford an adequate remedy in the event of an unauthorized disclosure of confidential information. In addition, others may independently develop technology similar to ours, otherwise avoiding the confidentiality agreements, or produce patents that would materially and adversely affect our business, prospects, financial condition, and results of operations.

We may be unable to obtain or protect intellectual property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others, which could have a materially adverse effect on our business.

Our ability to compete effectively will depend on our ability to maintain the proprietary nature of our compounds and the proprietary compounds of others with which we have entered into licensing agreements. We have filed patent applications and expect to file a number of additional patent applications in the coming years. There can be no assurance that any of these patent applications will ultimately result in the issuance of a patent with respect to the proprietary compounds owned by us or licensed to us. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the United States Patent and Trademark Office use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents issued to us or to others. Further, we rely on a combination of trade secrets, know-how, technology and nondisclosure, and other contractual agreements and technical measures to protect our rights in the proprietary compounds. If any trade secret, know-how or other proprietary information and/or compounds not protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.

40We ~~Table~~do not believe that the compounds we are currently developing infringe upon the rights of ~~Contents~~any third parties nor are they infringed upon by third parties; however, there can be no assurance that our compounds will not be found in the future to infringe upon the rights of others or be infringed upon by others. In such a case, others may assert infringement claims against us, and should we be found to infringe upon their patents, or otherwise impermissibly utilize their intellectual property, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties’ patent rights. In addition to any damages we might have to pay, we may be required to obtain licenses from the holders of this intellectual property, enter into royalty agreements, or redesign our drug candidates so as not to utilize this intellectual property, each of which may prove to be uneconomical or otherwise impossible. Conversely, we may not always be able to successfully pursue our claims against others that infringe upon our proprietary compounds. Thus, the proprietary nature of our technology or technology licensed by us may not provide adequate protection against competitors.

We do not believe that any of the drug candidates we are currently developing infringe upon the rights of any third parties nor are they infringed upon by third parties; however, there can be no assurance that our proprietary compounds will not be found in the future to infringe upon the rights of others or be infringed upon by others. In such a case, others may assert infringement claims against us, and should we be found to infringe upon their patents, or otherwise impermissibly utilize their intellectual property, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties’ patent rights. In addition to any damages we might have to pay, we may be required to obtain licenses from the holders of this intellectual property, enter into royalty agreements, or redesign our drug candidates so as not to utilize this intellectual property, each of which may prove to be uneconomical or otherwise impossible. Conversely, we may not always be able to successfully pursue our claims against others that infringe upon our proprietary compounds. Thus, the proprietary nature of our technology or technology licensed by us may not provide adequate protection against competitors.

Moreover, the cost to us of any litigation or other proceeding relating to our patents and other intellectual property rights, even if resolved in our favor, could be substantial, and the litigation would divert our management’s efforts. Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations.

Our potential collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return, which could have a materially adverse effect on our business.

We may have to rely substantially upon strategic collaborations for ~~marketing and the commercialization of our drug candidates, and we may rely even more on strategic collaborations for~~ R&D, ofmarketing ~~our~~and ~~other drug candidates~~commercialization. Our business will depend on our ability to sell drugs to both government agencies and to the general pharmaceutical market. We may have to sell our drugs through strategic partnerships with other pharmaceutical companies. If we are unable to establish or manage such strategic collaborations on terms favorable to us in the future, our revenue and drug development may be limited. To date, we have not yet ~~marketed~~commercialized ~~or sold~~ any of our drug candidates.

Table of Contents

If we determine to enter into R&D collaborations during the early phases of drug development, our success will in part depend on the performance of our research collaborators. We will not directly control the amount or timing of resources devoted by our research collaborators to activities related to our drug candidates. Our research collaborators may not commit sufficient resources to our programs. If any research collaborator fails to commit sufficient resources, our preclinical or clinical development programs related to this collaboration could be delayed or terminated. Also, our collaborators may pursue existing or other development-stage products or alternative technologies in preference to those being developed in collaboration with us. Finally, if we fail to make required milestone or royalty payments to our collaborators, or to observe other obligations in our agreements with them, our collaborators may have the right to terminate those agreements.

Management of our relationships with our collaborators will require:

•· significant time and effort from our management team; •· coordination of our marketing and R&D programs with the marketing and R&D priorities of our collaborators; and •· effective allocation of our resources to multiple projects.

41 Table of Contents

Establishing strategic collaborations is difficult and time-consuming. Our discussion with potential collaborators may not lead to the establishment of collaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory or intellectual property position. Even if we successfully establish new collaborations, these relationships may never result in the successful development or commercialization of our drug candidates or the generation of sales revenue. To the extent that we enter into collaborative arrangements, our drug revenues are likely to be lower than if we directly marketed and sold any drugs that we may develop.

We may not be able to attract and retain highly skilled personnel or consultants, which could have a materially adverse effect on our business.

Our ability to attract and retain highly skilled personnel or consultants is critical to our operations and expansion. We face competition for these types of personnel from other pharmaceutical companies and more established organizations, many of which have significantly larger operations and greater financial, technical, human and other resources than us. We may not be successful in attracting and retaining qualified personnel or consultants on a timely basis, on competitive terms, or at all. If we are not successful in attracting and retaining these personnel or consultants, our business, prospects, financial condition and results of operations will be materially adversely affected.

We depend upon our senior management and their loss or unavailability could put us at a competitive disadvantage.

We depend upon the efforts and abilities of our senior management team. Leo Ehrlich, the Company’s Chief Executive and Financial Officer presently has no employment agreement with the Company. The loss of a member of the senior management team could have an adverse impact on our business. Competition for senior management is intense, and we may not be successful in attracting and retaining key personnel to replace such loss of a member of the senior management team, the inability of which could have an adverse effect on our business and results of operations.

The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises equipped with more substantial resources than us, which could cause us to cease operations.

The biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition based primarily on scientific and technological factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize technological developments and the ability to obtain government approval for testing, manufacturing and marketing.

We compete with biopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations. Many biopharmaceutical companies have focused their development efforts in the human therapeutics area, including cancer. Many major pharmaceutical companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies. These companies, as well as academic institutions, government agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capital on terms and conditions acceptable to us.

4229 Table of Contents

We are aware of numerous products under development or manufactured by competitors that are used for the prevention or treatment of certain diseases we have targeted for drug development. Various companies are developing biopharmaceutical products that potentially directly compete with our drug ~~candidates~~candidate even though their approach to such treatment is different.

For example, with respect to ~~Kevetrin~~Brilacidin, ~~our~~numerous ~~lead compound in development for treating cancers, there are many~~ drugs approved to treat various cancers and many more in the publicly disclosed pipeline. Our success depends on our ability to identify tumor types where Kevetrin has an advantage over existing therapies and those in the publicly disclosed pipeline. The same is true for our compound, Brilacidin. Numerous drugs are already FDA approved for the treatment of IBD, ABSSSI, and COVID-19. Although there is presently no drug approved for the prevention and treatment of oral mucositis for head and neck cancers, there are numerous clinical trials in progress and Kepivance is approved for limited use in patients with hematologic malignancies.

Our competition will be determined in part by the potential indications for which our investigational ~~drugs~~drug ~~are~~is developed and ultimately approved by regulatory authorities. Additionally, the timing of the market introduction of ~~some of~~ our potential ~~drugs~~drug or of competitors’ products may be an important competitive factor. Accordingly, the relative speed with which we can develop ~~drugs~~a drug; complete pre-clinical testing, clinical trials, and approval processes; and supply commercial quantities to market are likely to be important competitive factors. We expect that competition among drugs approved for sale will be based on various factors, including product efficacy, safety, reliability, availability, price and patent protection.

The successful development of biopharmaceuticals is highly uncertain. A variety of factors, including, but not limited to, unfavorable pre-clinical study results or failure to obtain regulatory approvals, could cause us to abandon development of our drug ~~candidates~~candidate, which could also cause us to cease operations and you may lose your entire investment.

Risks Related to the Securities Markets and Investments in Our Class A Common Stock

The sale of our Class A Common Stock to Aspire Capital may cause substantial dilution to our existing stockholders and the sale of the shares of Class A Common Stock acquired by Aspire Capital could cause the price of our Class A Common Stock to decline, which could have a materially adverse effect on our business.

On July 31, 2020, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 24-month term of the Purchase Agreement. The Company also issued 6,250,000 shares of its Class A Common Stock to Aspire Capital as a commitment fee. The Company has filed a registration statement to register the resale of any shares that Aspire Capital may purchase under the Purchase Agreement. To the extent Aspire Capital purchases shares under the Purchase Agreement and subsequently sells those shares, the other holders of our Class A Common Stock may experience dilution, which may be substantial. In addition, the sale of a substantial number of shares of our Class A Common Stock by Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

In addition to potential dilution associated with future fundraising transactions, we currently have significant numbers of securities outstanding that are exercisable for our common stock, which will result in significant additional dilution and downward pressure on our stock price.

43As ~~Table~~of September 22, 2022, there were 488.2 million shares of ~~Contents~~our Class A common stock outstanding and 15.6 million shares of our Class B common stock outstanding. In addition, as of June 30, 2022, there were outstanding stock options, a convertible note and preferred stock representing the potential issuance of approximately an additional 44.8 million shares of our common stock. The issuance of these shares in the future would result in significant dilution to our current stockholders and could adversely affect the price of our common stock and the terms on which we could raise additional capital. In addition, the issuance and subsequent trading of shares could cause the supply of our common stock available for purchase in the market to exceed the purchase demand for our common stock. Such supply in excess of demand could cause the market price of our common stock to decline.

As of September 22, 2021, there were 437.1 million shares of our Class A common stock outstanding and 15.6 million shares of our Class B common stock outstanding. In addition, as of June 30, 2021, there were outstanding stock options and a convertible note representing the potential issuance of approximately an additional 8.7 million shares of our common stock. The issuance of these shares in the future would result in significant dilution to our current stockholders and could adversely affect the price of our common stock and the terms on which we could raise additional capital. In addition, the issuance and subsequent trading of shares could cause the supply of our common stock available for purchase in the market to exceed the purchase demand for our common stock. Such supply in excess of demand could cause the market price of our common stock to decline.

Because our common stock is quoted on the OTC your ability to sell your shares in the secondary trading market may be limited.

Our Class A Common Stock is currently quoted on the OTC. Consequently, the liquidity of our Class A Common Stock is impaired, not only in the number of shares that are bought and sold, but also through delays in the timing of transactions, and coverage by security analysts and the news media, if any, of our Company. As a result, prices for shares of our Class A Common Stock may be lower than might otherwise prevail if our Class A Common Stock were listed on a national securities exchange.

Table of Contents

Because our Class A Common Stock is considered “penny stock” you may have difficulty selling them in the secondary trading market.

Federal regulations under the Securities Exchange Act of 1934 (the “Exchange Act”) regulate the trading of so-called “penny stocks,” which are generally defined as any security not listed on a national securities exchange, priced at less than $5.00 per share and offered by an issuer with limited net tangible assets and revenues. Since our Class A Common Stock currently is quoted on the OTC at less than $5.00 per share, our shares are “penny stocks” and may not be traded unless a disclosure schedule explaining the penny stock market and the risks associated therewith is delivered to a potential purchaser prior to any trade.

In addition, because our Class A Common Stock is not listed on any national securities exchange and currently is quoted at and trades at less than $5.00 per share, trading in our Class A Common Stock is subject to Rule 15g-9 under the Exchange Act. Under this rule, broker-dealers must take certain steps prior to selling a “penny stock,” which steps include:

	•	obtaining financial and investment information from the investor;

	•	obtaining a written suitability questionnaire and purchase agreement signed by the investor; and

	•	providing the investor a written identification of the shares being offered and the quantity of the shares.

If these penny stock rules are not followed by the broker-dealer, the investor has no obligation to purchase the shares. The application of these comprehensive rules will make it more difficult for broker-dealers to sell our Class A Common Stock and our stockholders, therefore, may have difficulty in selling their shares in the secondary trading market.

Our stock price may be volatile and your investment in our Class A Common Stock could suffer a decline in value.

44As ~~Table~~of June 30, 2022, the last closing price of ~~Contents~~our Class A Common Stock, as quoted on the OTC, was $0.03 per share, and on September 22, 2022, the last closing price was $0.04 per share. The price may fluctuate significantly in response to a number of factors, many of which are beyond our control. These factors include:

As of June 30, 2021, the last closing price of our Class A Common Stock, as quoted on the OTC, was $0.22 per share, and on September 22, 2021, the last closing price was $0.23 per share. The price may fluctuate significantly in response to a number of factors, many of which are beyond our control. These factors include:

	•	progress of our products through the regulatory process;

	•	results of preclinical studies and clinical trials;

	•	announcements of technological innovations or new products by us or our competitors;

	•	government regulatory action affecting our products or our competitors’ products in both the United States and foreign countries;

	•	developments or disputes concerning patent or proprietary rights;

	•	general market conditions for emerging growth and pharmaceutical companies;

	•	economic conditions in the United States or abroad;

	•	actual or anticipated fluctuations in our operating results;

	•	broad market fluctuations; and

	•	changes in financial estimates by securities analysts.

~~Short~~31 ~~sellers~~Table of ~~our stock may be manipulative and may drive down the market price of our common stock.~~Contents

Short selling is the practice of selling securities that the seller does not own but rather has borrowed or intends to borrow from a third party with the intention of buying identical securities at a later date to return to the lender. A short seller hopes to profit from a decline in the value of the securities, as the short seller expects to pay less in the covering purchase than it received in the sale. It is therefore in the short seller’s interest for the price of the stock to decline, and some short sellers publish, or arrange for the publication of, opinions or characterizations regarding the relevant issuer, often involving deliberate misrepresentations of the issuer’s business prospects and similar matters calculated to create negative market momentum. Penny stocks which do not trade on an exchange, such as our common stock, are particularly susceptible to short sales.

As a public entity in a highly digital world, we have been and in the future may be the subject of so-called “fake news,” a type of yellow journalism constructed to look legitimate while consisting of intentional misinformation and misrepresentations deliberately propagated by profiteering short sellers seeking to gain an illegal market advantage by spreading false information concerning the Company’s name, compounds, intellectual property, personnel, and affiliates. In the past, the publication of intentional misinformation concerning the Company by a disclosed short seller has been associated with the selling of shares of our common stock in the market on a large scale, resulting in a precipitous decline in the market price per share of our common stock. In addition, the publication of intentional misinformation may also result in lawsuits, the uncertainty and expense of which could adversely impact our business, financial condition and reputation. While we maintain directors’ and officers’ liability insurance, certain costs, such as those below a retention amount, are not covered by our insurance policies. In addition, our insurance carriers could refuse to cover some or all of these claims in whole or in part.

While utilizing all available tools to defend the Company and its assets against fake news, there is limited regulatory control, making fake news an ongoing concern for any public company. While we move forward in our business development strategies in good faith, there are no assurances that we will not face more fake news or similar tactics by bad actors in the future, and the market price of our common stock may decline as a result of their actions or the action of other short sellers.

45 Table of Contents

Our directors and executive officers own or control a sufficient number of shares of our common stock to control our Company, which could discourage or prevent a takeover, even if an acquisition would be beneficial to our stockholders.

At September 22, ~~2021~~2022, our directors and executive officers beneficially own or control approximately 2725% of the outstanding voting power of our common stock. ~~During the year ended June 30, 2021,~~ Mr. Ehrlich, ~~the~~holds ~~Company’s Chairman and CEO~~15,641,463 ~~purchased all his remaining~~ shares of ~~the~~our Class B common stock, ~~par~~each ~~value~~of ~~$0.0001~~which has ten votes per share., giving Mr. Ehrlich ~~holds~~significantly ~~15,641,463~~greater ~~shares~~voting ofpower ~~our~~than ~~Class~~if Ball ~~common~~of ~~stock~~his ~~after~~shares ~~this~~were ~~exercise~~Class A shares. Accordingly, our directors and executive officers, individually and as a group, may be able to influence the outcome of stockholder votes, involving votes concerning the election of directors, the adoption or amendment of provisions in our Articles of Incorporation and bylaws and the approval of certain mergers or other similar transactions, such as sales of substantially all of our assets. Such control by existing stockholders could have the effect of delaying, deferring or preventing a change in control of our Company.

We do not intend to pay any cash dividends in the foreseeable future and, therefore, any return on your investment in our Class A Common Stock must come from increases in the fair market value and trading price of the Class A Common Stock.

We have not paid any cash dividends on our Class A Common Stock and do not intend to pay cash dividends on our Class A Common Stock in the foreseeable future. We intend to retain future earnings, if any, for reinvestment in the development and expansion of our business. Any credit agreements, which we may enter into with institutional lenders, may restrict our ability to pay dividends. Whether we pay cash dividends in the future will be at the discretion of our board of directors and will be dependent upon our financial condition, results of operations, capital requirements and any other factors that the board of directors decides is relevant. Therefore, any return on your investment in our Class A Common Stock must come from increases in the fair market value and trading price of the Class A Common Stock.

We may issue additional equity shares to fund the Company’s operational requirements which would dilute your share ownership.

The Company’s continued viability depends on its ability to raise capital. Changes in economic, regulatory or competitive conditions may lead to cost increases. Management may also determine that it is in the best interest of the Company to develop new services or products. In any such case additional financing is required for the Company to meet its operational requirements. There can be no assurances that the Company will be able to obtain such financing on terms acceptable to the Company and at times required by the Company, if at all. In such event, the Company may be required to materially alter its business plan or curtail all or a part of its operational plans.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None

ITEM 2. PROPERTIES

Our current Company headquarters is located at 301 Edgewater Place - Suite 100, Wakefield, MA 01880, a suite that maintains our virtual offices, and if needed, the use of physical offices, meeting rooms, and business support services on a fee for use basis. All our employees and consultants work remotely.

ITEM 3. LEGAL PROCEEDINGS

On January 22, 2020, the Company filed a complaint against Cummings Properties, LLC in the Superior Court of the Commonwealth of Massachusetts (C.A. No. 20-77CV00101), seeking, among other things, declaratory relief that the lease for the Company’s prior principal executive offices did not automatically extend for an additional five years from September 2018, return of the Company’s security deposit, and damages. This action is in the preliminary stages and the Company is currently unable to determine the probability of the outcome or reasonably estimate the loss or gain, if any.

The information called for by this item is incorporated herein by reference to the information set forth in Note 810. Commitment and contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.

ITEM 4. MINE SAFETY DISCLOSURES

None

4632 Table of Contents

PART II

The Company’s Class A Common Stock symbol is “IPIX” and is quoted on the OTCQB. Quotations on the OTCQB reflect inter-dealer prices, without retail mark-up, mark-down or commission, and may not represent actual transactions.

Number of Shareholders

As of September 22, ~~2021~~2022, a total of approximately ~~437~~488,~~096~~225,~~222~~673 shares of the Company’s Class A common stock are outstanding and held by approximately 6866 shareholders of record, including Cede & Co., the nominee for the Depository Trust & Clearing Corporation and consequently that number does not include beneficial owners of our common stock who hold their stock in “street name” through their brokers. In addition, as of September 22, 2022, a total of shares of 15,641,463 shares of the Company’s Class B common stock are outstanding and held by one stockholder of record.

Dividends

The Company has not paid any cash dividends to our shareholders since its inception. The Company currently intends to retain any earnings for use in its business, and therefore does not anticipate paying cash dividends to holders of our common stock in the foreseeable future. The accrued dividend aton the balance sheet represents a portion of the unpaid accrued dividend to our Series B 5% convertible preferred stockholders. See Notes 1415 and 1516 of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.

ITEM 6. ~~SELECTED FINANCIAL DATA~~[RESERVED]

Not applicable.

47 Table of Contents

ITEM 7. MANAGEMENT’S DISCUSSION AND FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our expectations related to the progress, continuation, timing and success of drug discovery and development activities conducted by the Company, other statements regarding our future product development and regulatory strategies, including with respect to specific indications ~~such as, among others, COVID-19~~; our ability to obtain additional capital to fund our operations, changes in our research and development spending, realizing new revenue streams and obtaining future out-licensing or collaboration agreements that include up-front, milestone and/or royalty payments, our ability to realize up-front milestone and royalty payments under current and future agreements, future research and development spending and projections relating to the level of cash we expect to use in operations, our working capital requirements and our future headcount requirements. In some cases, forward-looking statements can be identified by the use of terms such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” “will,” or “continue,” or the negative thereof or other comparable terms. These statements are based on current expectations, projections and assumptions made by management and are not guarantees of future performance. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, these expectations or any of the forward-looking statements could prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties including, but not limited to the factors set forth under the heading “Item 1A. Risk Factors” under Part I of this Annual Report on Form 10-K, and in other reports we file with the SEC. All forward-looking statements are made as of the date of this report and, unless required by law, we undertake no obligation to update any forward-looking statements.

Table of Contents

The following discussion of our financial condition and results of operations should be read in conjunction with our accompanying audited financial statements and related notes to those statements included elsewhere in this Annual Report on Form 10-K.

Our fiscal year ends on June 30. When we refer to a fiscal year, we are referring to the year in which the fiscal year ends. Therefore, fiscal ~~2021~~2022 refers to the fiscal year ended June 30, ~~2021~~2022.

Management’s Plan of Operation

The Company ~~devotes~~historically devoted most of its efforts and resources on drug development, regulatory matters, and clinical trials. Presently, ~~our~~the ~~efforts~~Company ~~are~~does ~~primarily~~not ~~focused~~have onsufficient ~~evaluating~~financial ~~our~~resources ~~drug~~to ~~candidate~~advance ~~Brilacidin;~~our asdrug acandidates ~~therapeutic~~meaningfully. ~~for~~Contingent ~~coronaviruses,~~upon ~~particularly~~sufficient ~~SARS-CoV-2~~funding, ~~the~~we ~~novel~~anticipate ~~coronavirus~~that ~~responsible~~our ~~for~~efforts ~~COVID-19;~~would ~~for~~primarily ~~decreasing~~focus ~~the~~on ~~incidence~~advancement of ~~severe~~our ~~oral mucositis as a complication of chemoradiation; for treatment of IBD; and for treatment of skin infections. Our other~~ drug candidate, ~~Kevetrin,~~Brilacidin is for ~~the~~decreasing ~~treatment of cancer. We anticipate using our expertise to manage and perform what we believe are~~ the ~~most~~incidence ~~critical aspects~~ of ~~the~~severe ~~product~~oral ~~development~~mucositis ~~process,~~as ~~which~~a ~~include:~~complication ~~(i) design and oversight~~ of ~~clinical~~chemoradiation ~~trials;~~in ~~(ii)~~Oral ~~development and execution of strategies for the protection and maintenance of intellectual property rights; and (iii) interactions with regulatory authorities domestically and internationally~~Mucositis. We expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.

48In ~~Table~~the ordinary course of ~~Contents~~business, we engage in a continual review of opportunities to license our drug compound(s)/ indications and enter into partnering, joint development or similar arrangements with other companies. We may generally at any time have such opportunities in various stages of active review, including, for example, entry into indications of interest and term sheets and participation in preliminary discussions and negotiations. Any such transaction could be material to us.

InThe ~~the~~Company ~~ordinary~~is ~~course~~monitoring ofBeaMedical’s ~~business,~~progress ~~we engage~~ in aadvancing ~~continual~~its ~~review~~novel oflaser-based ~~opportunities~~thermal toablation ~~license~~technology ~~our~~platform ~~drug~~targeting ~~compounds~~epilepsy and ~~enter~~oncology ~~into partnering~~procedures, ~~joint development or similar arrangements with other companies. We currently,~~ and ~~generally~~we ~~at any time,~~ have ~~such~~been ~~opportunities~~informed inthat ~~various~~BeaMedical’s ~~stages~~first ofFDA-related ~~active~~development ~~review,~~milestone ~~including,~~via ~~for~~the ~~example,~~510(k) ~~entry~~pathway ~~into~~is ~~indications~~anticipated ofto ~~interest~~occur ~~and~~within ~~term~~the ~~sheets and participation in preliminary discussions and negotiations~~year. ~~Any such transaction could be material to us.~~

As a result of the advent of the COVID-19 pandemic, we were approached by several organizations, including two academic institutions having Biosafety Level 3 Laboratories (BSL-3), interested in evaluating Brilacidin as an experimental new drug for COVID-19 and its underlying coronavirus (SARS-CoV-2). Early research indicated that Brilacidin was a promising therapeutic candidate and subsequent extensive pre-clinical research in multiple human cell lines have lent further evidence and support for continued research into Brilacidin’s antiviral properties. Brilacidin has shown consistent in vitro inhibition in a cell-type independent manner in different strains of coronaviruses, alphaviruses and bunyaviruses. In light of the ongoing pandemic and drug development environment, we have prioritized development of Brilacidin for COVID-19, including the conduct of a Phase 2 randomized, blinded, placebo-controlled clinical trial of Brilacidin in patients hospitalized with moderate-to-severe COVID-19. The trial has fully enrolled, with the Company preparing for study unblinding, statistical analysis and reporting of data.

Brilacidin formulation development work is in progress: For treating ulcerative colitis, we are engaged in the development of an oral formulation (i.e. capsule or tablet). For treating oral mucositis we are engaged in optimizing an oral rinse formulation for the treatment of severe oral mucositis.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of financial condition and results of operations are based upon our accompanying financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Note 3. Significant Accounting Policies and Recent Accounting Pronouncements, to the financial statements included in Part II, Item 8 of this Annual Report on Form 10-K, describes the significant accounting policies and methods used in the preparation of the Company’s financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.

Recently Issued Accounting Pronouncements

See Note 3. Significant Accounting Policies and Recent Accounting Pronouncements to the consolidated financial statements, included in Part II, Item 8 of this Annual Report on Form 10-K, for a discussion of recent accounting pronouncements and their effect, if any, on our financial statements.

Results of Operations

We expect to incur losses from operations for the next few years. WeContingent upon sufficient funding, we expect to incur increasing research and development expenses, including expenses related to additional clinical trials for our proprietary programs. We currently anticipate that future budget expenditures will be approximately $104.2 million for the next 12 months, including approximately $82.2 million for ~~clinical~~development activities, supportive research, and drug ~~product~~manufacturing. However, continuing operations for the next 12 months from the date of this filing is very much dependent upon our ability to raise ~~equity~~capital from existing or new financing sources. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

4934 Table of Contents

Revenue

We generated revenue of $018,000 and $0.4 ~~million~~ for the fiscal years ended June 30, ~~2021~~2022 and ~~2020~~2021, respectively. Revenue during the fiscal ~~years~~year ended June 30, ~~2020~~2022 represented the ~~initial non-refundable~~ payment from the exclusive license agreement signed with Alfasigma (see Note 78. Exclusive License Agreement and Patent Assignment Agreement of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K).

We incurred operating expenses of approximately $96.09 million and $59.10 million for the fiscal years ended June 30, ~~2021~~2022 and ~~2020~~2021, respectively.

Research and Development Expenses for Proprietary Programs

Below is a summary of our research and development expenses for our proprietary programs by categories of costs for the fiscal years presented (rounded to nearest thousand):

	Year ended				Change
	June 30,				~~2021~~2022 Vsvs. ~~2020~~2021
	2021		2020		$			%
	2022		2021		$			%
Clinical studies and development research	$	63,~~056~~631,000	$	16,~~616~~056,000		4(2,~~440~~425,000	)		~~275~~(40	)%
Officers’ payroll and payroll tax expenses related to R&D department		—		232,000		(232,000	)		(100	)%
Employees payroll and payroll tax expenses related to R&D department		641,000		398,000		243,000			61	%
Employees payroll and payroll tax expenses related to R&D department		398,000		382,000		16,000			4	%
Stock-based compensation - employee		100,000		59,000		41,000			69	%
Stock-based compensation – officer		—		47,000		(47,000	)		(100	)%
Stock-based compensation - consultants		60,000		125,000		(65,000	)		(52	)%
Stock-based compensation – employee		59,000		104,000		(45,000	)		(43	)%
Depreciation and amortization expenses		382,000		378,000		4,000			1	%
Stock-based compensation – consultants		125,000		38,000		87,000			229	%
Total	$	4,814,000	$	7,016,000		(2,202,000	)		(31	)%
Depreciation and amortization expenses		378,000		373,000		5,000			1	%
Total	$	7,016,000	$	2,792,000		4,224,000			151	%

Fiscal ~~2021~~2022 compared to Fiscal ~~2020~~2021 –- Research and development expenses for proprietary programs ~~increased~~decreased during the year ended June 30, ~~2021~~2022 compared with the year ended June 30, ~~2020~~2021, primarily due to ~~more~~less spending on our Brilacidin program for the fiscal year ~~2021~~2022.

~~Officers’~~Employees payroll ~~decreased~~and payroll tax expenses increased during the year ended June 30, ~~2021~~2022 ~~because~~compared with the ~~Company’s~~year ~~President~~ended ~~and~~June ~~Chief~~30, ~~Medical~~2021, ~~Officer~~due ~~resigned~~to ona ~~December~~new ~~19,~~hire ~~2019~~of an employee during the first quarter of fiscal 2022.

~~Employees~~Stock-based ~~payroll~~compensation ~~and~~for ~~payroll~~employees ~~tax expenses~~ increased during the year ended June 30, ~~2021~~2022 ~~compared~~due ~~with~~to ~~the~~one ~~year~~new ~~ended~~issuance ~~June~~of 30500,000 ~~2020,~~stock ~~due~~options to ~~more~~purchase ~~employees~~shares ~~engaged~~of Company’s common stock to the Company’s Senior Vice President, Clinical Sciences and Portfolio Management in ~~preclinical~~October, ~~development~~2021 ~~after~~(see ~~June~~note 3014. Equity Incentive Plans, ~~2020~~Stock-Based Compensation, ~~which~~Exercise ~~led~~of toOptions and Warrants Outstanding of the ~~increase~~Notes to Consolidated Financial Statements included in ~~employees’~~Part ~~payroll~~II, ~~during~~Item ~~the~~8 ~~year~~in ~~ended~~this ~~June~~Annual ~~30,~~Report ~~2021~~on Form 10-K).

Stock-based compensation ~~for~~- ~~employee~~consultants decreased during the year ended June 30, ~~2021~~2022 due to ~~equity-based~~less ~~awards~~options being issued to anconsultants ~~employee in 2016 and in 2017 being fully expensed~~ during the year ended June 30, ~~2020,~~2022 ~~therefore,~~compared ~~less~~with ~~stock-based compensation – employee was incurred during~~ the year ended June 30, 2021.

50Our ~~Table~~research and development expenses include costs related to preclinical and clinical trials, outsourced services and consulting, officers’ payroll and related payroll tax expenses, other wages and related payroll tax expenses, stock-based compensation, depreciation and amortization expenses. Clinical studies and development expenses may decrease in future reporting periods depending on the Company’s current and future financial liquidity. We manage our proprietary programs based on scientific data and achievement of ~~Contents~~research plan goals. Accordingly, the accurate assignment of time and costs to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on an individual program basis.

~~Stock-based~~35 ~~compensation~~Table -of ~~consultants increased during the year ended June 30, 2021 due to more options being issued to consultants during the year ended June 30, 2021 compared with the year ended June 30, 2020.~~Contents

Our research and development expenses include costs related to preclinical and clinical trials, outsourced services and consulting, officers’ payroll and related payroll tax expenses, other wages and related payroll tax expenses, stock-based compensation, depreciation and amortization expenses. Clinical studies and development expenses may increase in future reporting periods depending on the Company’s current and future financial liquidity. We manage our proprietary programs based on scientific data and achievement of research plan goals. Accordingly, the accurate assignment of time and costs to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on an individual program basis.

General and Administrative Expenses

General and administrative expenses consist mainly of compensation and associated fringe benefits not included in the cost of research and development expenses for proprietary programs and include other management, business development, accounting, information technology and administration costs, including patent filing and prosecution, recruiting, consulting and professional services, travel and meals, sales commissions, facilities, depreciation and other office expenses.

Below is a summary of our general and administrative expenses (rounded to nearest thousand):

	Year ended				Change
	June 30,				~~2021~~2022 Vsvs. ~~2020~~2021
	2021		2020		$			%
	2022		2021		$			%
Insurance and health expense	$	~~405~~277,000	$	~~473~~405,000		(68128,000	)		(1432	)%
Directors fee		150,000		50,000		100,000			200	%
Directors’ fees		150,000		150,000		—			-	%
Rent and utility expense		~~100~~74,000		~~133~~100,000		(3326,000	)		(2526	)%
Stock-based compensation – officer & directors		—		237,000		(237,000	)		(100	)%
Stock-based compensation - officers & directors		423,000		—		423,000			-	%
Business development expense		~~141~~29,000		~~377~~141,000		(~~236~~112,000	)		(6379	)%
Other G&A		167,000		159,000		8,000			5	%
Patent write off		141,000		—		141,000			-	%
Total	$	963,000	$	1,429,000		(466,000	)		(33	)%
Other G&A		129,000		167,000		(38,000	)		(23	)%
Total	$	1,223,000	$	963,000		260,000			27	%

Fiscal ~~2021~~2022 compared to Fiscal ~~2020~~2021 - General and administrative expenses ~~decreased~~increased during the ~~fiscal~~year ~~2021~~ended June 30, 2022, primarily due to the ~~decrease~~increase in stock-based compensation - officers & directors of $~~237~~423,000 ~~(see~~and ~~Note~~increase ~~13.~~in ~~Equity~~patent ~~Transactions~~write ofoff ~~the~~relating ~~Notes~~ to ~~Consolidated~~Kevetrin ~~Financial~~of ~~Statements~~$141,000, ~~included~~offset inby ~~Part~~a ~~II,~~decrease ~~Item 8~~ in ~~this~~insurance ~~Annual~~expense ~~Report~~of on$128,000 ~~Form 10-K)~~ and a decrease in ~~business~~other ~~development~~G&A expense of $~~236~~38,000 due to less business development consultants’ fees and business events during ~~fiscal~~the year ended June 30, 2022. Stock-based compensation for officers and directors increased during the year ended June 30, 2022 due to one new issuance of 3 million stock options to purchase shares of the Company’s common stock to the Company’s two independent directors and the CEO in October, 2021 (see note 14. Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K).

Officers’ payroll and payroll tax expenses

Below is a summary of our Officers’ payroll and payroll tax expenses (rounded to nearest thousand):

	Year ended				Change
	June 30,				~~2021~~2022 Vsvs. ~~2020~~2021
	2021		2020		$			%
	2022		2021		$			%
Officers’ payroll and payroll tax expenses	$	~~499~~428,000	$	~~480~~499,000		19(71,000	)		4(14	)%

Fiscal ~~2021~~2022 compared to Fiscal ~~2020~~2021 - ~~There~~The ~~was~~decrease ~~a slight increase~~ in officers’ payroll and payroll tax expenses for the Company during the ~~fiscal~~year ~~2021~~ended June 30, 2022 was due to the ~~increase~~adjustment into officer’s accrued payroll taxes.

51 Table of Contents

Professional fees

Below is a summary of our Professional fees (rounded to nearest thousand):

	Year ended				Change
	June 30,				~~2021~~2022 Vsvs. ~~2020~~2021
	2021		2020		$			%
	2022		2021		$			%
Audit Fee, legal and professional fees	$	~~537~~452,000	$	~~357~~537,000		~~180~~(85,000	)		50(16	)%

~~Fiscal~~36 ~~2021~~Table ~~compared~~of ~~to Fiscal 2020 - Professional fees increased during the fiscal 2021 primarily related to the increases in legal fees and other professional fees in 2021.~~ Contents

Fiscal 2022 compared to Fiscal 2021 - Professional fees decreased during the year ended June 30, 2022, primarily related to fewer transactions in fiscal 2022 compared to the prior year. Professional fees during the year ended June 30, 2021 primarily related to the 2020 Securities Purchase Agreement and issuance of Series B-2 preferred stock.

Other Operating Income and (Loss)

There was an increase in other expense which represents equity in loss from an investment for the period from June 9, 2022 (date of acquisition) to June 30, 2022 was $22,000 (see Note 4. – Equity Investment of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K).

Other Income (Expense)

Below is a summary of our other income (expense) (rounded to nearest thousand):

	Year ended						Change
	June 30,						~~2021~~2022 Vsvs. ~~2020~~2021
	2021			2020			$			%
	2022			2021			$			%
Interest expense – debt	$	(155,000	)	$	(208,000	)		(53,000	)		(25	)%
Other Income	$	172,000		$	—			172,000			—	%
Interest expense – preferred stock liability		(4,702,000	)		(52,000	)		4,650,000			8,942	%
Change in fair value of preferred stock	$	(177,000	)	$	—			(177,000	)		—	%
Change in fair value – Series B preferred stock		—			102,000			(102,000	)		(100	)%
Interest expense - debt		(68,000	)		(155,000	)		87,000			(56	)%
Warrants modification expense		—			(1,212,000	)		(1,212,000			(100	)%
Interest expense - preferred stock liability		(47,000	)		(4,702,000	)		4,655,000			(99	)%
Impairment expense of operating lease		—			(643,000	)		(643,000	)		(100	)%
Other Income (Expense), net	$	(120,000	)	$	(4,857,000	)		4,737,000			(98	)%
Other Income (Expense), net	$	(4,857,000	)	$	(2,013,000	)		2,844,000			141	%

Fiscal ~~2021~~2022 compared to Fiscal ~~2020~~2021

There was aan ~~decrease~~increase in ~~interest~~other ~~expenses~~income ~~paid~~which onrepresents the ~~note~~forgiveness ~~payable – related party, because~~ of the ~~decrease~~PPP ~~in the note payable balance due to the Company’s Chairman and CEO~~Loan. He exercised his options to purchase 3.1 million shares of Class B common stock by the cancellation of debt during the year ended June 30, 2021 compared to the year ended June 30, 2020 (see Note 11. Convertible Note Payable – Related Party of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K).

There was an increase in ~~interest~~change ~~expense~~in –fair value of preferred stock ~~liability during the year ended June 30, 2021 compared with the year ended June 30, 2020~~ related to ~~the new issuances of~~ Series B-2 ~~preferred~~5% ~~stock~~convertible ~~in January and February, 2021. The interest expense –~~ preferred stock ~~liability of 2021 consists mainly of beneficial conversion feature and warrant discounts of $4,663,000 and issuance costs paid of $25,000 and accrued dividend of $15,000~~.

There was a decrease in ~~change~~interest inexpenses ~~fair~~paid ~~value~~on ~~related to~~ the ~~Series~~note Bpayable ~~preferred~~- ~~stock~~related ~~during~~party, because the ~~year~~Company ~~ended~~repaid ~~June 30~~$1,033,000 ~~2021~~of ~~compared with~~ the ~~year~~note ~~ended~~payable ~~June~~to ~~30,~~Mr. ~~2020~~Ehrlich, ~~due to~~ the ~~valuation~~Company’s ofChairman ~~the~~and ~~warrants~~CEO toduring ~~purchase~~the ~~Preferred~~year ~~stock~~ended ~~performed~~June in30, ~~2020~~2022.

52There ~~Table~~was a decrease in interest expense – preferred stock liability during the year ended June 30, 2022 compared with the year ended June 30, 2021 related to the 5% accrued dividend associated with the Series B-2 preferred stock. The interest expense - preferred stock liability of ~~Contents~~2022 consists of accrued dividend of $47,000. The interest expense - preferred stock liability of 2021 consists of beneficial conversion feature and warrant discounts of $4,663,000 and issuance costs paid of $24,000 and accrued dividend of $15,000.

There was a decrease in warrants modification expense of approximately $1,212,000 during the year ended June 30, 2021 compared with the year ended June 30, 2020, due to modification expense in connection with the extension of the termination date for each warrant in 2020. The Company did not have this expense in the year ended June 30, 2021.

There was a decrease in impairment expense of operating lease of approximately $643,000, related to the operating lease right-of-use asset associated with the office space vacated by the Company in December 2019.

Net Losses

We incurred net losses of $137.90 million and $613.69 million for the years ended June 30, ~~2021~~2022 and ~~2020~~2021, respectively, because of the above-mentioned factors.

Liquidity, Going Concern and Capital Resources

Projected Future Working Capital Requirements - Next 12 Months

As of June 30, ~~2021~~2022, we had approximately $103.28 million in cash compared to $610.02 million of cash as of June 30, ~~2020~~2021, and as of the date of this filing, we have approximately $~~11.~~3.2 million in cash. WeContingent upon sufficient funding, we currently anticipate that future budget expenditures will be approximately $104.2 million for the next 12 months, including approximately $82.2 million for ~~clinical~~development activities, supportive research, and drug ~~product~~manufacturing. Alternatively, if we decide to pursue a more aggressive plan with our clinical trials, we will require additional sources of capital during the fiscal year 2022 to meet our working capital requirements for our planned clinical trials. Potential sources for capital include grant funding for COVID-19 research and equity financings (see below). There can be no assurances that we will be successful in receiving any grant funding for our programs.

Table of Contents

This assessment is based on current estimates and assumptions regarding our clinical development programs and business needs. Actual working capital requirements could differ materially from this above working capital projection.

On July 31, 2020, the Company entered into a new common stock purchase agreement (the “2020 Agreement”) with Aspire Capital which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 24-month term of the 2020 Agreement.

Our ability to successfully raise sufficient funds through the sale of equity securities, when needed, is subject to many risks and uncertainties and even if we are successful, future equity issuances would result in dilution to our existing stockholders. Our risk factors are described under the heading “Risk Factors” in Part I, Item 1A and elsewhere in this Annual Report on Form 10-K.

IfIn the event that we are unable to ~~generate~~raise ~~enough~~additional ~~working~~funds ~~capital~~ from ~~our current or future financing agreements with Aspire Capital when needed or secure additional sources of funding~~others, itwe may be ~~necessary~~required to ~~significantly~~delay, reduce ~~our~~or ~~current~~severely ~~rate~~curtail ofour ~~spending~~operations ~~through reductions in staff and delaying, scaling back~~ or ~~stopping~~otherwise ~~certain~~impede ~~research~~our ~~and~~on-going ~~development~~business ~~programs~~efforts, ~~including~~which ~~more~~could ~~costly~~have ~~Phase~~a 2material ~~and~~adverse ~~Phase~~effect ~~3 clinical trials~~ on our ~~wholly-owned~~future ~~development~~business, ~~programs~~operating asresults, ~~these~~financial ~~programs~~condition ~~progress~~and ~~into~~long-term ~~later stage development~~prospects. ~~Insufficient~~The ~~liquidity~~Company ~~may~~expects ~~also require us~~ to ~~relinquish~~seek ~~greater rights~~ to ~~product~~obtain ~~candidates~~additional atfunding anthrough ~~earlier~~business ~~stage of~~ development oractivities on(for ~~less~~example ~~favorable~~licensing ~~terms~~and topartnerships) us and ~~our~~future ~~stockholders~~equity ~~than~~issuances. weThere ~~would~~can ~~otherwise~~be ~~choose~~no inassurance ~~order~~as to ~~obtain~~the ~~up-front~~availability ~~license~~or ~~fees~~terms ~~needed~~upon towhich ~~fund~~such ~~operations.~~financing ~~These~~and ~~events~~capital ~~could~~might ~~prevent~~be usavailable ~~from~~to ~~successfully executing our operating plan~~us.

53Going ~~Table of Contents~~Concern

Our financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have negative working capital of $0.9 million and have incurred losses since inception of $122.2 million. We expect to incur further losses in the development of our business and have been dependent on raising capital to fund operations from inception. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Shelf Registration Statement - Current Status

The Company ~~has~~does ~~an effective shelf registration statement on Form S-3, registering the sale of up to $60 million of the Company’s securities. However, in the future, the Company may~~ not satisfy the conditions for use of Form S-3 for primary offerings of securities, inand ~~which~~as ~~case~~a result, the Company generally may only utilize Form S-1 to register the sale of its securities,. ~~although~~ Form S-1 offers less flexibility on the timing and types of offerings compared to Form S-3.

Cash Flows

The following table provides information regarding our cash position, cash flows and capital expenditures for the years ended June 30, ~~2021~~2022 and ~~2020~~2021 (rounded to nearest thousand):

	Year ended						Change
	June 30,						Increase/
	2021			2020			(Decrease)
	2022			2021			(Decrease)
							%
Net cash used in operating activities	$	(96,~~495~~280,000	)	$	(49,~~156~~495,000	)		~~128~~(34	)%
Net cash used in investing activities		(724,080,000	)		(9172,000	)		~~(21~~5,567	)%
Net cash provided by financing activities		133,~~743~~973,000			913,~~686~~743,000			42(71	)%
Net increase (decrease) in cash	$	4(6,~~176~~387,000	)	$	54,~~439~~176,000			(23253	)%

~~The~~38 ~~increase~~Table ~~in net cash used in operating activities~~ of $5.3 million versus the prior-year was mainly due to the increase in our loss from operations of $7.2 million, largely attributable to an increase in spending for clinical research and development expenses of $4.4 million. This also included the repayment of accrued officers’ salaries of $1.2 million. Contents

The ~~use~~decrease ofin net cash ~~principally~~used ~~resulted~~in ~~from~~operating ~~our~~activities ~~losses~~of ~~from~~$3.2 ~~operations,~~million ~~mentioned~~versus ~~above,~~the asprior-year ~~adjusted~~was ~~for~~mainly ~~non-cash~~due ~~charges~~to ~~for~~the ~~stock-based~~decrease ~~compensation~~in ofour loss from operations to $07.20 million, ~~patent~~largely ~~amortization~~attributable ofto ~~$0.4~~a ~~million,~~decrease in interest expense on– preferred stock of $4.6 million, an increase in stock based compensation of $400,000 and ~~changes~~a change in ~~our~~accrued ~~working~~officers’ ~~capital~~salaries ~~accounts~~and payroll taxes of $(352,000) in the current year compared to $(1,223,000) in the prior-year.

Investing activities

The ~~decrease~~increase in net cash used in investing activities of $4.0 million versus the prior-year was due primarly to ~~decrease~~the investment in ~~spending~~BeaMedical inof ~~patent~~$4.0 ~~costs~~million.

Financing activities

The decrease in net cash provided by financing activities of $9.8 million versus the prior-year was due to decreases in proceeds from issuances of Series B Preferred stock and sales of common stock.

In 2022, we raised approximately $5.0 million in net cash proceeds, from exercise of warrants to purchase preferred stock, offset by repayment of note payable to officer of $1.0 million.

In 2021, we raised approximately $14.6 million in net cash proceeds, from exercise of warrants to purchase preferred stock and the issuance of common stock, offset by purchase of treasury stock of $0.7 million and repayment of note payable to officer of $0.2 million.

In 2020, we raised approximately $9.7 million in net cash proceeds, from exercise of warrants to purchase preferred stock and the issuance of common stock, offset by purchase of treasury stock of $0.06 million.

54 Table of Contents

Requirement for Additional Working Capital

The Company, contingent on future sales of its securities, currently expects to incur total operating expenses of approximately $104.2 million for the next 12 months, including approximately $82.2 million for ~~clinical~~development activities, supportive research, and drug ~~product development~~manufacturing. The Company has limited experience with pharmaceutical ~~drug~~product development. As such, this budget estimate may change in the future. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or a change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget and on our projected timeline of drug development.

~~The~~In ~~Company~~the ~~will~~event bethat we are unable to ~~proceed~~or ~~with~~raise ~~its~~additional ~~planned~~funds ~~drug~~from ~~development programs~~others, ~~meet~~we ~~its~~may ~~administrative~~be ~~expense~~required ~~requirements,~~to ~~capital costs~~delay, reduce or ~~staffing~~severely ~~costs~~curtail ~~without~~our ~~accessing~~operations ~~its~~or ~~financing~~otherwise ~~available~~impede ~~with~~our ~~Aspire~~on-going ~~Capital~~business ~~of approximately $30 million~~efforts, of which ~~approximately~~could ~~$25.4~~have ~~million~~a ~~remains~~material asadverse ofeffect ~~the~~on ~~date~~our offuture ~~this~~business, ~~filing.~~operating ~~Management believes~~results, asfinancial ofcondition ~~the~~and ~~date~~long-term ofprospects. ~~this~~The ~~filing~~Company ~~that~~expects ~~the~~to ~~funding~~seek ~~amount~~to ~~from~~obtain ~~Aspire~~additional ~~Capital~~funding ~~will~~through bebusiness ~~available~~development asactivities ~~needed~~(for byexample ~~the~~licensing ~~Company~~ and ~~that~~partnerships) ~~adverse~~and ~~market~~future ~~conditions~~equity inissuances. ~~the~~There ~~Company’s~~can ~~common~~be ~~stock~~no ~~price~~assurance ~~and~~as ~~trading~~to ~~volume,~~the ~~will~~availability ~~not~~or ~~prevent~~terms ~~the~~upon ~~Company~~which ~~from~~such ~~funding~~financing ~~its~~and ~~working~~ capital ~~requirements~~might ~~for~~be ~~the~~available ~~next~~to ~~12 months from the date of this filing~~us.

In the event that we are unable to generate sufficient cash from our 2020 Agreement with Aspire Capital or raise additional funds from others, we may be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our future business, operating results, financial condition and long-term prospects. The Company expects to seek to obtain additional funding through business development activities (i.e. licensing and partnerships) and future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available to us.

Commitments and Contingencies

Please see Note 910. Commitments and Contingencies of the Notes to Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K, for a discussion of ~~recent~~ contractual commitments and contingent liability - disputed invoices.

Equity Transactions

~~From~~During ~~July~~the 31year ended June 30, ~~2020~~2022, ~~(date~~the Company issued 5,072 shares of ~~agreement)~~its toSeries ~~September~~B-2 ~~14,~~5% ~~2020,~~convertible ~~the~~preferred ~~Company~~stock, ~~has~~for ~~generated~~aggregate ~~additional~~gross proceeds of approximately $15.80 million, ~~under~~upon exercise of 3,036 Series 1 warrants and 2,036 Series 2 warrants issued by the ~~2020~~Company. ~~Agreement~~With ~~with~~regard ~~Aspire~~to ~~Capital~~the ~~from~~exercise of these 5,072 warrants, the ~~sale~~Company recorded gross proceeds of approximately 8.$5.0 million to the preferred stock liability. During the years ended June 30, 2022, the convertible preferred stockholder converted a total of 4,452 shares of ~~its~~Series B-2 preferred stock into a total of approximately 69,901,865 shares of common stock. ~~Since~~There ~~September~~were ~~14,~~620 ~~2020,~~shares weof ~~have~~Series ~~not~~B-2 ~~obtained~~5% ~~financing~~convertible ~~through~~preferred ~~Aspire~~stock ~~Capital~~outstanding as of June 30, 2022.

~~During~~39 ~~the~~Table ~~year ended June 30, 2021, the Company issued 3,053 shares~~ of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of $3.0 million, upon exercise of 3,053 Series 1 warrants issued by the Company. In addition, the Company issued 2,053 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of $2.0 million, upon exercise of 2,053 Series 2 warrants issued by the Company.Contents

55 Table of Contents

Subsequent Events

Equity Transactions

From July 1, 2021 to the date of the issuance of the accompanying financial statements, the Company issued 2,036 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of $2.0 million, upon exercise of 2,036 Series 1 warrants issued by the Company. In addition, the Company issued 1,000 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of $1.0 million, upon exercise of 1,000 Series 2 warrants issued by the Company. At the same time, there were 3,036 preferred stock shares converted to approximately 18.9 million shares of common stock.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements, as defined in Item 304(a)(4)(ii) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

Recently Issued Accounting Pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operation, financial position or cash flow.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

5640 Table of Contents

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

INNOVATION PHARMACEUTICALS INC.

INDEX TO FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA

	Page
Report of Independent Registered Public Accounting Firms		F-1
Report of Independent Registered Public Accounting Firms (Firm ID 6117)		F-1
Financial Statements of Innovation Pharmaceuticals Inc.
Consolidated Balance Sheets as of June 30, 2021 and 2020		F-2
Consolidated Balance Sheets as of June 30, 2022 and 2021		F-2
Consolidated Statements of Operations for the years ended June 30, 2021 and 2020		F-3
Consolidated Statements of Operations for the years ended June 30, 2022 and 2021		F-3
Consolidated Statements of Stockholders’ Equity for the years ended June 30, 2021 and 2020		F-4 - F-5
Consolidated Statements of Stockholders’ Equity for the years ended June 30, 2022 and 2021		F-4
Consolidated Statements of Cash Flows for the years ended June 30, 2021 and 2020		F-6
Consolidated Statements of Cash Flows for the years ended June 30, 2022 and 2021		F-5
Notes to Consolidated Financial Statements		F-76

5741 Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Innovation ~~Pharmaceuticals~~Pharmaceutical, Inc.

Wakefield, MA

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Innovation Pharmaceuticals, Inc. (the Company) as of June 30, ~~2021~~2022 and ~~2020~~2021, and the related consolidated statements of operations, changes in stockholders’ equity ~~(deficit)~~, and cash flows for the years then ended, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, ~~2021~~2022 and ~~2020~~2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern Considerations

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has negative working capital, has suffered losses and negative cash flow from operations, which raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s ~~consolidated~~ financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the ~~consolidated~~ financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our ~~audit~~audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the ~~consolidated~~ financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the ~~consolidated~~ financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit ~~Matters~~Matter

The critical audit matter communicated below is a matter arising from the ~~audits~~current period audit of the consolidated financial statements that ~~were~~was communicated or required to be communicated to the audit committee and that: (1) ~~relate~~relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit ~~matters~~matter below, providing a separate ~~opinions~~opinion on the critical audit ~~matters~~matter or on the accounts or disclosures to which ~~they~~it ~~relate~~relates.

Going Concern – Disclosure

The consolidated financial statements of the Company are prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations. As noted in “Going Concern Considerations” above, the Company has a negative working capital, negative cash flow from operations and has a history of recurring net losses. The Company has contractual obligations, such as commitments for repayments of accounts payable, accrued liabilities, leases and a convertible note payable - related party (collectively “obligations”). Currently, management’s forecasts and related assumptions illustrate their judgements as to the Company’s ability to meet its obligations through management of expenditures, implementation of planned business operations, obtaining additional debt financing, and issuance of capital stock for additional funding to meet its operating needs. Should there be constraints on the ability to implement its planned business operations or access financing through stock issuances, the Company will continue to manage cash outflows and meet the obligations through debt financing.

We identified management’s assessment of the Company’s ability to continue as a going concern as a critical audit matter. Management made judgments regarding the Company’s ability to effectively implement its plans to provide the necessary cash flows to fund the Company’s obligations as they become due. Specifically, the judgments with the highest degree of impact and subjectivity in determining the Company’s ability to effectively implement it include its ability to manage expenditures, its ability to access funding from the capital market, its ability to obtain debt financing, and the successful implementation of its planned business operations. Auditing the judgments made by management required a high degree of auditor judgment and an increased extent of audit effort.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included the following, among others: (i) evaluating the probability that the Company will be able to access funding from the capital market; (ii) evaluating the probability that the Company will be able to manage expenditures (iii) evaluating the probability that the Company will be able to obtain debt financing, and (iv) evaluating the implementation of its planned business operations.

Stock-Based Compensation

As described in Note ~~13 and~~ 14 to the consolidated financial statements, the Company recorded stock-based compensation related to the issuance of common stock, and stock options issued to employees and ~~warrants~~third-party service providers. Management establishes their estimates for the value of the stock-based compensation related to common stock issued for services using historical stock price information. Management uses a valuation model requiring various inputs to establish their estimates for the value of stock options ~~and warrants~~.

The principal considerations for our determination that performing procedures relating to stock-based compensation is a critical audit matter are due to the material impact it has on the consolidated financial statements.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others, evaluating the reasonableness of the historical stock price information used by management for the valuation of the common stock along with evaluating the reasonableness of the input’s management used in the valuation model related to the stock options and warrants to determine the stock-based compensation expense.

/s/ Pinnacle Accountancy Group of Utah We have served as the Company’s auditor since 2018. Pinnacle Accountancy Group of Utah(a dba of Heaton & Company, PLLC)Farmington, UtahSeptember 28, 2022

We have served as the Company’s auditor since 2019.

Pinnacle Accountancy Group of Utah

(a dba of Heaton & Company, PLLC)

Farmington, Utah

September 27, 2021

F-1

Table of Contents

INNOVATION PHARMACEUTICALS INC.

CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, ~~2021~~2022 AND ~~2020~~2021

(Rounded to nearest thousand except for share data)

	June 30,			June 30,
	2021			2020
	2022			2021
ASSETS
Current Assets:
Cash	$	103,~~194~~807,000		$	610,~~018~~194,000
Prepaid expenses and other current assets		~~495~~145,000			92495,000
Total Current Assets		103,~~689~~952,000			610,~~110~~689,000
Equity investment		3,978,000			—
Other Assets:
Patent costs - net		2,~~754~~312,000			32,~~060~~754,000
Deferred offering costs		~~778~~59,000			—778,000
Security deposit		78,000			78,000
Total Other Assets		32,~~610~~449,000			3,~~138~~610,000
Total Assets	$	1410,~~299~~379,000		$	914,~~248~~299,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable - (including related party payables of approx. $1,511,000 and $1,498,000, respectively)	$	2,563,000		$	2,043,000
Accounts payable - (including related party payables of approx. $1,511,000 and $1,511,000, respectively)	$	2,567,000		$	2,563,000
Accrued expenses - (including related party accruals of approx. $8,000 and $19,000, respectively)		348,000			59,000
Accrued expenses - (including related party accruals of approx. $12,000 and $8,000, respectively)		92,000			348,000
Accrued salaries and payroll taxes - (including related party accrued salaries of approx. $1,915,000 and $2,777,000, respectively)		1,992,000			3,215,000
Accrued salaries and payroll taxes - (including related party accrued salaries of approx. $1,563,000 and $1,915,000, respectively)		1,640,000			1,992,000
Operating lease - current liability		~~165~~197,000			~~138~~165,000
Note payable - related party		1,283,000			1,822,000
Convertible note payable - related party		250,000			1,283,000
Accrued dividend - Series B 5% convertible preferred stock		1562,000			1315,000
Loan payable		~~172,000~~—			79172,000
Total Current Liabilities		64,~~538~~808,000			76,~~369~~538,000
Other Liabilities:
Operating lease - long term liability		252,000			417,000
Series B 5% convertible preferred stock liability at $1,080 stated value; 620 shares and 0 shares issued and outstanding at June 30, 2022 and 2021, respectively		786,000			—
Total Liabilities		6,790,000			7,786,000
Operating lease - long term liability		55,000			252,000
Commitments and contingencies (Note 9)
Total Liabilities		5,649,000			6,790,000
Commitments and contingencies (Note 10)
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 designated shares, no shares issued and outstanding		—			—
Common Stock - Class A, $.0001 par value, 600,000,000 shares authorized, 426,673,198 shares and 329,829,992 shares issued as of June 30, 2021 and 2020, respectively, 418,157,142 shares and 329,170,544 shares outstanding as of June 30, 2021 and 2020, respectively.		42,000			33,000
Common Stock - Class A, $.0001 par value, 600,000,000 shares authorized, 496,741,729 shares and 426,673,198 shares issued as of June 30, 2022 and 2021, respectively, 488,225,673 shares and 418,157,142 shares outstanding as of June 30, 2022 and 2021, respectively.		49,000			42,000
Common Stock - Class B, (10 votes per share); $.0001 par value, 100,000,000 shares authorized, 18,000,000 shares and 1,818,180 shares issued as of June 30, 2021 and 2020, respectively, and 15,641,463 shares and 1,818,180 shares outstanding as of June 30, 2021 and 2020, respectively		2,000			—
Common Stock - Class B, (10 votes per share); $.0001 par value, 100,000,000 shares authorized, 18,000,000 shares issued as of June 30, 2022 and 2021, respectively, and 15,641,463 shares outstanding as of June 30, 2022 and 2021, respectively		2,000			2,000
Additional paid-in capital		~~124~~129,~~835~~090,000			~~102~~124,~~819~~835,000
Accumulated deficit		(~~115~~122,~~116~~157,000	)		(~~101~~115,~~244~~116,000	)
Treasury Stock, at cost (10,874,593 shares and 659,448 shares as of June 30, 2021 and June 30, 2020, respectively)		(2,254,000	)		(146,000	)
Treasury Stock, at cost (10,874,593 shares as of June 30, 2022 and 2021, respectively)		(2,254,000	)		(2,254,000	)
Total Stockholders’ Equity		74,~~509~~730,000			17,~~462~~509,000
Total Liabilities and Stockholders’ Equity	$	1410,~~299~~379,000		$	914,~~248~~299,000

The accompanying notes are an integral part of these consolidated financial statements

F-2

Table of Contents

INNOVATION PHARMACEUTICALS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED JUNE 30, ~~2021~~2022 AND ~~2020~~2021

(Rounded to nearest thousand except for shares and per share data)

	For the Years Ended
	June 30,
	2021			2020
	2022			2021
Revenues	$	—18,000		$	~~423,000~~—
Operating expenses:
Research and development expenses		74,~~016~~814,000			27,~~792~~016,000
General and administrative expenses		~~963~~1,223,000			1963,~~429,~~000
Officers’ payroll and payroll tax expenses		~~499~~428,000			~~480~~499,000
Professional fees		~~537~~452,000			~~357~~537,000
Total operating expenses		96,~~015~~917,000			59,~~058~~015,000
Loss from operations		(9,015,000	)		(4,635,000	)
Other Operating Income and (Loss)
Equity in loss from equity investment		(22,000	)		—
Total Other Operating Income and (Loss)		(22,000	)		—
Loss from operations		(6,921,000	)		(9,015,000	)
Other expenses
Change in fair value of preferred stock		—			102,000
Other income		172,000			—
Interest expense – debt		(155,000	)		(208,000	)
Change in fair value of preferred stock		(177,000	)		—
Interest expense – preferred stock		(4,702,000	)		(52,000	)
Interest expense - debt		(68,000	)		(155,000	)
Warrants modification expense		—			(1,212,000	)
Interest expense - preferred stock		(47,000	)		(4,702,000	)
Impairment expense of operating lease		—			(643,000	)
Total other expenses		(120,000	)		(4,857,000	)
Total other expenses		(4,857,000	)		(2,013,000	)
Loss before provision for income taxes		(7,041,000	)		(13,872,000	)
Loss before provision for income taxes		(13,872,000	)		(6,648,000	)
Provision for income taxes		—			—
Net loss	$	(137,~~872~~041,000	)	$	(613,~~648~~872,000	)
Net loss per share, basic and diluted	$	(0.0401	)	$	(0.0304	)
Basic and Diluted Weighted Average Common Shares Outstanding		~~386~~503,~~163~~867,~~208~~136			~~238~~386,~~436~~163,~~372~~208

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Table of Contents

INNOVATION PHARMACEUTICALS INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE YEARS ENDED JUNE 30, ~~2021~~2022 AND ~~2020~~2021

(Rounded to nearest thousand, except for shares data):

	Common Stock A						Common Stock B					Additional
	Par Value			~~Par Value~~			Par Value			~~Par Value~~		Paid-in			Accumulated			Treasury Stock
	Shares			$	0.0001		Shares			$	0.0001	Capital			Deficit			Shares		Amount			Total
Balance at June 30, 2019		202,631,923		$	21,000			909,090		$	91	$	90,537,000		$	(94,596,000	)		228,218	$	(91,000	)	$	(4,129,000	)
Balance at June 30, 2020		329,170,544			33,000			1,818,180			-		102,819,000			(101,244,000	)		659,448		(146,000	)		1,462,000
Stock options issued to consultant for services at $0.089 - $0.43		—			—			—			—		34,000			—			—		—			34,000
Shares sold to Aspire Capital under 2020 Agreement at $0.20 - $0.22 range		22,500,000			2,000			-			1,000		4,600,000			-			-		-			4,603,000
Stock options issued to employee for services at $0.398 - $1.37		—			—			—			—		76,000			—			—		—			76,000
Shares issued as commitment fee of $1,438,000 on 7/31/2020 at $0.23, net of amortization of offering costs of $120,000		6,250,000			1,000			-			-		1,437,000			-			-		-			1,438,000
Stock options issued to officer as equity awards at $0.1 to $0.705		—			—			—			—		205,000			—			—		—			205,000
Offering cost		-			-			-			-		(659,000	)		-			-		-			(659,000	)
Shares issued to consultant for services at $0.84 - $1.38		—			—			—			—		5,000			—			—		—			5,000
Shares issued to employee for services at $0.132 to $0.398		-			-			-			-		16,000			-			-		-			16,000
Shares issued to employee for services at $0.132 - $1.37		—			—			—			—		28,000			—			—		—			28,000
Stock options issued to employee for services at $0.132 to $0.398		-			-			-			-		44,000			-			-		-			44,000
Shares issued to officer as equity awards at $0.1 to $0.705		—			—			—			—		330,000			—			—		—			330,000
Stock options issued to consultant for services at $0.14 to $0.43		-			-			-			-		123,000			-			-		-			123,000
Issuance of 1,525,500 shares to directors and Consultant		1,525,000			—			—			—		—			—			—		—			—
Issuance of 2,200,000 shares of Common Stock Class B to Officer & 412,238 shares were withheld for tax purposes as Treasury shares		-			-			2,200,000			-		242,000			-			-		-			242,000
Issuance of 1,066,667 shares to Officer & 421,611 shares were withheld for tax purposes as Treasury shares		1,066,667			—			—			—		—			—			—		—			—
Issuance of shares for tax purposes as Treasury Shares		-			-			(412,238	)		-		-			-			412,238		(90,000	)		(90,000	)
Issuance of 58,394 shares to employee & 9,619 shares were withheld for tax purposes as Treasury shares		58,394			—			—			—		—			—			—		—			—
Issuance of 58,394 shares to employee & 21,606 shares were withheld for tax purposes as Treasury shares		58,394			-			-			-		-			-			-		-			-
Issuance of shares for tax purposes as Treasury Shares		(~~431~~21,~~230~~606	)		—-			—-			—-		—-			—-			~~431~~21,~~230~~606		(553,000	)		(553,000	)
Conversion of preferred stocks to common stock		116,319,790			11,000			—			—		4,906,000			—			—		—			4,917,000
Cancellation of debt for the purchase of 909,090 shares of Common Stock Class B & 181,096 shares were withheld for tax purposes as Treasury shares		-			-			909,090			-		100,000			-			-		-			100,000
Excess of exercise price of 8,912 warrants over fair value		—			—			—			—		2,580,000			—			—		—			2,580,000
Issuance of shares for tax purposes as Treasury Shares		-			-			(181,096	)		-		-			-			181,096		(37,000	)		(37,000	)
To reverse the option expense & stock awards granted for our resigned CMO		—			—			—			—		(251,000	)		—			—		—			(251,000	)
To record Series B Discount - Warrants		-			-			-			-		1,410,000			-			-		-			1,410,000
To adjust the 41 Pref stock from $982.5 to $535.12		—			—			—			—		18,000			—			—		—			18,000
To record issuance costs Series 1 & 2 Warrants		-			-			-			-		(10,000	)		-			-		-			(10,000	)
Cancellation of debt for the purchase of 909,090 shares of Common Stock Class B		—			—			909,090			—		100,000			—			—		—			100,000
To record beneficial conversion feature associated with the issuance of the 5,089 shares of Series B-2 preferred stock		-			-			-			-		3,253,000			-			-		-			3,253,000
Exercise of 8,000,000 warrants at $0.38		8,000,000			1,000			—			—		3,039,000			—			—		—			3,040,000
Conversion of 10,207 preferred stocks into 68,034,812 common stocks		68,034,812			7,000			-			-		10,022,000			-			-		-			10,029,000
Warrants modification expense		—			—			—			—		1,212,000			—			—		—			1,212,000
Cancellation of 6,980,583 Class A shares to satisfy the purchase of 13,072,730 shares of Common Stock Class B		(6,980,583	)		(1,000	)		13,072,730			1,000		1,438,000			-			6,980,583		(1,438,000	)		-
Net loss		—			—			—			—		—			(6,648,000	)		—		—			(6,648,000	)
Shares were withheld for tax purposes as Treasury Shares		(854,419	)		-			(1,765,203	)		-		-			-			2,619,622		(540,000	)		(540,000	)
Balance at June 30, 2020		329,170,544			33,000			1,818,180			—		102,819,000			(101,244,000	)		659,448		(146,000	)		1,462,000
Net loss		-			-			-			-		-			(13,872,000	)		-		-			(13,872,000	)
Balance at June 30, 2021		418,157,142		$	42,000			15,641,463		$	2,000	$	124,835,000		$	(115,116,000	)		10,874,593	$	(2,254,000	)	$	7,509,000
Offering cost		-			-			-			-		(718,000	)		-			-		-			(718,000	)
Conversion of 4,452 preferred stock into 69,901,865 common stocks		69,901,865			7,000			-			-		4,367,000			-			-		-			4,374,000
Shares issued for exercise of options		166,666			-			-			-		23,000			-			-		-			23,000
Shares issued to employee for services		-			-			-			-		8,000			-			-		-			8,000
Stock options issued to consultant for services		-			-			-			-		60,000			-			-		-			60,000
Stock options issued to director for services		-			-			-			-		423,000			-			-		-			423,000
Stock options issued to employee for services		-			-			-			-		92,000			-			-		-			92,000
Net loss		-			-			-			-		-			(7,041,000	)		-		-			(7,041,000	)
Balance at June 30, 2022		488,225,673			49,000			15,641,463			2,000		129,090,000			(122,157,000	)		10,874,593		(2,254,000	)		4,730,000

F-4 Table of Contents

Shares sold to Aspire Capital under 2020 Agreement at $0.20 - $0.22 range	22,500,000			2,000		—			1,000		4,600,000			—		—		—			4,603,000
Shares issued as commitment fee of $1,438,000 on 7/31/2020 at $0.23, net of amortization of offering costs of $120,000	6,250,000			1,000		—			—		1,437,000			—		—		—			1,438,000
Offering cost	—			—		—			—		(659,000	)		—		—		—			(659,000	)
Shares issued to employee for services at $0.132 to $0.398	—		——			—			—		16,000			—		—		—			16,000
Stock options issued to employee for services at $0.132 to $0.398	—			—		—			—		44,000			—		—		—			44,000
Stock options issued to consultant for services at $0.14 to $0.43	—			—		—			—		123,000			—		—		—			123,000
Issuance of 2,200,000 shares of Common Stock Class B to Officer & 412,238 shares were withheld for tax purposes as Treasury shares	—			—		2,200,000			—		242,000			—		—		—			242,000
Issuance of shares for tax purposes as Treasury Shares	—			—		(412,238	)		—		—			—		412,238		(90,000	)		(90,000	)
Issuance of 58,394 shares to employee & 21,606 shares were withheld for tax purposes as Treasury shares	58,394			—		—			—		—			—		—		—			—
Issuance of shares for tax purposes as Treasury Shares	(21,606	)		—		—			—		—			—		21,606		(3,000	)		(3,000	)
Cancellation of debt for the purchase of 909,090 shares of Common Stock Class B & 181,096 shares were withheld for tax purposes as Treasury shares	—			—		909,090			—		100,000			—		—		—			100,000
Issuance of shares for tax purposes as Treasury Shares	—			—		(181,096	)		—		—			—		181,096		(37,000	)		(37,000	)
To record Series B Discount - Warrants	—			—		—					1,410,000			—		—		—			1,410,000
To record issuance costs Series 1 & 2 Warrants	—		——			—			—		(10,000	)		—		—		—			(10,000	)
To record beneficial conversion feature associated with the issuance of the 5,089 shares of Series B-2 preferred stock	—			—		—			—		3,253,000			—		—		—			3,253,000
Conversion of 10,207 preferred stocks into 68,034,812 common stocks	68,034,812			7,000		—			—		10,022,000			—		—		—			10,029,000
Cancellation of 6,980,583 Class A shares to satisfy the purchase of 13,072,730 shares of Common Stock Class B	(6,980,583	)		(1,000	)	13,072,730			1,000		1,438,000			—		6,980,583		(1,438,000	)		—
Shares were withheld for tax purposes as Treasury Shares	(854,419	)		—		(1,765,203	)		—		—			—		2,619,622		(540,000	)		(540,000	)
Net loss	—			—		—			—		—			(13,872,000	)	—		—			(13,872,000	)
Balance at June 30, 2021	418,157,142		$	42,000		15,641,463		$	2,000	$	124,835,000		$	(115,116,000	)	10,874,593	$	(2,254,000	)	$	7,509,000

The accompanying notes are an integral part of these consolidated financial statements.

F-54 Table of Contents

INNOVATION PHARMACEUTICALS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED JUNE 30, ~~2021~~2022 AND ~~2020~~2021

(Rounded to nearest thousand)

	2021			2020
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(137,~~872~~041,000	)	$	(613,~~648~~872,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation		183,000			427,000
Patent write off		141,000			—
Amortization of patent costs		378,000			372,000
Stock based compensation		583,000			183,000
Depreciation of equipment		—			1,000
Amortization of patent costs		382,000			378,000
Interest expense-preferred stock		4,663,000			52,000
Gain on forgiveness of loans payable		(172,000	)		—
Change in fair value of preferred stock		—			(102,000	)
Interest expense-preferred stock		—			4,663,000
Warrants modification expense		—			1,212,000
Change in fair value of preferred stock		177,000			—
Impairment expense of operating lease		—			643,000
Equity in loss from equity investment		22,000			—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		~~(403~~350,000	)		(46403,000	)
Accounts payable		~~520~~4,000			~~(84~~520,000	)
Accrued expenses		~~289~~(256,000	)		~~(26~~289,000	)
Accrued officers’ salaries and payroll taxes		(1352,~~223,~~000	)		52(1,223,000	)
Operating lease liability		(~~138~~165,000	)		(88138,000	)
Accrued dividend		1547,000			—15,000
Loan payable		~~93,000~~—			7993,000
Net cash used in operating activities		(96,~~495~~280,000	)		(49,~~156~~495,000	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Patent costs		(72,000	)		(91,000	)
Equity Investment contribution		(4,000,000	)		—
Net cash used in investing activities		(72,000	)		(91,000	)
Patent costs		(80,000	)		(72,000	)
Net cash used in investing activities		(4,080,000	)		(72,000	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Sale of common stock, net of offering costs		~~4,603,000~~—			—4,603,000
Proceeds from issuance of Series B Preferred stocks, net of financing costs		~~4,990,000~~—			—4,990,000
Proceeds from exercise of preferred stock warrants		54,~~017~~983,000			65,~~701~~017,000
Proceeds from exercise of common stock warrants		—			3,040,000
Proceeds from exercise of options		23,000			—
Purchase of treasury stock		~~(670,000~~—	)		(55670,000	)
Repayment of note payable to officer		(~~197~~1,033,000	)		—(197,000	)
Net cash provided by financing activities		133,~~743~~973,000			913,~~686~~743,000
NET DECREASE IN CASH		4,176,000			5,439,000
NET INCREASE (DECREASE) IN CASH		(6,387,000	)		4,176,000
CASH, BEGINNING OF YEAR		610,~~018~~194,000			~~579~~6,018,000
CASH, END OF YEAR	$	103,~~194~~807,000		$	610,~~018~~194,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	$	59,000		$	~~216~~59,000
Cash paid for income taxes	$	—		$	—
SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW
INVESTING AND FINANCING ACTIVITIES
Initial warrant valuation	$	—		$	1,212,000
Shares issued as deferred offering costs	$	—		$	1,438,000
Shares issued as deferred offering costs	$	1,438,000		$	—
Cancellation of 6,980,583 Class A shares for the purchase of 13,072,730 shares of Common Stock Class B	$	—		$	1,438,000
Cancellation of 6,980,583 Class A shares for the purchase of 13,072,730 shares of Common Stock Class B	$	1,438,000		$	—
Conversion of Series B Convertible Preferred stock to Common stock	$	4,374,000		$	10,029,000
Conversion of Series B Convertible Preferred stock to Common stock	$	10,029,000		$	4,907,000
Cancellation of shareholder debt for the purchase of 909,090 shares of Common Stock Class B shares	$	—		$	342,000
Excess of exercise price of warrants at $850-$950 over fair value of $535	$	—		$	2,598,000
Dividend paid on Series B-2 Preferred Shares	$	—		$	13,000
Cancellation of shareholder debt for the purchase of 909,090 shares of Common Stock Class B shares	$	342,000		$	100,000
Dividend paid by Series B-2 Preferred Shares	$	13,000		$	—

The accompanying notes are an integral part of these consolidated financial statements.

F-65 Table of Contents

INNOVATION PHARMACEUTICALS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED JUNE 30, ~~2021~~2022 AND ~~2020~~ 2021

1. Basis of Presentation and Nature of Operations

Innovation Pharmaceuticals Inc. was incorporated on August 1, 2005 in the State of Nevada. Effective June 5, 2017, the Company amended its Articles of Incorporation and changed its name from Cellceutix Corporation to Innovation Pharmaceuticals Inc. On February 15, 2019, the Company formed IPIX Pharma Limited (“IPIX Pharma”), a wholly-owned subsidiary incorporated under the Companies Act 2014 of Ireland. IPIX Pharma is a Private Company Limited by Shares. The subsidiary is intended to serve as a key hub for strategic collaboration with European companies and medical communities in addition to providing cost-saving efficiencies and flexibility with respect to developing Brilacidin under European Medicines Agency standards.

The Company is a clinical stage biopharmaceutical company. The Company’s common stock is quoted on OTCQB, symbol “IPIX.”

Basis of Consolidation

These consolidated financial statements include the accounts of Innovation Pharmaceuticals Inc., a Nevada corporation, and our wholly-owned subsidiary, IPIX Pharma, an Ireland limited company. All significant intercompany transactions and balances have been eliminated in consolidation. There was no translation gain and loss for the year ended June 30, ~~2021~~2022 and ~~2020~~2021.

Nature of Operations - Overview

We are in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of inflammatory diseases, cancer, dermatology and anti-infectives. Our strategy is to use our business and scientific expertise to maximize the value of our pipeline. Wewhich ~~will~~presently doincludes ~~this~~Brilacidin by ~~focusing~~advancing ~~initially~~indications onalong ~~our~~the ~~lead~~regulatory ~~compounds,~~pathway as well as seeking additional health care-related investment opportunities with the aim of diversifying the Company’s assets. Ongoing activities include Brilacidin ~~and~~drug ~~Kevetrin~~manufacturing, scientific report writing, and ~~advancing~~supportive ~~them~~research asactivities. ~~quickly~~The Company also acquired an interest in BT BeaMedical Technologies Ltd. (formerly known as ~~possible~~Squalus ~~along~~Medical ~~the~~Ltd.), ~~regulatory~~a ~~pathway~~private company developing a novel image guided surgical laser platform. WeManagement ~~aim~~is focused on other avenues of business development, including, but not limited to, ~~develop~~joint ~~the~~ventures, ~~highest~~mergers ~~quality~~and ~~data~~acquisitions, strategic investments, and ~~broadest~~licensing ~~intellectual~~agreements, ~~property~~for tothe ~~support~~purpose ~~our~~of ~~compounds~~diversifying corporate assets. While no assurances are expressed or implied that any agreement will be consummated in the future, the Company is committed toward executing on opportunities at hand.

In December 2020, the U.S. Food and Drug Administrations (FDA) approved the Company’s Investigational New Drug (IND) application to proceed with initiation of a randomized, placebo-controlled Phase 2 clinical trial of Brilacidin in moderate-to-severe hospitalized patients with COVID-19. Similar regulatory approval was obtained from the Russian Ministry of Health. The clinical trial is in progress.

We currently own all development and marketing rights to our products, other than the license rights granted to Alfasigma S.p.A. in July 2019 for the development, manufacturing and commercialization of locally-administered Brilacidin for ulcerative proctitis/ulcerative proctosigmoiditis (“UP/UPS”). In order to successfully develop and market our products, we may have to partner with additional companies. Prospective partners may require that we grant them significant development and/or commercialization rights in return for agreeing to share the risk of development and/or commercialization.

~~F-7~~2. ~~Table~~Liquidity, ofGoing ~~Contents~~Concern and Management’s Plan

2Our financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. ~~Liquidity~~For the fiscal year ended June 30, 2022, the Company had a net loss of $7.0 million and negative cash flow from operations of $6.3 million. As of June 30, 2022, the Company has negative working capital of $0.9 million. As of June 30, 2022, the Company’s cash amounted to $3.8 million and current liabilities amounted to $4.8 million. The Company has expended substantial funds on its clinical trials and expects to continue our spending on research and development expenditures. We expect to incur further losses in the development of our business and have been dependent on funding operations from inception. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

AsThese offactors ~~June~~raise ~~30,~~a ~~2021,~~substantial doubt about the Company’s ~~cash~~ability ~~amounted~~ to ~~$10.2~~continue ~~million~~as ~~and~~a ~~current~~going ~~liabilities amounted to $6~~concern.5 ~~million.~~ The ~~Company~~accompanying ~~has~~financial ~~expended~~statements ~~substantial~~do ~~funds~~not oninclude ~~its~~any ~~clinical~~adjustments ~~trials~~to ~~and~~reflect ~~expects~~the topossible ~~continue~~future ~~our~~effects ~~spending~~ on ~~research~~the recoverability and ~~development~~classification ~~expenditures.~~of ~~Our~~assets ~~net~~or ~~losses incurred for~~ the ~~years~~amounts ~~ended June 30, 2021~~ and ~~2020,~~classifications ~~amounted~~of toliabilities ~~$13.9~~that ~~million~~may ~~and~~result ~~$6.6~~from ~~million,~~the ~~respectively,~~possible ~~and~~inability ~~we had working capital~~ of ~~approximately~~the ~~$4.2~~Company ~~million~~to atcontinue ~~June~~as ~~30, 2021 and~~ a ~~working~~going ~~capital deficit of approximately $(1~~concern.~~3) million at June 30, 2020.~~

On July 31, 2020, the Company entered into a new common stock purchase agreement (the “2020 Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 24F-~~month term of the 2020 Agreement. In consideration for entering into the 2020 Agreement, the Company issued to Aspire Capital~~ 6~~,250,000~~ ~~shares~~Table of its Class A Common Stock as a commitment fee. The commitment fee of approximately $1.4 million was recorded as deferred financing costs and additional paid-in capital and this asset will be amortized over the life of the 2020 Agreement. As of June 30, 2021, the available balance was $25.4 million.Contents

We anticipate that future budget expenditures will be approximately $10.2 million for the next 12 months, including approximately $8.2 million for clinical activities, supportive research, and drug product. Alternatively, if we decide to pursue a more aggressive plan with our clinical trials, we will require additional sources of capital during the fiscal year 2022 to meet our working capital requirements for our planned clinical trials. Potential sources for capital include grant funding for COVID-19 research and equity financings. There can be no assurances that we will be successful in receiving any grant funding for our programs.

Management believes that the amounts available from Aspire Capital and under the Company’s effective shelf registration statement will be sufficient to fund the Company’s operations for the next 12 months.

If we are unable to generate enough working capital from our current or future financing agreements with Aspire Capital when needed or secure additional sources of funding, it may be necessary to significantly reduce our current rate of spending through reductions in staff and delaying, scaling back or stopping certain research and development programs, including more costly Phase 2 and Phase 3 clinical trials on our wholly-owned development programs as these programs progress into later stage development. Insufficient liquidity may also require us to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to us and our stockholders than we would otherwise choose in order to obtain up-front license fees needed to fund operations. These events could prevent us from successfully executing our operating plan.

3. Significant Accounting Policies and Recent Accounting Pronouncements

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, valuation of equity grants and income tax valuation. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

Cash

Cash consist of bank deposits. There were no cash equivalents at June 30, 2022 and 2021.

Intangible Assets - Patents

Costs incurred to file patent applications and acquired intangibles are capitalized when the Company believes that there is a high likelihood that the patent will be issued and there will be future economic benefit associated with the patent. These costs will be amortized on a straight-line basis over a 12 - 17 years life from the date of patent filing. All costs associated with abandoned patent applications are expensed. In addition, the Company will review the carrying value of patents for indicators of impairment on a periodic basis and if it determines that the carrying value is impaired, it values the patent at fair value. As of June 30, 2022 and 2021, carrying value of patent was approximately $2,312,000 and $2,754,000, respectively. Amortization expense for the fiscal years ended June 30, 2022 and 2021, was approximately $382,000 and $378,000, respectively.

As of June 30, 2022, the Company expensed the costs associated with obtaining patents that have not yet resulted in products or gained market acceptance and the Company has or will let these patents go abandoned. During the years ended June 30, 2022 and 2021, the patent expenses were insignificant.

In accordance with the provisions of the applicable authoritative guidance, the Company’s long-lived assets and amortizable intangible assets are tested for impairment whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The Company assesses the recoverability of such assets by determining whether their carrying value can be recovered through undiscounted future operating cash flows, including its estimates of revenue driven by assumed market segment share and estimated costs. If impairment is indicated, the Company measures the amount of such impairment by comparing the fair value to the carrying value. During the years ended June 30, 2022 and 2021, the Company has recorded patent write offs of approximately $141,000 and $0, respectively and included in general and administrative expenses.

F-7

Table of Contents

Certain Risks and Uncertainties

Product Development

We devote significant resources to research and development programs in an effort to discover and develop potential future product candidates. The product candidates in our pipeline are at various stages of preclinical and clinical development. The path to regulatory approval includes three phases of clinical trials in which we collect data to support an application to regulatory authorities to allow us to market a product for treatment of a specified disease. There are many difficulties and uncertainties inherent in research and development of new products, resulting in a high rate of failure. To bring a drug from the discovery phase to regulatory approval, and ultimately to market, takes many years and significant cost. Failure can occur at any point in the process, including after the product is approved, based on post-market factors. New product candidates that appear promising in development may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain necessary regulatory approvals, limited scope of approved uses, reimbursement challenges, difficulty or excessive costs of manufacture, alternative therapies or infringement of the patents or intellectual property rights of others. Uncertainties in the FDA approval process and the approval processes in other countries can result in delays in product launches and lost market opportunities. Consequently, it is very difficult to predict which products will ultimately be submitted for approval, which have the highest likelihood of obtaining approval and which will be commercially viable and generate profits. Successful results in preclinical or clinical studies may not be an accurate predictor of the ultimate safety or effectiveness of a drug or product candidate.

Expenditures for research, development, and engineering of products are expensed as incurred. For the years ended June 30, 2022 and 2021, the Company incurred approximately $4.8 million and $7.0 million of research and development costs, respectively.

Concentrations of Credit Risk

The Company maintains its cash in bank deposit and checking accounts that at times exceed federally insured limits of $250,000. Approximately $3.5 million is subject to credit risk at June 30, 2022. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Commitments and Contingencies

The Company follows Subtopic 450-20 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. The Company’s legal costs associated with contingent liabilities are recorded to expense as incurred.

Accrued Outsourcing Costs

Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors, or collectively “CROs.” These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate the estimates to determine if adjustments are necessary or appropriate based on information we receive.

F-8

Table of Contents

~~Basic~~Income ~~Loss per Share~~Taxes

~~Basic~~Deferred income tax assets and ~~diluted~~liabilities ~~loss~~arise ~~per~~from ~~share~~temporary isdifferences ~~computed~~associated ~~based~~with ondifferences between the ~~weighted-average~~financial ~~common~~statements ~~shares~~ and ~~common~~tax ~~share~~basis ~~equivalents~~of ~~outstanding~~assets ~~during~~and ~~the~~liabilities, ~~period.~~as ~~Common~~measured ~~share~~by ~~equivalents~~the ~~consist~~enacted oftax ~~stock options~~rates, ~~restricted~~which ~~stock,~~are ~~warrants~~expected ~~and~~to ~~convertible~~be ~~related~~in ~~party~~effect ~~notes~~when ~~payable~~these differences reverse. ~~Common~~Deferred ~~share~~tax ~~equivalents~~assets ~~were~~and ~~excluded~~liabilities ~~from~~are classified as current or non-current, depending upon the ~~computation~~classification of ~~diluted~~the ~~earnings~~asset ~~per~~or ~~share~~liabilities ~~for~~to ~~the~~which ~~years~~they ~~ended~~relate. ~~June~~Deferred ~~30,~~tax ~~2021~~assets and ~~2020,~~liabilities ~~because~~not ~~their~~related ~~effect~~to ~~was~~an ~~anti~~asset or liability are classified as current or non-~~dilutive~~current depending on the periods in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company has generated net losses since inception and accordingly has not recorded a provision for income taxes. The deferred tax assets were primarily comprised of federal and state tax net operating loss, or NOL, carryforwards. Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these tax assets, a full valuation allowance has been established to offset the deferred tax assets. Additionally, the future utilization of the NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that could occur in the future. If necessary, the deferred tax assets will be reduced by any carryforwards that expire prior to utilization as a result of such limitations, with a corresponding reduction of the valuation allowance.

The Company follows the provisions of FASB ASC 740-10 “Uncertainty in Income Taxes” (ASC 740-10). The Company has not recognized a liability as a result of the implementation of ASC 740-10. A reconciliation of the beginning and ending amount of unrecognized tax benefits has not been provided since there is no unrecognized benefit since the date of adoption. The Company has not recognized interest expense or penalties as a result of the implementation of ASC 740-10. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.

Basic and Diluted Loss per Share

Basic and diluted loss per share are computed based on the weighted-average common shares and common share equivalents outstanding during the period. Except with respect to certain voting, conversion and transfer rights and as otherwise expressly provided in the Company’s Articles of Incorporation or required by applicable law, shares of the Company’s Class A common stock and Class B common stock have the same rights and privileges and rank equally, share ratably and are identical in all respects as to all matters. Accordingly, basic and diluted net income (loss) per share are the same for both classes. Common share equivalents consist of stock options, restricted stock, warrants, convertible related party notes payable, and convertible preferred stock. Common share equivalents were excluded from the computation of diluted earnings per share for the years ended June 30, 2022 and 2021, because their effect was anti-dilutive.

F-9

Table of Contents

Weighted average shares of common stock outstanding used in the calculation of basic and diluted earnings per share were as follows:

	Year Ended
	June 30,
	2021			2020
	2022			2021
Net loss per share, basic and diluted	$	(0.0401	)	$	(0.0304	)
Net loss per common shares outstanding:
Common stock - Class A	$	(0.04	)	$	(0.03	)
Common stock - Class B	$	(1.46	)	$	(5.84	)
Total of Class A and Class B	$	(0.04	)	$	(0.03	)
Weighted average shares outstanding:
Class A common stock		~~376~~488,~~659~~225,~~381~~673			~~237~~376,~~298~~659,~~768~~381
Class B common stock		915,~~503~~641,~~827~~463			19,~~137~~503,~~604~~827
Total weighted average shares outstanding		~~386~~503,~~163~~867,~~208~~136			~~238~~386,~~436~~163,~~372~~208
Antidilutive securities not included:
Stock options		68,~~017~~268,~~294~~269			216,~~457~~779,~~124~~935
Stock options arising from convertible note payable and accrued interest		2508,~~567,476~~448			32,~~666~~567,~~190~~476
Restricted stock grants		~~116~~58,~~786~~392			116,~~787~~786
Total		8,701,556			25,240,101
Convertible preferred stock		36,000,000			-
Total		44,835,109			9,464,197

Treasury Stock

The Company accounts for treasury stock using the cost method. There were 8,516,056 shares of Class A common stock and 2,358,537 shares of Class B common stock held in treasury, purchased at a total cumulative cost of approximately $2.3 million as of June 30, ~~2021.~~2022 ~~There~~and ~~were~~2021 ~~659,448 shares of Class A common stock held in treasury, purchased at a total cumulative cost of $146,000 as of June 30, 2020~~ (see Note 1415. Equity Transactions).

Treasury stock, representing shares of the Company’s common stock that have been acquired for payroll tax withholding on vested stock grants and to satisfy the exercise price on vested stock options, is recorded at its acquisition cost and these shares are not considered outstanding.

Revenue Recognition

OnThe ~~July 1, 2019, the~~ Company ~~adopted~~follows the ~~new~~guidance of accounting standard ASC 606 (Topic 606), Revenue from Contracts with Customers, and all the related amendments ~~using the modified retrospective method applied to those contracts which were not completed as of July 1, 2019~~. The adoption of ASC 606 did not have an impact on the Company’s consolidated financial statements or cash flows, for the Company had no revenue and no contracts which were not completed as of July 1, 2019.

~~F-9~~The ~~Table~~Company has acquired and further developed license rights to Functional Intellectual Property (“functional IP”) that it licenses to customers for defined license periods. A functional IP license is a license to intellectual property that has significant standalone functionality that does not include supporting or maintaining the intellectual property during the license period. The Company’s patented drug formulas have significant standalone functionality in their abilities to treat a disease or condition. Further, there is no expectation that the Company will undertake any activities to change the functionality of ~~Contents~~the drug formulas during the license periods (see Note 8. Exclusive License Agreement and Patent Assignment Agreement).

The Company has acquired and further developed license rights to Functional Intellectual Property (“functional IP”) that it licenses to customers for defined license periods. A functional IP license is a license to intellectual property that has significant standalone functionality that does not include supporting or maintaining the intellectual property during the license period. The Company’s patented drug formulas have significant standalone functionality in their abilities to treat a disease or condition. Further, there is no expectation that the Company will undertake any activities to change the functionality of the drug formulas during the license periods (see Note 7. Exclusive License Agreement to the consolidated financial statements).

Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.

Pursuant to ASC 606, a customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps:

	(i)	identify the contract(s) with a customer;
	(ii)	identify the performance obligations in the contract, including whether they are distinct in the context of the contract;
	(iii)	determine the transaction price, including the constraint on variable consideration;
	(iv)	allocate the transaction price to the performance obligations in the contract; and
	(v)	recognize revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct. If a promised good or service is not distinct, it is combined with other performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

F-10

Table of Contents

The terms of the Company’s licensing agreement include the following:

	(i)	up-front fees;
	(ii)	milestone payments related to the achievement of development, regulatory, or commercial goals; and
	(iii)	royalties on net sales of licensed products.

F-10 Table of Contents

License of Intellectual Property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other performance obligations in the contract. For licenses that are combined with other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Milestone Payments: At the inception of each arrangement that includes developmental and regulatory milestone payments, the Company evaluates whether the achievement of each milestone specifically relates to the Company’s efforts to satisfy a performance obligation or transfer a distinct good or service within a performance obligation. If the achievement of a milestone is considered a direct result of the Company’s efforts to satisfy a performance obligation or transfer a distinct good or service and the receipt of the payment is based upon the achievement of the milestone, the associated milestone value is allocated to that distinct good or service. If the milestone payment is not specifically related to the Company’s effort to satisfy a performance obligation or transfer a distinct good or service, the amount is allocated to all performance obligations using the relative standalone selling price method. The Company also evaluates the milestone to determine whether they are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price to be allocated, otherwise, such amounts are constrained and excluded from the transaction price. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the transaction price. Any such adjustments to the transaction price are allocated to the performance obligations on the same basis as at contract inception. Amounts allocated to a satisfied performance obligation shall be recognized as revenue, or as a reduction of revenue, in the period in which the transaction price changes.

Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied) in accordance with the royalty recognition constraint.

Accounting for Stock Based Compensation

The stock-based compensation expense incurred by the Company for employees, non-employees and directors in connection with its ~~stock~~equity ~~option~~incentive plan is based on ~~the employee model of~~ ASC 718, and the fair market value of the ~~options~~equity awards is measured at the grant date. Under ASC 718 employee is defined as “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. tax regulations.”

OnAwards ~~July~~with ~~1, 2019, the Company adopted ASU 2018~~service-~~07,~~based ~~Compensation~~vesting –conditions ~~Stock~~only: ~~Compensation~~Expense ~~(Topic~~is ~~718):~~recognized ~~Improvements~~on toa ~~Nonemployee Share~~straight-~~Based~~line ~~Payment~~basis ~~Accounting.~~over ~~Beginning~~the ~~with~~requisite ~~the~~service ~~adoption~~period of ~~ASU 2018-07 options granted to our consultants are accounted for in~~ the ~~same manner as options issued to employees~~award.

Awards with service-based vesting conditions only – Expense recognized on a straight-line basis over the requisite service period of the award.

F-11

Table of Contents

Awards with performance-based vesting conditions: – Expense is not recognized until it is determined that it is probable the performance-based conditions will be met. When achievement of a performance-based condition is probable, a catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis over the requisite service period basis until a higher performance-based condition is met, if applicable.

Awards with market-based vesting conditions: – Expense recognized on a straight-line basis over the requisite service period, which is the lesser of the derived service period or the explicit service period if one is present. However, if the market condition is satisfied prior to the end of the requisite service period, the Company will accelerate all remaining expense to be recognized.

Awards with both performance-based and market-based vesting conditions: –If if an award vesting or exercisability is conditional upon the achievement of either a market condition or performance or service conditions, the requisite service period is generally the shortest of the explicit, implicit, and derived service period.

We have elected to use the Black-Scholes-Merton pricing model to determine the fair value of stock options on the dates of grant. Restricted stock units are measured based on the fair market values of the underlying stock on the dates of grant. The grant date is also the valuation date for the non-employee awards. We recognize stock-based compensation using the straight-line method.

~~4. Patents, net~~ Investments

For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. For those investments in which the Company does not have such significant influence, the Company applies the accounting guidance for certain investments in debt and equity securities.

Recent Accounting Pronouncements

In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity’s Own Equity (Subtopic 815-40), which simplifies the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. This ASU (1) simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock; (2) revises the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification; and (3) revises the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share for convertible instruments by using the if-converted method. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Adoption is either through a modified retrospective method or a full retrospective method of transition. The adoption of this standard will not materially impact the Company’s consolidated financial statements in 2022.

The FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326). This standard requires a financial asset to be presented at the net amount expected to be collected. The financial assets of the Company in scope of ASU 2016-13 will primarily be accounts receivable. The Company will estimate an allowance for expected credit losses on accounts receivable that result from the inability of customers to make required payments. In estimating the allowance for expected credit losses, consideration will be given to the current aging of receivables, historical experience, and a review for potential bad debts. The Company will adopt this guidance in the first quarter of fiscal 2023 and does not expect the adoption to have an impact on its results of operations, financial position, and disclosures.

F-12

Table of Contents

4. Equity Investment

BT BeaMedical Technologies Ltd. (formerly known as Squalus Medical Ltd.)

On June 9, 2022, the Company entered into a Series A Preferred Share Purchase Agreement (the “Purchase Agreement”) with BT BeaMedical Technologies Ltd. (formerly known as Squalus Medical Ltd.), a company established under the laws of the State of Israel (“BTL”), pursuant to which the Company purchased 55,556 shares of BTL’s Series A Redeemable Preferred Shares (the “Series A Shares”) and a warrant to purchase 27,778 Series A Shares for aggregate consideration of $4,000,000, or approximately $72.00 per Series A Share. Following the closing under the Purchase Agreement, the Company owns approximately 35.7% of BTL’s issued and outstanding equity securities and approximately 41.6% of BTL’s equity securities on a fully diluted basis. The Company also entered into customary investor rights and indemnification agreements with BTL. The Company therefore recorded an equity investment on our June 30, 2022 consolidated balance sheet.

The Company’s equity in losses in excess of its investment are accounted for under the equity method consisted of the following as of June 30, 2022 (rounded to nearest thousand):

Investment Name	Ownership Interest			Carrying Amount
BT BeaMedical Technologies Limited (“BTL”)		35.7	%
Total contributions				$	4,000,000
Less: Share of the loss in investment in BTL					(22,000	)
Equity losses in excess of investment				$	3,978,000

The Company invested approximately $4,000,000 in BTL as of June 30, 2022. The cash balance in BTL at June 30, 2022 was approximately $3.8 million. During the year ended June 30, 2022, BTL incurred a loss of approximately $63,000, and accordingly, the Company recorded its share of the loss in investment in BTL, in accordance with the provisions in the purchase agreement, of approximately $22,000 in the accompanying consolidated statement of operations.

We were committed to fund BTL for our share of its liabilities at June 30, 2022. The Company will continue providing additional equity contributions in 2023 and for the foreseeable future.

Summarized balance sheet information for the Company’s equity method investee BTL as of June 30, 2022 is presented in the following table (rounded to nearest thousand):

Current assets
Cash	$	3,850,000
Other current assets		1,000
Total assets	$	3,851,000
Current liabilities	$	(195.000	)
Total liabilities	$	(195,000	)

Summarized income statement information for the Company’s equity method investee BTL is presented in the following table for the period from June 9, 2022 (date of acquisition) to June 30, 2022 (rounded to nearest thousand):

Net sales and revenue	$	-
Research and development costs		7,000
Administrative expenses		55,000
Total operating expense	$	62,000
Loss from operations	$	62,000
Other expense		1,000
Net loss	$	63,000

F-13

Table of Contents

5. Patents, net

Patents, net consisted of the following (rounded to nearest thousand):

		Useful life (years)	June 30, 2021			June 30, 2020
	Useful life(years)		June 30,2022			June 30,2021
Purchased Patent Rights- Brilacidin and related compounds		14	$	4,082,000		$	4,082,000
Purchased Patent Rights-Anti-microbial- surfactants and related compounds		12		144,000			144,000
Patents - Kevetrin and related compounds		17		1,280,000			1,208,000
Patents – Brilacidin, and other compounds		17		1,146,000			1,280,000
				5,506,000			5,434,000
Total patents cost				5,372,000			5,506,000
Less: Accumulated amortization for Brilacidin, Anti-microbial- surfactants and related compounds				(2,373,000	)		(2,069,000	)
Less: Accumulated amortization				(3,060,000	)		(2,752,000	)
Accumulated amortization for Patents-Kevetrin and related compounds				(379,000	)		(305,000	)
Patents, net			$	2,312,000		$	2,754,000
Total			$	2,754,000		$	3,060,000

The patents are amortized on a straight-line basis over the useful lives of the assets, determined to be 12-17 years from the date of acquisition.

Amortization expense for the years ended June 30, ~~2021~~2022 and ~~2020~~2021 was approximately $382,000 and $378,000, respectively. During the fiscal years ended June 30, 2022 and 2021, the Company has written off the patent costs relating to Kevetrin of approximately $~~372~~141,000 and $0, respectively and included these in general and administrative expenses.

At June 30, ~~2021~~2022, the future amortization period for all patents was approximately ~~4.18~~12 years to ~~16.75~~17 years. Future estimated amortization expenses are approximately $~~379~~371,000 for each year from ~~2022~~2023 to ~~2026~~2025, $361,000 for the year ending June 30, 2026 and a total of $~~859~~838,000 for the year ending June 30, 2027 and thereafter.

F6. Accrued Expenses -12 ~~Table~~Related ofParties ~~Contents~~and Other

5. Accrued Expenses – Related Parties and Other

Accrued expenses consisted of the following (rounded to nearest thousand):

	June 30, 2021		June 30, 2020
	June 30, 2022		June 30, 2021
Accrued research and development consulting fees	$	~~340~~80,000	$	40340,000
Accrued rent (Note 10) - related parties		8,000		8,000
Accrued rent - related parties (Note 11. Related Party Transactions)		8,000		8,000
Accrued interest (Note 11) - related parties		—		11,000
Accrued interest - related parties (Note 12. Convertible Note Payable - Related Party)		4,000		-
Total	$	~~348~~92,000	$	59348,000

67. Accrued Salaries and Payroll Taxes - Related Parties and Other

Accrued salaries and payroll taxes consisted of the following (rounded to nearest thousand):

	June 30, 2021		June 30, 2020
	June 30, 2022		June 30, 2021
Accrued salaries - related parties	$	1,~~785~~492,000	$	21,~~647~~785,000
Accrued payroll taxes - related parties		~~130~~71,000		130,000
Accrued salaries – others		—		279,000
Withholding tax - payroll		77,000		77,000
Accrued salaries – employee		—		91,000
Total	$	1,640,000	$	1,992,000
Withholding tax - payroll		77,000		68,000
Total	$	1,992,000	$	3,215,000

7.F-14 ~~Exclusive~~Table ~~License~~of ~~Agreement~~ Contents

8. Exclusive License Agreement and Patent Assignment Agreement

On July 18, 2019, the Company entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of UP/UPS.

Under the terms of the License Agreement, Alfasigma made an initial upfront non-refundable payment of $0.4 million to the Company in July, 2019 and will make additional payments of up to $24.0 million to the Company based upon the achievement of certain milestones, including a $1.0 million payment due following commencement of the first Phase 3 clinical trial of Brilacidin for UP/UPS and an additional $1.0 million payment upon the filing of a marketing approval application with the U.S. Food and Drug Administration or the European Medicines Agency. At this time, Alfasigma has completed a Phase 1 clinical trial with Brilacidin. In addition to the milestones, Alfasigma will pay a royalty to the Company equal to six percent of net sales of Brilacidin for UP/UPS, subject to adjustment as provided in the License Agreement. The Company received an initial upfront non-refundable payment of $0.4 million and reported as revenue in July, 2019 and the Company did not receive any further payment during the years ended June 30, 2022 and 2021.

~~The~~On April 13, 2022, the Company ~~generated~~entered ~~revenue~~a ofPatent $0Assignment ~~million~~Agreement ~~and~~with $0Fox Chase Chemical Diversity Center, Inc.4 ~~million~~(“FCCDC”), ~~for~~pursuant to which the ~~years~~Company ~~ended~~assigned ~~June~~the 30title, ~~2021~~rights and ~~2020,~~interest ~~respectively.~~in ~~Revenue~~and ~~during~~to the ~~years~~applications ~~ended~~of ~~June~~certain ~~30,~~patents ~~2020~~in ~~represented~~accordance ~~the~~with ~~initial~~an ~~non-refundable~~earlier ~~payment~~collaborative ofresearch ~~$0.4~~agreement ~~million~~related ~~received~~to ~~from~~antifungal ~~Alfasigma.~~drug discovery work to which the Company had rights.

FOn May 3, 2022, the Company received payment of $18,000 from FCCDC based on FCCDC’s third-13party ~~Table~~license of ~~Contents~~broad-spectrum anti-fungals and a separate agreement between the Company and FCCDC. Some of the preliminary data used in the FCCDC research program had been obtained as part of an earlier collaboration with the Company supported by funding from the National Institutes of Health. Additional payments from FCCDC to the Company may also be made in the future.

89. Operating Leases

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives. Our variable lease payments primarily consist of maintenance and other operating expenses from our real estate leases. Variable lease payments are excluded from the ROU assets and lease liabilities and are recognized in the period in which the obligation for those payments is incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease and non-lease components. We have elected to account for these lease and non-lease components as a single lease component. We are also electing not to apply the recognition requirements to short-term leases of twelve months or less and instead will recognize lease payments as expense on a straight-line basis over the lease term.

The Company determined that the operating lease right-of-use asset was fully impaired on December 31, 2019. As such, the Company recognized an impairment loss of approximately $643,000, after recording amortization of the right-of-use asset for July, August, and September 2019 totaling approximately $27,000, resulting in a carrying value of $0 since December 31, 2019. The Company vacated the leased office space in December 2019, and in January 2020 the Company initiated a lawsuit against the lessor relating to an automatic extension of the lease for the office space and related matters (See Note 910. Commitments and Contingencies).

~~The~~F-15 ~~components~~Table of ~~lease expense and supplemental cash flow information related to leases for the year are as follows:~~Contents

	Year Ended June 30, 2021
Lease Cost
Operating lease cost (included in general and administrative in the Company’s consolidated statement of operations)	$	86,000
Variable lease cost		12,000
	$	98,000
Other Information
Cash paid for amounts included in the measurement of lease liabilities for the year ended June 30, 2021	$	134,000
Weighted average remaining lease term – operating leases (in years)		2.5
Average discount rate – operating leases		18	%

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

The supplemental balance sheet information related to leases for the year is as follows:

	Year Ended June 30, 2022
Lease Cost
Operating lease cost (included in general and administrative in the Company’s consolidated statements of operations)	$	59,000
Variable lease cost		12,000
	$	71,000
Other Information
Cash paid for amounts included in the measurement of lease liabilities for the year ended June 30, 2022	$	164,000
Weighted average remaining lease term - operating leases (in years)		1.25
Average discount rate - operating leases		18	%

	At June 30, 2021
Operating leases
Short-term operating lease liabilities	$	165,000
Long-term operating lease liabilities		252,000
Total operating lease liabilities	$	417,000

The supplemental balance sheet information related to leases for the period is as follows:

F-14 Table of Contents

	At June 30, 2022
Operating leases
Short-term operating lease liabilities	$	197,000
Long-term operating lease liabilities		55,000

Total operating lease liabilities	$	252,000

The following table provides maturities of the Company’s lease liabilities at June 30, ~~2021~~2022 as follows:

	Operating Leases
Fiscal Year Ending June 30,
2022	$	223,000
2023	$	223,000
2023		223,000
2024 (remaining 3 months)		57,000
2024 (remaining 3 months)		60,000
Total lease payments		280,000
Total lease payments		506,000
Less: Imputed interest/present value discount		(28,000	)
Less: Imputed interest/present value discount		(89,000	)
Present value of lease liabilities	$	252,000
Present value of lease liabilities	$	417,000

Operating lease cost for the years ended June 30, ~~2021~~2022 was approximately $8659,000. Operating lease cost for the years ended June 30, ~~2020~~2021 was approximately $~~117~~86,000.

9.F-16 ~~Commitments~~Table ~~and~~of ~~Contingencies~~Contents

10. Commitments and Contingencies

Litigation

On January 22, 2020, the Company filed a complaint against Cummings Properties, LLC in the Superior Court of the Commonwealth of Massachusetts (C.A. No. 20-77CV00101), seeking, among other things, declaratory relief that the lease ~~for~~terminated in September 2018, because the Company’s prior principal executive offices did not automatically extend for an additional five years from September 2018, return of the Company’s security deposit, and damages. The total lease amount is approximately $0.6 million. The Company is currently unable to determine the probability of the outcome or reasonably estimate the loss or gain, if any.

Contractual Commitments

The Company has total non-cancellable contractual minimum commitments of approximately $41.80 million to contract research organizations as of June 30, ~~2021~~2022. Expenses are recognized when services are performed by the contract research organizations.

Contingent Liability - Disputed Invoices

As ~~described~~disclosed in Note 67. Accrued Salaries and Payroll Taxes, the Company accrued payroll to Dr. Krishna Menon, ex-President of Research of approximately $1,443,000 for his past services with the Company, and this amount was included in accrued salaries and payroll taxes. As described in Note 1011. Related Party Transactions, the Company has a payable to Kard Scientific, Inc. (“KARD”) of approximately $1,486,000 for its research and development expenses and this amount was included in accounts payable. KARD is a company owned by Dr. Menon. Dr. Menon’s employment was terminated with the Company on September 18, 2018, and Dr. Menon resigned from the Company’s Board of Directors on December 11, 2018. Dr. Menon, on behalf of himself and KARD, demanded payment of these amounts in October 2019; however, the Company disputes the underlying basis for these amounts and notified Dr. Menon in November 2019 of the Company’s intent not to pay them.

All of the above disputed invoices were reflected as current liabilities as of June 30, ~~2021~~2022.

1011. Related Party Transactions

Pre-clinical Studies

The Company previously engaged KARD to conduct specified pre-clinical studies. The Company did not have an exclusive arrangement with KARD. All work performed by KARD needed prior approval by the executive officers of the Company, and the Company retained all intellectual property resulting from the services by KARD. The Company no longer uses KARD. At June 30, ~~2021~~2022 and ~~2020~~2021, the accrued research and development expenses payable to KARD was approximately $1,486,000 and this amount was included in accounts payable. Dr. Menon, the Company’s ex-principal shareholder and Director, on behalf of himself and KARD, demanded payment of these amounts in October 2019; however, the Company disputes the underlying basis for these amounts and notified Dr. Menon in November 2019 of the Company’s intent not to pay them.

~~F-15~~At ~~Table~~June 30, 2022 and 2021, rent payables to KARD of ~~Contents~~approximately $8,000, were included in accrued expenses.

~~Share~~12. ~~Issuance~~Convertible Note Payable - Related Party

On February 23, 2020, the Company issued (i) options for the purchase of 500,000 shares of Class A common stock at an exercise price of $0.10 per share, which is 110% of the previous per share closing price of $0.09 on February 21, 2020, and (ii) 500,000 shares of Class A common stock to each member of the Company’s Board of Directors, consisting of Leo Ehrlich, Barry Schechter and Zorik Spektor.

Other related party transactions are disclosed in Note 11. Convertible Note Payable - Related Party below.

11. Convertible Note Payable - Related Party

The Ehrlich Promissory Note C is an unsecured demand note with Mr. Ehrlich, the Company’s Chairman and CEO, that originated in 2010, bears 9% simple interest per annum and is convertible into the Company’s Class A common stock at $0.50 per share.

On December 29, 2010, the Company issued 18,000,000 Equity Incentive Options to purchase Class B common stock to Mr. Ehrlich, which are exercisable at $0.11 per share. On May 8, 2012, the Company did not have the ability to repay the Ehrlich Promissory Note C loan of approximately $2,022,000 and agreed to change the interest rate from 9% simple interest to 10% simple interest, and the Company issued 2,000,000 Equity Incentive Options exercisable at $0.51 per share equal to 110% of the closing bid price of $0.46 per share on May 7, 2012. ~~Options~~All ~~are~~these options were valid for ten years from the date of issuance and expired in May, 2022.

On January 29, 2019, the Company issued 909,090 shares of Class B common stock at the option exercise price of $0.11 per share to Mr. Ehrlich for his partial exercise of his option, paid by the cancellation of debt to Mr. Ehrlich of $100,000 to satisfy the exercise price (as permitted pursuant to the terms of the option agreement).

F-17

Table of Contents

On March 30, 2020, the Company issued 909,090 shares of Class B common stock at the option exercise price of $0.11 per share to Mr. Ehrlich for his partial exercise of his option, paid by the cancellation of debt to Mr. Ehrlich of $100,000 to satisfy the exercise price (as permitted pursuant to the terms of the option agreement).

On September 8, 2020, the Company issued 1,787,762 shares of Class B common shares (net of 412,238 shares of Class B common shares withheld to satisfy taxes) at the option exercise price of $0.11 per share to Mr. Ehrlich for his partial exercise of his option, paid by the cancellation of debt to Mr. Ehrlich of $242,000 to satisfy the exercise price (as permitted pursuant to the terms of the option agreement).

During the year ended June 30, 2022, the Company repaid the principal of $1,033,000 to Mr. Ehrlich, the Company’s Chairman and CEO. As of June 30, ~~2021~~2022 and ~~2020~~June 30, 2021, the principal balance of this convertible note payable to Mr. Ehrlich, the Company’s Chairman and CEO was approximately $1250,~~283,~~000 and $1,~~822~~283,000, respectively.

As of June 30, ~~2021~~2022 and ~~2020~~2021, the balance of accrued interest payable was $04,000 and $110,~~000,~~ respectively (see Note 56. Accrued Expenses –- Related Parties and Other).

As of June 30, ~~2021~~2022 and ~~2020~~2021, the total outstanding balances of principal and interest were approximately $1254,~~283,~~000 and $1,~~833~~283,000, respectively.

~~F-16~~13. ~~Table~~Loan ~~of Contents~~payable

12. Loan payable

On May 10, 2020 and April 19, 2021, the Company received loan proceeds in the amount of approximately $93,000 and $79,000, respectively, under the Paycheck Protection Program (“PPP”) and it was recorded under loan payable. The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the eight-week period.

~~The~~During ~~Company~~the ~~applied~~year ~~for~~ended June 30, 2022, the ~~forgiveness~~Company obtained the approval of the ~~first~~forgiveness ~~loan~~of ~~and~~the ~~such~~above ~~application~~mentioned istwo inloans, ~~process.~~and ~~The~~the Company ~~intends~~recorded tothe ~~apply~~total ~~for~~loan forgiveness of ~~the~~$172,000 ~~second~~under ~~PPP~~other ~~loan during fiscal 2022~~income.

1314. Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding

Stock-based Compensation –- Stock Options

2016 Equity Incentive Plan (the “2016 Plan”)

On June 30, 2016, the Board of Directors adopted the Company’s 2016 Plan. The 2016 Plan became effective upon adoption by the Board of Directors on June 30, 2016.

On February 23, 2020, the Board of Directors approved an amendment to Section 4.1 of the 2016 Plan to increase the annual limit on the number of awards under such Plan to outside directors from 250,000 to 1,500,000. On October 10, 2021, the Board of Directors approved amendments to the 2016 Plan to increase the number of shares of common stock available for issuance thereunder to 225,000,000 shares and to increase the annual limit on the number of awards under such Plan to outside directors from 1,500,000 to 5,000,000, among other changes.

Up to 20225,000,000 shares of the Company’s Class A common stock may be issued under the 2016 Plan (subject to adjustment as described in the 2016 Plan).

Stock Options

The fair value of options granted for the years ended June 30, 2021 and 2020 was estimated on the date of grant using the Black-Scholes-Merton Model that uses assumptions noted in the following table.

	Years Ended June 30,
	2021		2020
Expected term (in years)	3 – 10		3 - 10
Expected stock price volatility	89.88% to 109.33%		73.68% to 92.21%
Risk-free interest rate	0.31% to 0.68%		0.41% to 1.50%
Expected dividend yield		0		0

F-17 Table of Contents

The components of stock-based compensation expense included in the Company’s Consolidated Statement of Operations for the years ended June 30, 2021 and 2020 are as follows (rounded to nearest thousand):

	Years ended June 30,
	2021		2020
Stock-based compensation – officers	$	—	$	298,000
Stock-based compensation – employees		59,000		104,000
Stock-based compensation – consultants		124,000		39,000
Reversal of forfeited stock-based compensation		—		(251,000	)
– included in Research and Development expenses		183,000		190,000
Stock-based compensation – officers – included in General and Administration expenses		—		237,000
Total Stock-based compensation, net	$	183,000	$	427,000

During the year ended June 30, 2021 and 2020

On June 11, 2021, the Company agreed to issue 105,000 stock options to purchase shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.22 per share and vested immediately. The value of these options was approximately $15,000. During the year ended June 30, 2021, the Company recorded approximately $15,000 of related stock-based compensation. The assumptions we used in the Black Scholes option-pricing model were disclosed above.

On February 10, 2021, the Company agreed to issue 75,000 stock options to purchase shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.38 per share and vest 33 1/3% on February 10, 2021, 33 1/3% on July 1, 2021, and 33 1/3% on January 1, 2022. The value of these options was approximately $20,000. During the year ended June 30, 2021, the Company recorded approximately $13,000 of related stock-based compensation. The assumptions we used in the Black Scholes option-pricing model were disclosed above.

On September 11, 2020, the Company also issued to Ms. Jane Harness, the Senior Vice President, Clinical Sciences and Portfolio Management of the Company, 58,394 shares of the Company’s common stock. The Company also issued 172,987 options to purchase common stock. These stock options with 3 years vesting period were valued at approximately $33,000 and these 58,394 shares of the Company’s common stock were valued at approximately $13,000, based on the closing bid price as quoted on the OTC on September 11, 2020 at $0.22 per share. During the year ended June 30, 2021, the Company recorded approximately $12,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $9,000 of stock option expense and $3,000 of stock awards.

On July 23, 2020, the Company agreed to issue 100,000 stock options to purchase shares of the Company’s common stock to two consultants for their one-year contracts. These options were issued with an exercise price of $0.32 per share and vest 33 1/3% on July 23, 2020, 33 1/3% on January 23, 2021, and 33 1/3% on July 23, 2021. The value of these options was approximately $28,000. During the year ended June 30, 2021, the Company recorded approximately $27,000 of related stock-based compensation. The assumptions we used in the Black Scholes option-pricing model were disclosed above.

On May 18, 2020, the Company agreed to issue 500,000 stock options to purchase shares of the Company’s common stock each to two consultants for their one-year contracts. These options were issued with an exercise price of $0.14 per share and vest 33 1/3% on July 1, 2020, 33 1/3% on January 1, 2021, and 33 1/3% on July 1, 2021. The value of these options was approximately $78,000. During the years ended June 30, 2021 and 2020, the Company recorded approximately $53,000 and $25,000 of related stock-based compensation, respectively. The assumptions we used in the Black Scholes option-pricing model were disclosed above.

F-18

Table of Contents

OnStock March 20, 2020, the Company agreed to issue 250,000 stock options to purchase shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.086 per share and vested immediately. The value of these options was approximately $12,000. During the year ended June 30, 2020, the Company recorded approximately $12,000 of related stock-based compensation. The assumptions we used in the Black Scholes option-pricing model were disclosed above. Options

OnThe ~~February~~fair ~~23,~~value ~~2020,~~of ~~the Company issued 500,000~~ options ~~each~~granted ~~to our Chairman and CEO and two other Board members, with 1,500,000 options in total, which are exercisable~~ for 10the years atended ~~$0.10~~June ~~per share of common stock. These stock options~~30, ~~which~~2022 ~~were vested immediately, were valued at approximately $102,000~~ and we2021 ~~recognized~~was ~~approximately~~estimated ~~$102,000~~on ofthe ~~stock-based~~date ~~compensation costs and charged to additional paid-in capital as~~ of ~~June~~grant ~~30,~~using ~~2020. The assumptions we used in~~ the Black -Scholes ~~option~~-~~pricing~~Merton ~~model~~Model ~~were~~that ~~disclosed~~uses ~~above.~~assumptions ~~The~~noted ~~Company~~in ~~also~~the ~~issued~~following ~~500,000 shares of Class A common stock each to our Chairman and CEO and two other Board members, which shares were vested on June 30, 2020 (See Note 14~~table. ~~Equity Transactions).~~

On September 1, 2019, the Company also issued to Ms. Jane Harness, the Senior Vice President, Clinical Sciences and Portfolio Management of the Company, 58,394 shares of the Company’s common stock. The Company also issued 172,987 options to purchase common stock. These stock options with 3 years vesting period were valued at approximately $20,000, based on the closing bid price as quoted on the OTC on August 30, 2019 at $0.132 per share. During the year ended June 30, 2021, the Company recorded approximately $9,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $7,000 of stock option expense and $2,000 of stock awards. During the year ended June 30, 2020, the Company recorded approximately $7,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $5,000 of stock option expense and $2,000 of stock awards.

	Years Ended June 30,
	2022		2021
Expected term (in years)	5-10		3-10
Expected stock price volatility	80.84 to 112.37%		89.88 to 109.33%
Risk-free interest rate	0.69% to 1.61%		0.31 to 0.68%
Expected dividend yield		0		0

OnThe ~~September~~components ~~1, 2019, the Company issued to Dr. Arthur Bertolino, the President and Chief Medical Officer~~ of ~~the Company, 1,066,667 shares of common~~ stock.-based ~~The~~compensation ~~Company~~expense ~~also~~included ~~issued~~in ~~617,839 stock options to purchase shares of~~ the Company’s ~~common~~Statements stock. These stock options were valued at approximately $71,000, based on the closing bid price as quoted on the OTC on August 30, 2019 at $0.132 per share. Due to the fact that Dr. Bertolino resigned on December 19, 2019, the Company recorded the forfeiture of ~~this~~Operations ~~2019~~for ~~options and shares after 60 days of his resignation. During~~ the ~~year~~years ended June 30, ~~2020,~~2022 ~~the Company reversed the stock-based compensation expenses of approximately $251,000 in total based on the amount of those unvested options~~ and ~~stock~~2021 ~~awards~~are weas ~~expensed~~follows ~~in the current year~~ (~~see~~rounded ~~below Note~~ to ~~Forfeiture~~nearest ~~of options~~thousand). :

On September 1, 2018, the Company also issued to Ms. Harness 58,394 shares of the Company’s common stock. The Company also issued 172,987 options to purchase common stock. These stock options are valued at approximately $63,000, based on the closing bid price as quoted on the OTCQB on August 31, 2018 at $0.40 per share. During the year ended June 30, 2021, the Company recorded approximately $29,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $21,000 of stock option expense and $8,000 of stock awards. During the year ended June 30, 2020, the Company recorded approximately $29,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $21,000 of stock option expense and $8,000 of stock awards.

	Years ended June 30,
	2022		2021

Research and development expenses	$	160,000	$	183,000
General and administrative expenses		423,000		-
Total stock-based compensation expense	$	583,000	$	183,000

On September 1, 2017, the Company agreed to grant to Ms. Harness under the 2016 Plan (i) 58,394 shares of restricted stock and (ii) a ten-year option to purchase 172,987 shares of the Company’s Class A common stock at an exercise price of $0.705 per share. The 58,394 shares were valued at approximately $41,000 and the 172,987 stock options valued at approximately $112,000. Both shares and options were planned to be amortized over 3 years to September 1, 2020 unless the other vesting requirements are met sooner. During the year ended June 30, ~~2021,~~2022 ~~the Company recorded approximately $8,000 of stock-based compensation expense in connection with the foregoing equity awards including approximately $6,000 of stock option expense~~ and $2,000 of stock awards. During the year ended June 30, 2020, the Company recorded approximately $51,000 of stock-based compensation expense in connection with the foregoing equity awards including approximately $37,000 of stock option expense and $14,000 of stock awards.2021

Directors and Employee

On October 10, 2021, the Compensation Committee approved the issuance of 1 million stock options to purchase shares of the Company’s common stock each to 2 independent directors of the Company, and 1 million stock options to purchase shares of Company’s common stock to Mr. Ehrlich, the CEO, which are exercisable for 10 years at $0.24 per share of common stock. These 3 million stock options with 1 year vesting period were valued at approximately $585,000. During the years ended June 30, 2022, the Company recorded approximately $423,000 of stock-based compensation costs and charged to additional paid-in capital as of June 30, 2022. The assumptions used in the Black Scholes option-pricing model are disclosed above.

On October 10, 2021, the Company also issued to Ms. Jane Harness, the Senior Vice President, Clinical Sciences and Portfolio Management of the Company, 500,000 options to purchase common stock, which are exercisable for 10 years at $0.24 per share of common stock. These stock options with 1 year vesting period were valued at approximately $98,000. During the years ended June 30, 2022, the Company recorded approximately $71,000 of related stock-based compensation. The assumptions used in the Black Scholes option-pricing model are disclosed above.

On September 11, 2020, the Company issued to Ms. Harness 58,394 shares of the Company’s common stock. The Company also issued 172,987 options to purchase common stock. These stock options with 3 years vesting period were valued at approximately $33,000 and these 58,394 shares of the Company’s common stock were valued at approximately $13,000, based on the closing bid price as quoted on the OTC on September 11, 2020 at $0.22 per share. During the year ended June 30, 2022, the Company recorded approximately $15,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $11,000 of stock option expense and $4,000 of stock awards. During the year ended June 30, 2021, the Company recorded approximately $12,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $9,000 of stock option expense and $3,000 of stock awards.

F-19

Table of Contents

On ~~September~~February 123, ~~2016~~2020, the Company ~~and~~issued ~~Ms.~~(i) ~~Harness~~options ~~entered~~for ~~into an executive employment agreement as~~ the ~~Company’s~~purchase ~~VP, Clinical Sciences and Project Management, effective on September 1, 2016. Commencing on September 1, 2016, the Company agreed to pay Ms. Harness an annual salary~~ of ~~$250~~500,000. ~~In addition, the Company agreed to grant to Ms. Harness under the Company 2016 Equity Incentive Plan 58,394~~ shares of ~~restricted stock. Ten-year options to purchase 172,987 shares of the Company’s~~ common stock ~~were also granted~~ at an exercise price of $10.3710 per share~~. The 58~~,~~394~~ ~~shares were valued at approximately $80,000,~~ which ~~were~~is ~~amortized~~110% ~~over~~of ~~three~~the ~~years~~previous toper ~~September~~share 1,closing ~~2019. The 172,987 stock options were valued at approximately $220,000 and will be exercisable for 10 years at an exercise~~ price of $10.2609 ~~per~~on ~~share.~~February ~~They~~21, ~~were amortized over 3 years to September 1~~2020, ~~2019.~~and ~~During~~(ii) ~~the year ended June 30~~500,000 ~~2021,~~shares ~~the~~of ~~Company~~Class ~~recorded~~A ~~approximately~~common ~~$0 of~~ stock~~-based~~ ~~compensation~~to ~~expense~~each inmember ~~connection~~of ~~with~~ the ~~foregoing equity awards. During the year ended June 30, 2020, the~~ Company’s ~~recorded~~Board ~~approximately~~of ~~$17~~Directors,~~000~~ consisting of ~~stock-based~~Leo ~~compensation expense in connection with the foregoing equity awards including approximately $12~~Ehrlich,~~000~~ ofBarry ~~stock~~Schechter ~~option expense~~ and ~~$5,000~~Zorik ~~of stock awards~~Spektor.

On September 1, 2019, the Company issued to Ms. Harness 58,394 shares of the Company’s common stock. The Company also issued 172,987 options to purchase common stock. These stock options with a 3 year vesting period were valued at approximately $20,000, based on the closing bid price as quoted on the OTC on August 30, 2019 at $0.132 per share. During the year ended June 30, 2022, the Company recorded approximately $9,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $6,000 of stock option expense and $3,000 of stock awards. During the year ended June 30, 2021, the Company recorded approximately $9,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $7,000 of stock option expense and $2,000 of stock awards.

On September 1, 2018, the Company issued to Ms. Harness 58,394 shares of the Company’s common stock. The Company also issued 172,987 options to purchase common stock. These stock options are valued at approximately $63,000, based on the closing bid price as quoted on the OTCQB on August 31, 2018 at $0.40 per share. During the year ended June 30, 2022, the Company recorded approximately $5,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $4,000 of stock option expense and $1,000 of stock awards. During the year ended June 30, 2021, the Company recorded approximately $29,000 of stock-based compensation expense in connection with the foregoing equity awards, including approximately $21,000 of stock option expense and $8,000 of stock awards.

Consultants

On January 1, 2022, the Company agreed to issue stock options to purchase 75,000 shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.044 per share and vest 33 1/3% on January 1, 2022, 33 1/3% on July 1, 2022 and 33 1/3% on January 1, 2023. The value of these options was approximately $3,000. During the year ended June 30, 2022, the Company recorded approximately $2,000 of related stock-based compensation. The assumptions used in the Black Scholes option-pricing model are disclosed above.

On July 30, 2021, the Company agreed to issue stock options to purchase 100,000 shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.27 per share and vest 33 1/3% on July 30, 2021, 33 1/3% on January 30, 2022, and 33 1/3% on July 30, 2022. The value of these options was approximately $19,000. During the year ended June 30, 2022, the Company recorded approximately $18,000 of related stock-based compensation. The assumptions used in the Black Scholes option-pricing model are disclosed above.

On July 1, 2021, the Company agreed to issue stock options to purchase 225,000 shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.21 per share and vest 33 1/3% on July 1, 2021, 33 1/3% on January 1, 2022, and 33 1/3% on July 1, 2022. The value of these options was approximately $33,000. During the year ended June 30, 2022, the Company recorded approximately $32,000 of related stock-based compensation. The assumptions used in the Black Scholes option-pricing model are disclosed above.

On February 10, 2021, the Company agreed to issue stock options to purchase 75,000 shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.38 per share and vest 33 1/3% on February 10, 2021, 33 1/3% on July 1, 2021, and 33 1/3% on January 1, 2022. The value of these options was approximately $20,000. During the years ended June 30, 2022 and 2021, the Company recorded approximately $7,000 and $13,000 of related stock-based compensation, respectively. The assumptions used in the Black Scholes option-pricing model are disclosed above.

On July 23, 2020, the Company agreed to issue stock options to purchase 100,000 shares of the Company’s common stock to one consultant for his one-year contract. These options were issued with an exercise price of $0.32 per share and vest 33 1/3% on July 23, 2020, 33 1/3% on January 23, 2021, and 33 1/3% on July 23, 2021. The value of these options was approximately $28,000. During the years ended June 30, 2022 and 2021, the Company recorded approximately $1,000 and $27,000 of related stock-based compensation, respectively. The assumptions used in the Black Scholes option-pricing model are disclosed above.

F-20

Table of Contents

On May 18, 2020, the Company agreed to issue stock options to purchase 500,000 shares of the Company’s common stock each to two consultants for their one-year contracts. These options were issued with an exercise price of $0.14 per share and vest 33 1/3% on July 1, 2020, 33 1/3% on January 1, 2021, and 33 1/3% on July 1, 2021. The value of these options was approximately $78,000. During the years ended June 30, 2022 and 2021, the Company recorded approximately $0 and $53,000 of related stock-based compensation, respectively.

Exercise of options

~~There~~During ~~were~~the ~~exercises~~years ofended ~~options~~June to30, ~~purchase~~2022, ~~Class~~the BCompany ~~common~~received ~~stock~~approximately ~~during~~$23,000 ~~the~~of ~~years~~net ~~ended~~proceeds ~~June~~from 30the exercise of 166,666 ~~2021~~stock ~~and~~options ~~2020~~at $0.14 per share. The details of exercises of options to purchase Class B common stock during the years ended June 30, 2021 are disclosed in Note 1415. Equity Transactions.

Forfeiture of options

There was forfeiture of 2,245,000 options and 294,330 options to purchase Class A common stock during the years ended June 30, ~~2021~~2022 ~~relating to the expiry of options of 12 consultants. Dr. Bertolino resigned as President~~ and ~~Chief Medical Officer and as a member of the Board of Directors of the Company on December 19~~2021, ~~2019. On February 17~~respectively, ~~2020,~~relating ~~all 2,471,356 options he held were forfeited, representing the options he was granted since June 27, 2016~~ to ~~September 1, 2019. During~~ the ~~year~~expiry ~~ended June 30, 2020, the Company reversed the $251,000~~ of ~~unvested~~ options ~~and~~of ~~shares that were expensed in the current year and prior years~~consultants.

Stock Options Issued and Outstanding

The following table summarizes all stock option activity under the Company’s equity incentive plans:

	Number ofOptions			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
	Number of Options			Weighted Average Exercise Price		Weighted Average RemainingContractual Life(Years)		AggregateIntrinsic Value
Outstanding at June 30, 2019		22,669,883		$	0.24		2.41	$	1,340,000
Granted		3,540,826		$	0.09		7.44		—
Exercised		(909,090	)	$	0.11		—		—
Forfeited/expired		(2,498,521	)	$	0.67		—		—
Outstanding at June 30, 2020		22,803,098		$	0.18		1.83	$	5,857,312
Granted		452,987		$	0.27		6.96		—
Exercised		(16,181,820	)	$	0.11		—		—
Forfeited/expired		(294,330	)	$	0.55		—		—
Outstanding at June 30, 2021		6,779,935		$	0.35		4.45	$	345,923
Exercisable at June 30, 2021		6,017,294		$	0.37		4.12	$	309,108
Granted		3,900,000		$	0.24		8.75		—
Unvested stock options at June 30, 2021		762,641		$	0.20		7.07	$	36,815
Exercised		(166,666	)	$	0.14		—		—
Forfeited/expired		(2,245,000	)	$	0.54		—		—
Outstanding at June 30, 2022		8,268,269		$	0.25		6.91	$	—
Exercisable at June 30, 2022		4,436,949		$	0.26		5.10	$	—
Unvested stock options at June 30, 2022		3,831,320		$	0.23		9.06	$	—

F-2021 Table of Contents

Restricted Stock Awards Outstanding

The following summarizes our restricted stock activity:

				Weighted
				Average
	Number of			Grant Date
	Shares			Fair Value
Total awards outstanding at June 30, 2019		1,729,288		$	0.51
Total shares granted		2,625,061		$	0.11
Total shares vested		(2,637,561	)	$	0.29
Total shares forfeited		(1,600,001	)	$	0.22
Total unvested shares outstanding at June 30, 2020		116,787		$	0.32
Total shares granted		58,394		$	0.22
Total shares vested		(58,395	)	$	0.41
Total shares forfeited		—		$	—
Total unvested shares outstanding at June 30, 2021		116,786		$	0.22
Total shares granted		—		$	—
Total shares vested		(58,394	)	$	0.25
Total shares forfeited		—		$	—
Total unvested shares outstanding at June 30, 2022		58,392		$	0.19

Scheduled vesting for outstanding restricted stock awards at June 30, ~~2021~~2022 is as follows:

Year Ending June 30,

2022

2023

2024

Total

2023

2024

Total

Scheduled vesting

5838,~~394~~928

3819,~~928~~464

1958,~~464~~392

~~116,786~~

As of June 30, ~~2021~~2022, there was approximately $146,000 of net unrecognized compensation cost related to unvested restricted stock-based compensation arrangements. This compensation is recognized on a straight-line basis resulting in approximately $85,000 of compensation expected to be expensed over the next twelve months, and the total unrecognized stock-based compensation expense having a weighted average recognition period of 1.7812 years.

~~Stock~~15. ~~Warrants~~Equity ~~Outstanding~~Transactions

Warrants to Purchase Series B 5% convertible preferred stock (“2018 Series B 5% convertible preferred stock”)

On October 5, 2018, the Company entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) with one multi-family office for the sale of 2,000 shares of the Company’s newly-created Series B 5% convertible preferred stock (“Series B preferred stock” or “preferred stock”), for aggregate gross proceeds of approximately $2.0 million. Each share of preferred stock was initially sold together with three warrants: (i) a Series 1 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance (later extended to 15 months following issuance), (ii) a Series 2 warrant, which entitles the holder thereof to purchase 1.25 shares of preferred stock at $982.50 per share, or 2,500 shares of preferred stock in the aggregate for approximately $2.5 million in aggregate exercise price, for a period of up to 15 months following issuance, and (iii) a Series 3 warrant, which entitles the holder thereof to purchase 1.50 shares of preferred stock at $982.50 per share, or 3,000 shares of preferred stock in the aggregate for approximately $2.9 million in aggregate exercise price, for a period of up to 24 months following issuance.

F-21 Table of Contents

On May 9, 2019, the Company entered into a warrant restructuring and additional issuance agreement (the “Issuance Agreement”) with the holders of the Series B preferred stock and warrants pursuant to which the Company issued an additional 100 shares of Series B preferred stock and Series 4 warrants to purchase an additional 2,500 shares of preferred stock, and the holders of the Series B preferred stock and warrants agreed to exercise warrants to purchase up to $2.0 million of Series B preferred stock through November 2019 subject to the conditions set forth in the Issuance Agreement. The Series 4 warrant entitles the holder thereof to purchase 2,500 shares of preferred stock at $982.50 per share for approximately $2.5 million in aggregate exercise price, for a period of up to nine months following issuance. In addition, the Company extended the termination date for the Series 1 warrants by six months, and agreed to issue one additional share of preferred stock to the Series B investors for each five shares issued upon the exercise of the existing warrants or Series 4 warrants through November 9, 2019, up to a maximum of 400 shares of preferred stock. All 400 shares of preferred stock were issued from May 2019 to September, 2019.

On December 26, 2019, the Company extended the termination date for each series of warrants to December 31, 2021 and decreased the exercise price for each series of warrants to $850.00 per share of preferred stock. The warrants modification expense of $1,212,000 was computed as the incremental value of the modified warrants over the unmodified warrants on the modification date using a per share price of $0.05 per share, which was the market price on December 26, 2019. Assumptions used in the Black Scholes option-pricing model for these warrants were as follows:

Average risk-free interest rate	1.64	%
Average expected life-years	2
Expected volatility	99.03	%
Expected dividends	0	%

The warrants issued in connection with the Series B preferred stock are deemed to be free standing equity instruments and are recorded in permanent equity (additional paid in capital) based on a relative fair value allocation of proceeds (i.e. warrants’ relative fair value to the Series B preferred stock fair value (without the warrants)) with an offsetting discount to the Series B preferred stock.

During the period from October 5, 2018 (date of issuance of preferred stock and warrants) to June 30, 2020, the Company issued all 10,500 shares of its Series B 5% convertible preferred stock, for aggregate gross proceeds of $9.43 million. As of June 30, 2021 and 2020, all Series 1-4 warrants to purchase shares of Series B preferred stock were exercised, and no Series 1-4 warrants were outstanding.

Warrants to Purchase Series B-2 5% convertible preferred stock

See Note 14 for a description of the warrants to purchase shares of the Company’s Series B-2 5% convertible preferred stock.

F-22 Table of Contents

Warrants to Purchase Common Stock

On June 28, 2018, the Company entered into a Securities Purchase Agreement with Aspire Capital Fund, LLC (“Aspire Capital”), pursuant to which the Company agreed to sell up to $7.0 million of shares of the Company’s Class A common stock to Aspire Capital, without an underwriter or placement agent. The Company issued to Aspire Capital warrants to purchase 8,000,000 shares of its common stock exercisable for 5 years at an exercise price of $0.38 per share. The warrants were recorded within stockholders’ deficiency. The fair value of the warrants issued on June 28, 2018 was estimated on the date of issuance using the Black-Scholes-Merton Model. The value of the warrants issued was approximately $1.7 million. Assumptions used in the Black Scholes option-pricing model for these warrants were as follows:

Average risk-free interest rate	2.73	%
Average expected life-years	5
Expected volatility	52.77	%
Expected dividends	0	%

All 8,000,000 warrants to purchase shares of the Company’s common stock were exercised at an exercise price of $0.38 per share on June 18, 2020 and June 23, 2020.

14. Equity Transactions

$30 million Class A Common Stock Purchase Agreement with Aspire Capital

On July 31, 2020, the Company entered into the 2020 Stock Purchase Agreement (the “2020 Purchase Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”) which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 24-month term of the Agreement. In consideration for entering into the 2020 Purchase Agreement, the Company issued to Aspire Capital 6,250,000 shares of its Class A Common Stock as a commitment fee. The commitment fee of approximately $1.4 million was recorded as deferred financing costs and additional paid-in capital and this asset will be amortized over the life of the 2020 Purchase Agreement. The amortized amount of approximately $0.67 million was recorded to additional paid-in capital for the years ended June 30, 2022 and 2021. The unamortized portion is carried on the balance sheet as deferred offering costs and was approximately $0.1 million and $0.8 million at June 30, 2022 and 2021.

During the years ended June 30, 2022, the Company did not sell any shares to Aspire Capital under the 2020 Purchase Agreement. During the period from July 31, 2020 to June 30, ~~2021~~2022, the Company generated proceeds of approximately $4.6 million under the 2020 Purchase Agreement with Aspire Capital from the sale of approximately 22.5 million shares of its common stock. AsThe of2020 ~~June~~Purchase ~~30,~~Agreement ~~2021,~~expired ~~the~~on ~~available~~July ~~balance~~31, ~~under the 2020 Agreement was approximately $25~~2022.4 ~~million.~~

Class B Common Stock

On ~~January~~September 298, ~~2019~~2020, ~~the~~Mr. ~~Company~~Ehrlich ~~issued~~exercised ~~909,090~~2.2 million options to purchase 2.2 million shares of Class B common stock at the option exercise price of $0.11 per share. to Mr. Ehrlich paid for ~~his~~this ~~partial~~ exercise of his option, ~~paid~~ by the cancellation of debt to Mr. Ehrlich of $~~100~~242,000 to satisfy the exercise price (asSee ~~permitted~~Note ~~pursuant~~12. Convertible Note Payable – Related Party). The Company issued 1,787,762 shares of Class B common stock (net share issuance amount), to ~~the~~Mr. ~~terms~~Ehrlich. The remaining 412,238 shares of Class B common stock were withheld from Mr. Ehrlich for the ~~option~~payment ~~agreement)~~of payroll taxes.

On ~~March~~October 302, 2020, ~~the~~Mr. ~~Company~~Ehrlich ~~issued~~exercised 909,090 options to purchase 909,090 shares of Class B common stock at the option exercise price of $0.11 per share. to Mr. Ehrlich paid for ~~his~~this ~~partial~~ exercise of his option, ~~paid~~ by the cancellation of debt to Mr. Ehrlich of $100,000 to satisfy the exercise price (See Note 12. Convertible Note Payable – Related Party). The Company issued 727,994 shares of Class B common stock (net share issuance amount), to Mr. Ehrlich. The remaining 181,096 shares of Class B common stock were withheld from Mr. Ehrlich for the payment of payroll taxes.

OnF-22 ~~September~~Table ~~8, 2020, Mr. Ehrlich exercised 2.2 million options to purchase 2.2 million shares~~ of Class B common stock at the option exercise price of $0.11 per share. Mr. Ehrlich paid for this exercise of his option by the cancellation of debt to Mr. Ehrlich of $242,000 to satisfy the exercise price (See Note 11. Convertible Note Payable). The Company issued 1,787,762 shares of Class B common stock (net share issuance amount), to Mr. Ehrlich. The remaining 412,238 shares of Class B common stock were withheld from Mr. Ehrlich for the payment of payroll taxes.Contents

~~F-23~~On ~~Table~~December 28, 2020, Mr. Ehrlich exercised his option to purchase 13,072,730 shares of ~~Contents~~Class B common stock, at the option exercise price at $0.11 per shares for the shares, paid by the cancellation of 6,980,583 shares of Class A common stock held by Mr. Ehrlich of $1,438,000 to satisfy the exercise price. The total taxable compensation to Mr. Ehrlich for the 13,072,730 shares was approximately $540,000, based upon the closing stock price on December 29, 2020 of $0.21 a share. The Company withheld 1,765,203 shares of Class B common stock and cancelled an additional 854,419 shares of Class A common stock held by Mr. Ehrlich. As a result, the Company issued 11,307,527 shares of Class B common shares (net of 1,765,203 shares of Class B common shares withheld to satisfy taxes), and cancelled 7,835,002 shares of Class A common stock held by Mr. Ehrlich. These shares withheld are being reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

OnAs ~~October~~of 2,June ~~2020~~30, ~~Mr.~~2022 ~~Ehrlich~~and ~~exercised 909~~2021,~~090~~ ~~options to purchase 909,090 shares of Class B common stock at~~ the ~~option~~total ~~exercise~~issued ~~price~~number of $0.11 per share. Mr. Ehrlich paid for this exercise of his option by the cancellation of debt to Mr. Ehrlich of $100,000 to satisfy the exercise price (See Note 11. Convertible Note Payable to the consolidated financial statements). The Company issued 727,994 shares of Class B common stock ~~(net~~were ~~share~~18 ~~issuance~~million ~~amount),~~shares toand ~~Mr.~~the ~~Ehrlich.~~total ~~The~~outstanding ~~remaining~~number ~~181,096~~of shares of Class B common stock were ~~withheld from Mr~~15,641,463. ~~Ehrlich for the payment of payroll taxes.~~

On December 28, 2020, Mr. Ehrlich exercised his option to purchase 13,072,730 shares of Class B common stock, at the option exercise price at $0.11 per shares for the shares, paid by the cancellation of 6,980,583 shares of Class A common stock held by Mr. Ehrlich of $1,438,000 to satisfy the exercise price. The total taxable compensation to Mr. Ehrlich for the 13,072,730 shares was approximately $540,000, based upon the closing stock price on December 29, 2020 of $0.21 a share. The Company withheld 1,765,203 shares of Class B common stock and cancelled additional 854,419 shares of Class A common stock held by Mr. Ehrlich. As a result, the Company issued 11,307,527 shares of Class B common shares (net of 1,765,203 shares of Class B common shares withheld to satisfy taxes), and cancelled 7,835,002 shares of Class A common stock held by Mr Ehrlich. These shares withheld are being reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

As of June 30, 2021 and 2020, the total issued number of Class B common stock were 18 million shares and 1,818,180 shares, respectively, and the total outstanding number of Class B common stock were 15,641,463 shares and 1,818,180 shares, respectively.

Class A Common Stock

On February 23, 2020, the Company issued 500,000 options each to our Chairman and CEO and two other Board members (see Note 13) and the Company also issued 500,000 shares of Class A common stock each to our Chairman and CEO and two other Board members, which shares were vested on February 24, 2020. During the year ended June 30, 2020, the Company recorded approximately $237,000 of stock-based compensation expense to our Chairman and CEO and two other Board members including approximately $102,000 of stock option expense and $135,000 of stock awards.

Series B 5% convertible preferred stock purchase agreement (“2018 Series B 5% convertible preferred stock”)

On October 5, 2018, as modified on May 9, 2019 (see Warrant Restructuring and Additional Issuance Agreement as described above), the Company entered into a Securities Purchase Agreement with one multi-family office for the sale of an aggregate of 2,000 shares of the Company’s newly-created Series B preferred stock, for aggregate gross proceeds of approximately $2.0 million. An initial closing for the sale of 1,250 shares of the Series B preferred stock closed on October 9, 2018, and a second closing for the sale of 750 shares of the Series B preferred stock closed on October 12, 2018. Under the Securities Purchase Agreement, the Company also issued to the investors warrants to purchase up to an additional 8,000 shares of preferred stock.

The issuance costs associated with the Series B preferred stock transaction were attributed to the Series B preferred stock (without the warrants) and to the Series 1, Series 2 and Series 3 warrants based on their relative fair values. The issuance costs attributed to the warrants of $32,000 were reflected as a reduction to additional paid-in capital. The issuance costs associated with the Series B preferred stock liability of $41,000 was recorded immediately as an element of interest cost, which is reflected in interest expense - preferred stock. The Company recognized change in fair value of preferred stock liabilities of $0 and $102,000 under Other (income) expense in the accompanying consolidated Statements of Operations for the years ended June 30, 2021 and 2020, respectively.

F-24 Table of Contents

Underlying Series B preferred stock dividends, paid quarterly, was accrued as interest (given the liability classification of the Series B preferred stock) on a daily basis given fixed dividend terms under the Series B preferred stock. The Company recorded 5% dividend accretion on total outstanding Series B preferred stock up to June 30, 2020. The total dividends of approximately $0 and $52,000 are treated as interest expense – preferred stock during the years ended June 30, 2021 and 2020, respectively. Balance of unpaid dividends of $0 and $13,000 relating to 2018 Series B 5% convertible preferred stock was included at accrued dividend under current liabilities as of June 30, 2021 and 2020, respectively.

Terms of the 2018 Series B 5% convertible preferred stock

The rights and preferences of the preferred stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series B 5% Convertible Preferred Stock filed with the Nevada Secretary of State on October 5, 2018 (the “Certificate of Designation”). Each share of preferred stock has an initial stated value of $1,080 and may be converted at any time at the holder’s option into shares of the Company’s common stock at a conversion price equal of the lower of (i) $0.32 per share and (ii) 85% of the lowest volume weighted average price of the Company’s common stock on a trading day during the ten trading days prior to and ending on, and including, the conversion date. The conversion price may be adjusted following certain triggering events and subsequent equity sales and is subject to appropriate adjustment in the event of stock splits, stock dividends, recapitalization or similar events affecting the Company’s common stock.

2018 Series B 5% convertible preferred stock Warrants

See Note 13 for a description of the Series 1-4 warrants issued in connection with the 2018 Series B 5% convertible preferred stock.

No Series 1-4 warrants issued in connection with the 2018 Series B 5% convertible preferred stock were outstanding as of June 30, 2020.

Conversion of 2018 Series B 5% convertible preferred stock to common stock

During the year ended June 30, 2020, the two preferred stockholders converted 9,190 shares of 2018 Series B 5% convertible preferred stock into 116.3 million shares of common stock. As of June 30, 2020, all preferred stock to common stock were converted into common stock and there was no 2018 preferred stock was outstanding.

Series B-2 5% convertible preferred stock (“2020 Series B-2 5% convertible preferred stock”)

On December 4, 2020, the Company entered into a securities purchase agreement (the “Series B-2 Securities Purchase Agreement”) with KIPS Bay Select LP for the sale of an aggregate of 5,089 shares of the Company’s Series B-2 5% convertible preferred stock (the “Series B-2 preferred stock”), for aggregate gross proceeds of approximately $5.0 million. An initial closing for the sale of 3,053 shares of the Series B-2 preferred stock closed on December 9, 2020 for aggregate gross proceeds of approximately $3.0 million, and a second closing for the sale of 2,036 shares of the Series B-2 preferred stock closed on February 8, 2021 for aggregate gross proceeds of approximately $2.0 million. Under the Series B-2 Securities Purchase Agreement, the Company also issued to the investors warrants to purchase up to an additional 10,178 shares of preferred stock.

F-25 Table of Contents

The Series B-2 preferred stock is mandatorily redeemable under certain circumstances and, as such, is presented as a liability on the consolidated balance sheets. The Company has elected to measure the value of its preferred stock using the fair value method with offsetting discounts associated with the fair value allocated to the warrants and for the intrinsic value attributed to the beneficial conversion feature (“BCF”). The fair value of the Series B-2 preferred stock (without the warrants) will be assessed at each subsequent reporting date with changes in fair value recorded in the profit and loss as a separate line item below the “loss from operations” section (See ASC 480-10-35-5).

The warrants issued in connection with the Series B-2 preferred stock are deemed to be free standing equity instruments and are recorded in permanent equity (under additional paid in capital), based on a relative fair value allocation of proceeds, ~~(i.e.~~that is the warrants’ relative fair value to the Series B-2 preferred stock fair value (without the warrants)), with an offsetting discount to the Series B-2 preferred stock. Given that the Series B-2 preferred stock is convertible at any time under these features, the underlying warrant discounts were accreted upon issuance and recorded as interest, (resulting in no remaining discount to the Series B-2 preferred stock liability after the issuance).

The Company recorded the December 9, 2020 issuance of 3,053 shares Series B-2 Preferred Stock at approximately $2.1 million and the underlying Series 1 and Series 2 warrants at approximately $0.9 million in total by allocating the gross proceeds to Series B-2 preferred stock (without the warrants) and warrants based on their relative fair values or direct valuation as appropriate. The Company recorded BCF of approximately $1.8 million associated with the issuance of the 3,053 shares of Series B-2 preferred stock to additional paid-in capital. The Company then recorded interest of approximately $2.7 million for the BCF and warrant discounts as a first day interest given that the Series B-2 preferred shares can be converted at any time to common stock and given no set term.

The ~~Company recorded the February 8, 2021~~ issuance ofcosts ~~2,036~~associated ~~shares~~with the Series B-2 ~~Preferred~~preferred ~~Stock~~stock attransaction ~~approximately~~were ~~$1.5~~attributed ~~million~~to ~~and~~ the ~~underlying~~ Series ~~1 and Series~~ B-2 ~~warrants~~preferred atstock ~~approximately~~(without ~~$0.5~~the ~~million~~warrants) inand ~~total~~to ~~by allocating~~ the ~~gross~~Series ~~proceeds~~1 toand Series B-2 ~~preferred stock (without the~~ warrants) ~~and warrants~~ based on their relative fair values ~~or direct valuation as appropriate~~. The ~~Company~~issuance ~~recorded~~costs ~~BCF~~attributed ofto ~~approximately $1.5 million associated with~~ the ~~issuance~~warrants of ~~the~~approximately 2$10,~~036~~000 ~~shares~~were ofreflected ~~Series~~as ~~B-2~~a ~~preferred~~reduction ~~stock~~ to additional paid-in capital. The ~~Company~~issuances ~~then~~costs ~~recorded~~associated ~~interest~~with ofthe ~~approximately~~Series $B-2.0 ~~million~~preferred ~~for~~stock ~~the~~liability ~~BCF~~of ~~and~~$25,000 ~~warrant~~was ~~discounts~~recorded immediately as aan ~~first~~element ~~day~~of interest ~~given~~cost, ~~that~~which ~~the~~are ~~Series~~reflected ~~B-2~~in ~~preferred~~interest ~~shares~~expense ~~can~~- bepreferred ~~converted at any time to common~~ stock ~~and~~on ~~given~~December no11, ~~set term~~2020.

~~The issuance costs associated with the Series B~~F-223 ~~preferred~~Table stock transaction were attributed to the Series B-2 preferred stock (without the warrants) and to the Series 1 and Series 2 warrants based on their relative fair values. The issuance costs attributed to the warrants of approximately $10,000 were reflected as a reduction to additional paid-in capital. The issuances costs associated with the Series B-2 preferred stock liability of $25,000 was recorded immediately as an element of interest cost, which are reflected in interest expense - preferred stock. The change in fair value of the total Series B-2 preferred stock was $0 during the years ended June 30, 2021. Contents

~~Underlying~~The Company recorded the February 8, 2021 issuance of 2,036 shares Series B-2 ~~preferred~~Preferred ~~stock~~Stock ~~dividends,~~at ~~paid~~approximately ~~quarterly,~~$1.5 ~~was~~million ~~accrued~~and asthe ~~interest~~underlying ~~(given~~Series ~~the~~1 ~~liability~~and ~~classification~~Series of2 warrants at approximately $0.5 million in total by allocating the gross proceeds to Series B-2 preferred stock (without the warrants) and warrants based on atheir ~~daily~~relative ~~basis~~fair ~~given~~values ~~fixed~~or ~~dividend~~direct ~~terms~~valuation ~~under~~as appropriate. The Company recorded BCF of approximately $1.5 million associated with the issuance of the 2,036 shares of Series B-2 preferred stock to additional paid-in capital. The Company then recorded 5%interest ~~dividend~~of ~~accretion~~approximately on$2.0 ~~total~~million ~~outstanding~~for the BCF and warrant discounts as a first day interest given that the Series B-2 preferred shares can be converted at any time to common stock and given no set term. In addition to the ~~total~~aforesaid ~~dividends~~$2.7 ~~accrued~~million for the BCF and warrant discounts, the total interest of approximately $1547,000 ~~are~~and ~~treated~~$4.7 asmillion ~~interest~~was reported in Interest expense - preferred stock liability during the year ended June 30, 2022 and 2021, respectively, in the Consolidated Statements of Operations.

FThe change in fair value of the total Series B-262 ~~Table~~preferred stock were $177,000 and $0 during the year ended June 30, 2022 and 2021 in the Consolidated Statements of ~~Contents~~Operations.

Underlying Series B-2 preferred stock dividends, paid quarterly, was accrued as interest (given the liability classification of the Series B-2 preferred stock) on a daily basis given fixed dividend terms under the Series B-2 preferred stock. The Company recorded 5% dividend accretion on total outstanding Series B-2 preferred stock and the total dividends accrued of approximately $47,000 and $15,000 were treated as interest during the year ended June 30, 2022 and 2021, respectively, in the Consolidated Statements of Operations.

Terms of the 2020 Series B-2 5% convertible preferred stock

The rights and preferences of the preferred stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series B-2 5% Convertible Preferred Stock filed with the Nevada Secretary of State on December 4, 2020 (the “Certificate of Designation”). Each share of preferred stock has an initial stated value of $1,080 and may be converted at any time at the holder’s option into shares of the Company’s common stock at a conversion price equal of the lower of (i) $0.35 until August 15, 2021 and $0.50 thereafter, and (ii) 85% of the lowest volume weighted average price of the Company’s common stock on a trading day during the ten trading days prior to and ending on, and including, the conversion date. The conversion price may be adjusted following certain triggering events and subsequent equity sales and is subject to appropriate adjustment in the event of stock splits, stock dividends, recapitalization or similar events affecting the Company’s common stock.

The holders of the preferred stock are limited in the amount of stated value of the preferred stock they can convert on any trading day. The conversion cap limits conversions by the holders to the greater of $75,000 and an amount equal to 30% of the aggregate dollar trading volume of the Company’s common stock for the five trading days immediately preceding, and including, the conversion date. However, the conversion cap will be increased if the trading volume in the first 30 minutes of any trading session exceeds certain trailing average daily volume amounts. In addition, the holders of the preferred stock may not convert shares of preferred stock if, after giving effect to the conversion, a holder together with its affiliates would beneficially own in excess of 9.99% of the outstanding shares of the Company’s common stock.

Redemption Rights

Following 90 days after the scheduled date for the second closing date, the Company may elect to redeem the preferred stock for 120% of the aggregate stated value then outstanding, plus all accrued but unpaid dividends and all liquidated damages and other amounts due in respect of the preferred stock. The Company’s right to redeem the preferred stock is contingent upon it having complied with a number of conditions, including compliance with its obligations under the Certificate of Designation. Shares of preferred stock generally have no voting rights, except as required by law and except that the Company shall not take certain actions without the consent of the holders of the preferred stock.

F-24

Table of Contents

2020 Series B-2 5% convertible preferred stock warrants

Each share of preferred stock was sold together with two warrants: (i) a Series 1 warrant, which entitles the holder thereof to purchase one share of preferred stock at $982.50 per share, or 5,089 shares of preferred stock in the aggregate for approximately $5.0 million in aggregate exercise price, for a period of up to 18 months following issuance, and (ii) a Series 2 warrant, which entitles the holder thereof to purchase one ~~shares~~share of preferred stock at $982.50 per share, or 5,089 shares of preferred stock in the aggregate for approximately $5.0 million in aggregate exercise price, for a period of up to 24 months following issuance.

Subject to the satisfaction of certain circumstances, the Company may call for cancellation any or all of the warrants following 90 days after their issuance, for a payment in cash equal to 8% of the aggregate exercise price of the warrants being called. The warrants subject to any such call notice will be cancelled 10 days following the Company’s payment of the call fee, provided that the warrant holders have not exercised the warrants prior to cancellation.

F-27 Table of Contents

Exercise of 2020 Series B-2 5% convertible preferred stock warrants

During the ~~year~~years ended June 30, ~~2021~~2022, the Company issued 35,~~053~~072 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of approximately $25.0 million,~~999,573,~~ upon exercise of 3,~~053~~036 Series 1 warrants and exercise of 2,036 Series 2 warrants issued by the Company. InWith ~~addition,~~regard to the ~~Company~~exercise ~~issued 2,053 shares~~ of ~~its~~these ~~Series B-2~~ 5%,072 ~~convertible preferred stock~~warrants, ~~for~~the ~~aggregate~~Company recorded gross proceeds of approximately $~~2,017,073,~~5.0 ~~upon~~million ~~exercise~~to ofthe ~~2,053~~preferred ~~Series~~stock ~~2 warrants issued by the Company~~liability.

~~With~~As ~~regard to the exercise~~ of ~~these~~June 530,~~106~~ ~~warrants~~2022, ~~the~~there ~~Company~~was ~~recorded~~no ~~gross~~Series ~~proceeds~~1 ofand ~~approximately~~2 ~~$5,017,000~~warrants tooutstanding ~~the~~since ~~preferred~~all ~~stock~~warrants ~~liability.~~were ~~As of June 30~~exercised, ~~2021, 5,072 Series 1~~ and 2there ~~warrants~~were to620 ~~purchase 5,072~~ shares of Series B-2 5% convertible preferred stock ~~were~~ outstanding.

During the period from December 4, 2020 (date of securities purchase agreement) to June 30, 2021, the Company issued 3,053 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of approximately $3.0 million, upon exercise of 3,053 Series 1 warrants issued by the Company. In addition, the Company issued 2,053 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of approximately $2.0 million, upon exercise of 2,053 Series 2 warrants issued by the Company. With regard to the exercise of these 5,106 warrants, the Company recorded gross proceeds of approximately $5.0 million to the preferred stock liability.

As of June 30, 2021, there was 5,072 Series 1 and 2 warrants to purchase 5,072 shares of Series B-2 5% convertible preferred stock outstanding and there was no Series B-2 5% convertible preferred stock outstanding.

Conversion of 2020 Series B-2 5% convertible preferred stock to common stock

During the ~~year~~years ended June 30, ~~2021~~2022, the 2020 Series B-2 5% convertible preferred stockholder converted a total of 104,~~207~~452 shares of Series B-2 preferred stock into a total of 68approximately 69,~~034~~901,~~812~~865 shares of common stock. With regard to conversions, the Company reversed Series B-2 5% convertible preferred stock liability relating to the conversion and recorded $3.8 million as Additional paid-in capital at par value. The Company reversed the amount of approximately $3.8 million based on the proportion of Series B-2 5% convertible preferred stock converted relative to the original total issued.

During the period from December 4, 2020 (date of securities purchase agreement) to June 30, 2021, the 2020 Series B-2 5% convertible preferred stockholder converted a total of 10,207 shares of Series B-2 preferred stock into a total of 68,034,812 shares of common stock. With regard to conversions, the Company reversed Series B-2 5% convertible preferred stock liability relating to the conversion and recorded $10.0 million as Additional paid-in capital at par value. The Company reversed the amount of approximately $10~~,017,000~~.0 million based on the proportion of Series B-2 5% convertible preferred stock converted relative to the original total issued.

As of June 30, 2022 and 2021, ~~there are no 2020~~ Series B-2 5% convertible preferred stock ~~outstanding~~liability ~~and~~was ~~the~~approximately ~~2020~~$0.8 ~~Series~~million ~~B-2~~and ~~5% convertible preferred stock liability is~~ $0, respectively.

F-25

Table of Contents

2358537

The fair value of the Series B convertible preferred stock is measured in accordance with ASC 820 “Fair Value Measurement,” using option pricing methodologies, incorporating the following inputs:

	June 30, 2022

Expected dividend yield		5	%
Expected stock-price volatility		60	%
Risk-free interest rate		2.92	%
Stock price	$	0.03
Exercise price	$	982.5

Treasury Stock

Regarding the exercise of options to purchase 2.2 million shares of Class B common stock on September 8, 2020 by Mr. Ehrlich, the Company issued 1,787,762 shares of Class B common stock (net share issuance amount), to Mr. Ehrlich. The remaining 412,238 shares of Class B common stock were withheld from Mr. Ehrlich for the payment of payroll taxes and were reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

Regarding the exercise of options to purchase 909,090 shares of Class B common stock on October 2, 2020, the Company issued 727,994 shares of Class B common stock (net share issuance amount), to Mr. Ehrlich. The remaining 181,096 shares of Class B common stock were withheld ~~were withheld~~ from Mr. Ehrlich for the payment of payroll taxes and were reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

Regarding the exercise of options to purchase 13,072,730 shares of Class B common stock on December 28, 2020, the Company cancelled 6,980,583 shares of Class A common stock held by Mr. Ehrlich with a fair value of $1,438,000 to satisfy the exercise price. The Company withheld 1,765,203 shares of Class B common stock and cancelled an additional 854,419 shares of Class A common stock held by Mr. Ehrlich to satisfy tax withholding obligations. As a result, the Company issued 11,307,527 shares of Class B common shares (net of 1,765,203 shares of Class B common shares withheld to satisfy ~~taxes~~tax withholding obligations), and cancelled 7,835,002 shares of Class A common stock held by Mr. Ehrlich. Both the 1,765,203 shares of Class B common stock and the 7,835,002 shares of Class A common stock were reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

~~F-28~~There ~~Table~~were 8,516,056 shares of ~~Contents~~Class A common stock and 2,358,537 shares of Class B common stock held in treasury, purchased at a total cumulative cost of approximately $2.3 million as of June 30, 2022 and 2021.

~~There were 8,516,056 shares of Class A common stock and 2,358,537 shares of Class B common stock held in treasury, purchased at a total cumulative cost of approximately $2~~16.3 ~~million~~Fair asValue ~~of June 30, 2021.~~Measurements

~~There~~We ~~were~~disclose ~~659,448~~and ~~shares~~recognize ofthe ~~Class~~fair Avalue ~~common~~of ~~stock~~our assets and 0liabilities ~~shares~~using ofa ~~Class~~hierarchy Bthat ~~common~~prioritizes ~~stock~~the ~~held~~inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in ~~treasury,~~an ~~purchased~~orderly transaction between market participants at athe ~~total~~measurement ~~cumulative~~date. ~~cost~~The ofguidance ~~approximately~~establishes ~~$146,000~~three aslevels of ~~June~~the ~~30,~~fair ~~2020.~~value hierarchy as follows:

~~15.~~Level ~~Fair~~1: ~~Value~~Inputs ~~Measurement~~are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

~~The~~Level ~~Company~~2: ~~has~~Inputs ~~elected~~are toobservable, ~~measure~~unadjusted ~~its~~quoted ~~preferred~~prices ~~stock~~in ~~using~~active ~~the~~markets ~~fair~~for ~~value~~similar ~~method.~~assets ~~The~~or ~~fair~~liabilities, ~~value~~unadjusted ofquoted ~~the~~prices ~~preferred~~for ~~stock~~identical isor ~~the~~similar ~~estimated~~assets ~~amount~~or ~~that~~liabilities ~~would~~in bemarkets ~~paid~~that toare ~~redeem~~not ~~the~~active, ~~liability~~or inother aninputs ~~orderly~~that ~~transaction~~are ~~between~~observable ~~market~~or ~~participants~~can atbe ~~the~~corroborated ~~measurement~~by ~~date.~~observable ~~The~~market ~~Company~~data ~~calculates~~for substantially the ~~fair~~full ~~value~~term of: the related assets or liabilities; and

ALevel ~~financial~~3: ~~asset~~Unobservable orinputs ~~liability’s~~that ~~classification~~are ~~within~~significant to the ~~hierarchy~~measurement isof ~~determined~~the ~~based~~fair onvalue of the ~~lowest~~assets ~~level~~or ofliabilities ~~input~~ that isare ~~significant~~supported toby ~~the~~little ~~fair~~or ~~value~~no ~~measurement.~~market data.

~~The~~F-26 ~~three~~Table ~~levels~~ of ~~valuation hierarchy are defined as follows:~~Contents

•	Level 1:	Observable inputs such as quoted prices in active markets;
•	Level 2:	Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
•	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

Our financial instruments consist of cash and cash equivalents, short-term and long-term investments, accounts payable, accrued liabilities and preferred liability. At June 30, 2022 and 2021, the carrying values of cash and cash equivalents, accounts payable, and accrued liabilities approximated fair value due to their short-term maturities.

The Company has elected to measure its preferred stock using the fair value method. The fair value of the preferred stock is the estimated amount that would be paid to redeem the liability in an orderly transaction between market participants at the measurement date. The Company calculates the fair value of the Series B-2 Preferred stock using a lattice model that takes into consideration the future redemption value on the instrument, which is tied to the Company’s stock price.

These valuations are considered to be Level 3 fair value measurements as the significant inputs are unobservable and require significant management judgment or estimation. Considerable judgment is required in interpreting market data to develop the estimates of fair value. Accordingly, the Company’s estimates are not necessarily indicative of the amounts that the Company, or holders of the instruments, could realize in a current market exchange. Significant assumptions used in the fair value models include: the estimates of the redemption dates; credit spreads; dividend payments; and the market price of the Company’s common stock. The use of different assumptions and/or estimation methodologies could have a material effect on the estimated fair values.

The table below sets forth a reconciliation of the Company’s beginning and ending Level 3 Series B-2 preferred stock liability balance for the ~~year~~years ended June 30, 2022 and 2021:

	FY 2021
	FY 2022
Balance, beginning of period	$	—
Balance, July 1, 2020	$	-
Issuance of Series B-2 preferred stock at fair value		5,000,000
Exercise of Series 1 and 2 warrants		5,017,000
Conversion of Series B-2 preferred stock to common stock		(10,017,000	)
Change in fair value of Series B-2 preferred stock (1)	(—	(-	)
Balance, end of period	$	—
Balance, June 30, 2021	$	-
Exercise of Series 1 and 2 warrants		4,983,000
Conversion of Series B-2 preferred stock to common stock		(4,374,000	)
Change in fair value of Series B-2 preferred stock (1)		177,000
Balance, June 30, 2022	$	786,000

(1) Change in fair value of preferred stock is reported in interest expense—preferred stock.

⁽¹⁾	Change in fair value of preferred stock is reported in interest expense-preferred stock.
⁽²⁾	The 5% accrued dividend is reported in interest expense-preferred stock in the consolidated statements of operation and the remaining accrued dividends of $62,000 and $15,000 was included under current liability as of June 30, 2022 & 2021, respectively.

~~F-29~~17. ~~Table~~Income ofTaxes ~~Contents~~

16. Income Taxes

Deferred income tax assets and liabilities are recognized for the expected future tax consequences of events that have been reflected in the financial statements. Deferred tax assets and liabilities are determined based on the differences between the book values and the tax bases of particular assets and liabilities and the tax effects of net operating loss and capital loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized as income or expense in the period that included the enactment date.

The Company has ~~incurred~~a net operating ~~losses~~loss ~~since~~carry-forward ~~its~~for ~~inception~~federal and ~~therefore~~state no tax ~~liabilities~~purposes ~~have~~of ~~been~~approximately ~~incurred for the periods presented~~$105.8 ~~The~~million ~~amount~~at ofJune ~~unused~~30, ~~tax~~2022, ~~losses~~that ~~(“NOL”)~~is potentially available ~~for carryforward and~~ to beoffset ~~applied~~future ~~against~~ taxable income ~~in future years totaled approximately $98~~.7 ~~million at June 30, 2021.~~ The Tax Cuts and Jobs Act (the “Tax Act”) changes the rules on net operating loss (NOL) ~~carryforwards~~carry-forwards. The 20-year limitation was eliminated for losses incurred ~~for~~after ~~the~~January ~~2018~~1, ~~tax year~~2018, giving the taxpayer the ability to carry forward losses indefinitely. However, NOL carry forward arising after January 1, 2018, will now be limited to 80% of taxable income. ~~Internal~~The ~~Revenue~~$105.8 ~~Code~~million ~~Sec~~available at June 30, 2022 includes $51.0 ~~382~~million ~~places~~of ~~limitations~~post on2017 ~~the~~NOLs ~~utilization~~without expiration dates and $54.8 million of ~~net~~pre-2018 ~~operating~~NOLs ~~losses~~expiring from 2024 to 2037. Given the Company’s projections of taxable income for the years between 2024 and 2037, it’s likely these NOLs will expire unused.

F-27

Table of Contents

The income tax provision benefit differs from the amount of tax determined by applying the Federal and States statutory rates as follows:

	June 30, 2021			June 30, 2020
	June 30, 2022			June 30,2021
Book income at federal statutory rate		21.00	%		21.00	%
State income tax, net of federal tax benefit		6.32	%		6.32	%
Change in valuation allowance		(2539.3684	%)		(3025.4436	%)
Research and development credit	—		%		4.20	%
General business credit		12.42	%		—	%
Permanent difference	—	—	%	—	—	%
Change in Federal Statutory Rate	—	—	%	—	—	%
Others - net		(10.9610	%)		(1.0896	%)
Total		0.00	%		0.00	%

There was no current or deferred provision or benefit for income taxes for the fiscal years ended June 30, ~~2021~~2022 and ~~2020~~2021. The components of deferred tax assets as of June 30, ~~2021~~2022 and ~~2020~~2021 are as follows (rounded to nearest thousand):

	June 30, 2021			June 30, 2020
	June 30, 2022			June 30, 2021
Deferred tax assets:
Net operating loss carry forwards	$	2628,~~958~~888,~~015~~330		$	2326,~~160~~958,~~000~~015
Accrued payroll		806,829			~~807~~806,~~000~~829
Stock compensation		2,943,278			2,943,~~000~~278
Research and development credit		5,193,602			5,473,000
General business credit		6,068,138			5,193,602
Other		99,761			~~100~~99,~~000~~761
	$	3638,~~001~~806,~~485~~336		$	3236,~~483~~001,~~000~~485
Valuation allowance		(3638,~~001~~806,~~485~~336	)		(3236,~~483~~001,~~000~~485	)
Total deferred taxes	$	—-		$	—-

F-3028 Table of Contents

17. Subsequent Events

Equity Transactions

From July 1, 2021 to the date of the issuance of these financial statements, the Company issued 2,036 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of $2.0 million, upon exercise of 2,036 Series 1 warrants issued by the Company. In addition, the Company issued 1,000 shares of its Series B-2 5% convertible preferred stock, for aggregate gross proceeds of $1.0 million, upon exercise of 1,000 Series 2 warrants issued by the Company. At the same time, there were 3,036 preferred stock shares converted to approximately 18.9 million shares of common stock.

The Company has evaluated events subsequent to June 30, 2021 through the issuance of these financial statements and determined that there were no additional events requiring disclosure.

F-31 Table of Contents

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

There have been no changes in or disagreements with the Company’s accountants on accounting and financial disclosure.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

As of June 30, ~~2021~~2022, management, with the participation of our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act). Based on such evaluation, as of June 30, ~~2021~~2022, the principal executive officer and principal financial officer of the Company have concluded that the Company’s disclosure controls and procedures are effective.

Management’s Report on Internal Control Over Financial Reporting

Under Section 404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company’s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company’s internal control over financial reporting is effective.

Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. The Company’s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company’s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.

Internal controls over financial reporting, no matter how well designed, have inherent limitations. Therefore, internal control over financial reporting, even if determined to be effective, can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management has assessed the effectiveness of the Company’s internal control over financial reporting as of June 30, ~~2021~~2022. In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control-Integrated Framework (2013).” These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. The Company’s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal control over financial reporting.

Based on the Company’s processes and assessment, as described above, management has concluded that, as of June 30, ~~2021~~2022, the Company’s internal control over financial reporting was effective.

Table of Contents

This Annual Report on Form 10-K does not include an attestation report of the Company’s independent public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management’s report in this Annual Report on Form 10-K.

Changes in Internal Controls

There have been no changes in our internal control over financial reporting during the fourth quarter of the fiscal year ended June 30, ~~2021~~2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

Not applicable.

5843 Table of Contents

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

DIRECTORS AND EXECUTIVE OFFICERS OF THE COMPANY

The following provides information regarding current members of the Company’s Board of Directors (the “Board”), which consists of three members, and the Company’s executive officers. Each director is elected for a term ending at the next annual meeting of stockholders or until his or her successor is elected and qualified. Our executive officers are appointed by, and serve at the discretion of, the Board.

Name	Age	Position with the Company	Director Since
Leo Ehrlich	6364	Chief Executive Officer, Chief Financial Officer and Director	November 2007
Barry Schechter	5758	Director	October 2014
Zorik Spektor	6465	Director	April 2015
Jane Harness	5253	Sr. Vice President, Clinical Sciences and Portfolio Management	—-

Leo Ehrlich, has served as the Company’s Chief Executive Officer and Chief Financial Officer since November 5, 2010. Previously, he served as Chief Financial Officer of Cellceutix Pharma since its inception in June 2007. Mr. Ehrlich previously practiced as a Certified Public Accountant and received his BBA from Bernard Baruch College of the City University of New York.

The Board has determined that Mr. Ehrlich’s extensive knowledge of the Company, financial and industry knowledge and executive management experience make him a suitable member of the Company’s Board of Directors.

Barry Schechter, M.D., F.A.A.O., joined the Board on October 1, 2014 as an independent member. Dr. Schechter has been the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute since 2005. Dr. Schechter’s practice involves diseases of the ocular surface including dry eyes, allergies, infection, the latest in corneal, refractive, and cataract surgery, and glaucoma. In addition, Dr. Schechter is an expert consultant for Gerson Lehrman and Guidepoint Global regarding the business and technology of eye care and consults for several ophthalmic pharmaceutical companies. He is on the executive committee and heads the Scientific advisory board for Aperta Biosciences. He is the Medical Director for Amniochor. He is also on the editorial board for Advanced Ocular Care, a journal that reaches the top 10% of ophthalmologists and select optometrists. Dr. Schechter has reviewed articles for Cornea, the British Journal of Ophthalmology, and the Journal of the American Academy of Ophthalmology. He has lectured internationally and published on the subjects of treatment of ocular tumors, lens implants and dry eyes. Dr. Schechter has also written a textbook chapter on surgical techniques. Dr. Schechter is involved in clinical research ~~and consults for several ophthalmic pharmaceutical companies~~.

The Board has determined that Dr. Schechter’s extensive medical knowledge and consulting work make him a suitable member of the Company’s Board of Directors.

59Zorik ~~Table~~Spektor, M.D., F.A.A.P. was appointed as an independent member of ~~Contents~~the Board in April 2015. Dr. Spektor is a fellowship trained Pediatric Otolaryngologist and Head and Neck Surgeon and has been the Director of The Center for Pediatric ENT - Head and Neck Surgery in Boynton Beach, Florida since 1995. In addition, he is a Voluntary Assistant Professor of Surgery at the Department of Otolaryngology, University of Miami Leonard M. Miller School of Medicine, and an Affiliate Clinical Assistant Professor of Biomedical Science at Florida Atlantic University in Boca Raton, Florida. Dr. Spektor received his Bachelor’s Degree from Cornell University, and his Medical Doctorate at Albany Medical College of Union University in Albany, New York. Following Dr. Spektor’s completion of his residency training in Otolaryngology - Head and Neck Surgery at the University of Connecticut, he completed his fellowship in Pediatric Otolaryngology - Head and Neck Surgery at LeBonheur Children’s Medical Center in Memphis, Tennessee. Dr. Spektor is board certified in Otolaryngology - Head and Neck Surgery. He is a Fellow of the American Academy of Otolaryngology - Head and Neck Surgery and American Academy of Pediatrics. He is also a member of the American Society of Pediatric Otolaryngology and Society for Ear, Nose & Throat Advances in Children.

~~Zorik~~44 ~~Spektor,~~Table ~~M.D., F.A.A.P. was appointed as an independent member~~ of the Board in April 2015. Dr. Spektor is a fellowship trained Pediatric Otolaryngologist and Head and Neck Surgeon and has been the Director of The Center for Pediatric ENT – Head and Neck Surgery in Boynton Beach, Florida since 1995. In addition, he is a Voluntary Assistant Professor of Surgery at the Department of Otolaryngology, University of Miami Leonard M. Miller School of Medicine, and an Affiliate Clinical Assistant Professor of Biomedical Science at Florida Atlantic University in Boca Raton, Florida. Dr. Spektor received his Bachelor’s Degree from Cornell University, and his Medical Doctorate at Albany Medical College of Union University in Albany, New York. Following Dr. Spektor’s completion of his residency training in Otolaryngology – Head and Neck Surgery at the University of Connecticut, he completed his fellowship in Pediatric Otolaryngology – Head and Neck Surgery at LeBonheur Children’s Medical Center in Memphis, Tennessee. Dr. Spektor is board certified in Otolaryngology – Head and Neck Surgery. He is a Fellow of the American Academy of Otolaryngology – Head and Neck Surgery and American Academy of Pediatrics. He is also a member of the American Society of Pediatric Otolaryngology and Society for Ear, Nose & Throat Advances in Children.Contents

Prior to establishing the Center for Pediatric ENT –- Head and Neck Surgery in 1995, Dr. Spektor was on the faculty of the University of Connecticut Health Science Center, Hartford Hospital and Newington Children’s Hospital, now known as Connecticut Children’s Hospital. He has lectured and presented extensively in the field of pediatric otolaryngology, and has authored numerous peer-reviewed publications. Dr. Spektor has been a presenter as well as an invited speaker at local, national and international conferences. He continually conducts clinical research studies, which have produced significant advances in the field of otolaryngology and pediatric otolaryngology. During the past decade he has been selected as one of the nation’s top doctors by several independent rating agencies for many consecutive years. Dr. Spektor has served on advisory boards for several medical device and pharmaceutical companies and has been involved in significant advances in the field of otolaryngology and Pediatric Otolaryngology.

The Board has determined that Dr. Spektor’s extensive medical knowledge, research experience and broad industry exposure make him a suitable member of the Company’s Board of Directors.

Jane Harness, MP, MS is Senior Vice President, Clinical Sciences and Portfolio Management and joined the Company on September 1, 2016. Ms. Harness has over 20 years in domestic and international clinical drug development experience. Before joining the Company, she served as Vice President, Clinical Operations, at Revance Therapeutics in 2015 and as Head of Clinical Sciences, Dermatology and ATI Translational Research, at Novartis Institutes for Biomedical Research from 2010 to 2014. Before joining Novartis, Ms. Harness held the following notable positions at Pfizer over the prior 15 years: Global Clinical Lead, Inflammation and Immunology, Early Clinical Lead, Dermatology, and Clinical Trial Head and Process Improvement Lead, Experimental Medicine. Ms. Harness received a BS and MP (Protein Biochemistry) degree from University of Leicester, and a MS (Clinical Pharmacology) from University of Aberdeen.

CORPORATE GOVERNANCE

Corporate Governance Guidelines

We and our Board are committed to high standards of corporate governance as an important component in building and maintaining stockholder value. To this end, we have adopted corporate governance policies and practices to promote the effective functioning of the Board and its committees and to set forth a common set of expectations as to how the Board should manage its affairs and perform its responsibilities. We also closely monitor guidance issued or proposed by the SEC and the provisions of the Sarbanes-Oxley Act, as well as the emerging best practices of other companies. The current corporate governance guidelines are available on the Company’s website at http://www.ipharminc.com. Printed copies of our corporate governance guidelines may be obtained, without charge, by contacting the Corporate Secretary, Innovation Pharmaceuticals Inc., 301 Edgewater Place - Suite 100, Wakefield, MA 01880.

60 Table of Contents

The Board and Committees of the Board

The Company is governed by the Board, which currently consists of three members: Mr. Leo Ehrlich, Dr. Barry Schechter, and Dr. Zorik Spektor. The Board has established three committees: the Audit Committee, the Compensation Committee and the Nominating and Governance Committee. Each of the Audit Committee, Compensation Committee and Nominating and Governance Committee is comprised entirely of independent directors. The Board has adopted written charters for each of its committees which are available on the Company’s website at http://www.ipharminc.com. ACopies ~~copy~~ of the ~~Company’s~~charters ~~corporate~~are ~~governance guidelines is also~~ available on the Company’s website. Printed copies of these charters may be obtained, without charge, by contacting the Corporate Secretary, Innovation Pharmaceuticals Inc., 301 Edgewater Place - Suite 100, Wakefield, MA 01880. All directors are encouraged to attend meetings of stockholders, either in person or remotely, absent an unavoidable and irreconcilable conflict. Each director attended ~~more~~at ~~than~~least 75% of the aggregate number of Board meetings, ~~except Dr. Zorik Spektor~~ and the number of meetings held by all of the committees on which he served.

The Board’s Role in Risk Oversight

The Board has the responsibility to verify that the assets of the Company are properly safeguarded, that the appropriate financial and other controls are maintained, and that the Company’s business is conducted wisely and in compliance with applicable laws and regulations and proper governance. Included in these responsibilities is the Board’s oversight of the various risks facing the Company. In this regard, the Board seeks to understand and oversee critical business risks. The Board does not view risk in isolation. Risks are considered in virtually every business decision and as part of the Company’s business strategy. The Board recognizes that it is neither possible nor prudent to eliminate all risk. Indeed, purposeful and appropriate risk-taking is essential for the Company to be competitive and to achieve its objectives.

Audit Committee

The Audit Committee ~~met~~did ~~two~~not ~~times~~meet induring fiscal year ~~2021~~2022. The Audit Committee consists of Dr. Barry Schechter and Dr. Zorik Spektor, each of whom is “independent” as that term is defined under the Nasdaq Listing Rules. ~~The~~No member of the Audit Committee ~~oversees~~qualifies ~~our~~as ~~accounting~~an ~~and~~“audit committee financial ~~reporting~~expert” ~~processes~~as ~~and~~that ~~the~~term ~~audits~~is ofdefined ~~our~~by ~~financial~~applicable ~~statements~~SEC rules. The Company has not appointed an “audit committee financial expert” to the Audit Committee isin ~~responsible~~light ~~for~~of the Company’s limited financial resources and the fees and expenses associated with finding and appointing an “audit committee financial expert,” ~~among~~and ~~other~~the ~~things:~~relative simplicity of the Company’s financial statements.

•45 ~~selecting~~Table our independent auditors and pre-approving all auditing and non-auditing services permitted to be performed by our independent auditors; • reviewing with our independent auditors any audit problems or difficulties and management’s response; • reviewing and approving all proposed related-party transactions, as defined in Item 404 of Regulation S- K; • discussing the annual audited financial statements with management and our independent auditors; • reviewing major issues as to the adequacy of our internal controls and any special audit steps adopted in light of significant internal control deficiencies; • annually reviewing and reassessing the adequacy of our Audit Committee charter; • meeting separately and periodically with management and our internal and independent auditors; • reporting regularly to the full Board; and • such other matters that are specifically delegated to our Audit Committee by our Board from time to time.Contents

61 Table of Contents

Compensation Committee

The Compensation Committee ~~did~~held ~~not~~one ~~hold any~~ meeting in fiscal ~~2021~~2022. The Compensation Committee consists of Dr. Barry Schechter and Dr. Zorik Spektor, each of whom is “independent” as that term is defined under the Nasdaq Listing Rules. The Compensation Committee assists the Board in reviewing and approving the compensation structure of our directors and executive officers, including all forms of compensation to be provided to our directors and executive officers. Our Chief Executive Officer and Chief Financial Officer may not be present at any committee meeting during which his compensation is deliberated. The Compensation Committee is responsible for, among other things:

	•	approving and overseeing the compensation package for our executive officers;

	•	reviewing and making recommendations to the Board with respect to the compensation of our directors; and

	•	reviewing periodically and making recommendations to the Board regarding any long-term incentive compensation or equity plans, programs or similar arrangements, annual bonuses, employee pension and welfare benefit plans.

Under its charter, the Compensation Committee has sole authority to retain and terminate outside counsel, compensation consultants for the purpose of assisting the Compensation Committee in determining the compensation of the Chief Executive Officer or senior executive officers, or other experts or consultants, in each case, as it deems appropriate and including sole authority to approve such parties’ fees and other retention terms. The Compensation Committee may also form and delegate authority to subcommittees and may delegate authority to one or more designated members of the Compensation Committee. The Compensation Committee may from time to time seek recommendations from the executive officers of the Company regarding matters under the purview of the Compensation Committee, though the authority to act on such recommendation rests solely with the Compensation Committee.

Nominating and Governance Committee

The Nominating and Governance Committee did not hold any meetings in fiscal ~~2021~~2022. Our Nominating and Governance Committee consists of Dr. Barry Schechter and Dr. Zorik Spektor, each of whom is “independent” as that term is defined under the Nasdaq Listing Rules. The Nominating and Governance Committee assists the Board of Directors in identifying individuals qualified to become our directors and in determining the composition of the Board and its committees. ~~The Nominating and Governance Committee is responsible for, among other things:~~

• identifying and recommending to the Board nominees for election or re-election to the Board, or for appointment to fill any vacancy; • reviewing annually with the Board the current composition of the Board in light of the characteristics of independence, age, skills, experience and availability of service to us; • identifying and recommending to the Board the directors to serve as members of the Board’s committees; and • monitoring compliance with our Code of Ethics.

The Nominating and Governance Committee also oversees all aspects of the Company’s corporate governance functions on behalf of the Board and make recommendations to the Board regarding corporate governance issues.

62 Table of Contents

Qualifications for Directors

Directors are responsible for overseeing the Company’s business consistent with their fiduciary duty to stockholders. ~~This significant responsibility requires highly-skilled individuals with various qualities, attributes and professional experience.~~ The Board believes that there are general requirements for service on the Board that are applicable to all directors and that there are other skills and experience that should be represented on the Board as a whole but not necessarily by each director. The Board and the Nominating and Governance Committee of the Board consider the qualifications of directors and director candidates individually and in the broader context of the Board’s overall composition and the Company’s current and future needs.

In its assessment of each potential candidate, including those recommended by stockholders, the Nominating and Governance Committee considers the nominee’s judgment, integrity, experience, independence, understanding of the Company’s business or other related industries and such other factors the Nominating and Governance Committee determines are pertinent in light of the current needs of the Board. The Nominating and Governance Committee also takes into account the ability of a director to devote the time and effort necessary to fulfil his or her responsibilities to the Company.

The Board and the Nominating and Governance Committee require that each director be a recognized person of high integrity with a proven record of success in his or her field. In addition to the qualifications required of all directors, the Board assesses intangible qualities including the individual’s ability to ask difficult questions and, simultaneously, to work collegially.

The Board does not have a specific diversity policy, but considers diversity of race, ethnicity, gender, age, cultural background and professional experiences in evaluating candidates for Board membership.

Table of Contents

Stockholder Nominations

The Nominating and Governance Committee does not have a specific policy with regard to the consideration of candidates recommended by stockholders; however, any nominees proposed by our stockholders will be considered on the same basis as nominees proposed by the Board. If a stockholder wants to submit a candidate for consideration to the Board, that stockholder may submit his or her proposal to our Corporate Secretary:

	•	by sending a written request by mail to:
		Innovation Pharmaceuticals Inc. 301 Edgewater Place - Suite 100 Wakefield, MA 01880 Attention: Corporate Secretary
		Innovation Pharmaceuticals Inc. 301 Edgewater Place - Suite 100Wakefield, MA 01880 Attention: Corporate Secretary
	•	by calling our Corporate Secretary, at (978) 921-4125.

Code of Ethics

The Board has adopted a Code of Ethics that applies to the Company’s directors, officers and employees. A copy of this policy is available via our website at http://www.ipharminc.com. Printed copies of our Code of Ethics may be obtained, without charge, by contacting the Corporate Secretary, Innovation Pharmaceuticals Inc, 301 Edgewater Place - Suite 100, Wakefield, MA 01880. During the fiscal year ended June 30, ~~2021~~2022, there were no waivers of our Code of Ethics.

63 Table of Contents

Stockholder Communication with the Board of Directors

Stockholders may communicate with the Board, including non-management directors, by sending a letter to our Board, c/o Corporate Secretary, Innovation Pharmaceuticals Inc, 301 Edgewater Place - Suite 100, Wakefield, MA 01880 for submission to the Board or committee or to any specific director to whom the correspondence is directed. Stockholders communicating through this means should include with the correspondence evidence, such as documentation from a brokerage firm, that the sender is a current record or beneficial stockholder of the Company. All communications received as set forth above will be opened by the Corporate Secretary or his designee for the sole purpose of determining whether the contents contain a message to one or more of our directors. Any contents that are not advertising materials, promotions of a product or service, patently offensive materials or matters deemed, using reasonable judgment, inappropriate for the Board will be forwarded promptly to the Chairman of the Board, the appropriate committee or the specific director, as applicable.

Delinquent Section 16(a) Reports

Under U.S. securities laws, directors, executive officers and persons beneficially owning more than 10% of our common stock must report their initial ownership of the common stock, and any changes in that ownership, to the SEC. The SEC has designated specific due dates for these reports. Based solely on our review of copies of such reports filed with the SEC and written representations of our directors and executive officers, we believe that all persons subject to reporting filed the required reports on time in fiscal 2022 and prior fiscal years, other than the following late reports, each of which was reported on Form 4s filed September 28, 2022: (i) a Form 4 due October 12, 2021 for each of Messrs. Ehrlich, Schechter and Spektor and Ms. Harness, relating to stock option grants previously reported by the Company, (ii) Forms 4 due September 10, 2020, October 6, 2020, and December 30, 2020 for Mr. Ehrlich, relating to the exercise of stock options to purchase shares of Class B common stock, and the related cancellation of shares of Class A common stock and withholding of Class B common stock to satisfy the exercise price and tax withholding obligations in connection with the exercise of such stock options, all previously reported by the Company, (iii) a Form 4 due February 25, 2020 for each of Messrs. Ehrlich, Schechter and Spektor, relating to stock awards and stock option grants previously reported by the Company, (iv) Forms 4 due September 6, 2017 and September 15, 2020 for Ms. Harness relating to shares withheld upon the vesting of restricted stock grants, and (v) Forms 4 due September 4, 2019 and September 15, 2020 for Ms. Harness relating to stock awards and stock option grants previously reported by the Company.

Table of Contents

ITEM 11. EXECUTIVE COMPENSATION

SUMMARY COMPENSATION TABLE

The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our Chief Executive Officer and Chief Financial Officer and our Senior Vice President, Clinical Sciences and Portfolio Management, whom we refer to collectively as our named executive officers, for services rendered in all capacities during the noted periods.

Name and Principal Position	Year	Salary			Bonus~~(1)~~		~~Stock Awards~~StockAwards(1)		~~Option Awards~~OptionAwards(1)		Total
Leo Ehrlich	~~2021~~2022	$	515,850	(2)	$	—-	$	—-	$	—195,000	$	~~515~~710,850
Chief Executive and Financial Officer	~~2020~~2021	$	~~465~~515,850	(2)	$	—-	$	~~45,000~~-	$	~~34,152~~-	$	~~545~~515,~~002~~850
Jane Harness	~~2021~~2022	$	275,000		$	90150,~~750~~000	$	~~12,847~~	$	3397,~~041~~500	$	~~411~~522,~~638~~501
Sr. Vice President, Clinical Sciences and Portfolio Management	~~2020~~2021	$	275,000		$	90,750	$	712,~~708~~847	$	1933,~~768~~041	$	~~393~~411,~~226~~638

_____________

(1)

Amounts shown reflect the total grant date fair value of restricted stock and option awards, determined in accordance with ASC 718, made during fiscal years ~~2020~~2021 and ~~2021~~2022. Amounts shown do not represent cash payments made to Ms. Harness, amounts realized or amounts that may be realized. Refer to Notes 1214 to the accompanying financial statements for a discussion on the valuation of the restricted stock and option awards.

(2)

Includes $50,000 in director fees for Mr. Ehrlich’s service as a director of the Company.

64 Table of Contents

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

The following table sets forth all outstanding equity awards held by our named executive officers as of June 30, ~~2021~~2022.

	~~Option Awards~~	Option Awards						~~Stock Awards~~	Stock Awards
Name	~~Number of Securities Underlying Unexercised Options (#) Exercisable~~	Number of Securities Underlying UnexercisedOptions (#)Exercisable	~~Number of Securities Underlying Unexercised Options (#) Unexercisable~~	Number of Securities Underlying UnexercisedOptions (#)Unexercisable	~~Option Exercise Price ($)~~	Option Exercise Price($)	~~Option Expiration Date~~OptionExpirationDate	~~Number of Shares or Units That Have Not Vested (#)~~	Number of Shares or Units That Have Not Vested(#)		~~Market Value of Shares or Units of Stock That Have Not Vested(1) ($)~~	Market Value of Shares or Units of Stock That Have Not Vested(1)($)
Leo Ehrlich		2500,000~~,000~~		—	$	0.5110	52/823/~~2022~~2030		—			—
		500,000		—	$	0.10	2/23/2030		—			—
		—		1,000,000	$	0.24	10/10/2031		—			—
Jane Harness(2)		172,987		—	$	1.37	9/1/2026		—		$	—
		172,987		—	$	10.71	9/1/2027		—		$	—
		115,325		57,662	$	0.40	9/1/2028		19,465	(3)	$	4,282
		172,987		—	$	0.40	9/1/2028		—		$	—
		57,663		115,324	$	0.13	9/1/2029		38,929	(4)	$	8,564
		115,325		57,662	$	0.13	9/1/2029		19,465	(3)	$	584
		—		172,987	$	0.22	9/11/2030		58,394	(5)	$	12,847
		57,663		115,324	$	0.22	9/11/2030		38,929	(4)	$	1,168
		—		500,000	$	0.24	10/10/2031		—			—

~~_____________~~ (1) Market value is based on a stock price of $0.03, the closing price of the Company’s common stock on June 30, 2022, and the outstanding number of shares of restricted stock.

(1)	Market value is based on a stock price of $0.22, the closing price of the Company’s common stock on June 30, 2021, and the outstanding number of shares of restricted stock.
(2)	The remaining unvested stock options expiring in 2028 vest on September 1, 2021. The remaining unvested stock options expiring in 2029 vest in two equal annual installments on September 1, 2021 and 2022. The remaining unvested stock options expiring in 2030 vest in three equal annual installments on September 11, 2021, 2022 and 2023. The restricted stock vests in three equal annual installments beginning on September 1, 2019.
(3)	The restricted stock award vests on September 1, 2021.
(4)	The restricted stock award vests in two equal annual installments on September 1, 2021 and 2022.
(5)	The restricted stock award vests in three equal annual installments on September 11, 2021. 2022 and 2023.

Table of Contents

(2)	The remaining unvested stock options expiring in 2029 vest on September 1, 2022. The remaining unvested stock options expiring in 2030 vest in two equal annual installments on September 11, 2022 and 2023. The remaining unvested stock options expiring in 2031 vest on October 10, 2022.

(3)	The restricted stock award vests on September 1, 2022.

(4)	The restricted stock award vests in two equal annual installments on September 11, 2022 and 2023.

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

Mr. Ehrlich does not have a current employment agreement with the Company, and all of the stock options held by Mr. Ehrlich are fully vested. As previously disclosed, the Compensation Committee and Board approved a new employment agreement between the Company and Mr. Ehrlich on October 10, 2021. However, the parties never entered into the new employment agreement.

Pursuant to the employment agreement between Ms. Harness and the Company, the executive would be entitled to the following termination benefits:

	☐	For Cause or Without Good Reason. If the executive’s employment is terminated by the Company for “cause” or by the executive without “good reason” (each as defined in the employment agreements), the executive would be entitled to receive (i) all accrued but unpaid salary and accrued but unused vacation, (ii) reimbursement of unreimbursed business expenses, and (iii) any employee benefits which the executive may be entitled to under the Company’s employee benefits plans.

	☐	Without Cause or With Good Reason. If the executive’s employment is terminated by the Company without “cause” or by the executive with “good reason,” the executive would be entitled to receive (i) the payments outlined in the previous bullet, plus (ii) continued salary for six months. Such payments would be subject to the executive’s execution of a release in favor of the Company and the executive’s compliance with certain non-solicitation and non-disparagement covenants in the employment agreement.

	☐	Death or Disability. If the executive’s employment is terminated on account of the executive’s death or disability, the executive or her estate would be entitled to receive (i) the payments outlined in the first bullet above, plus (ii) an amount equal to her prorated target bonus for the fiscal year during which her employment is terminated.

	☐	Change in Control. If the executive’s employment is terminated by the Company without “cause” or by the executive with “good reason” within 12 months following a change of control, the executive would be entitled to receive (i) the payments outlined in the first bullet above, plus (ii) continued salary for nine months, plus (iii) the target bonus for the fiscal year during which her employment is terminated. Such payments would be subject to the executive’s execution of a release in favor of the Company and the executive’s compliance with certain non-solicitation and non-disparagement covenants in the employment agreement. The executive would also be entitled to reimbursement for certain health insurance expenses, and all of her outstanding equity awards would automatically vest, subject to certain equity awards other than stock options satisfying any applicable performance criteria.

6549 Table of Contents

For purposes of the employment agreement with Ms. Harness, a “change of control” means the occurrence of any of the following:

	☐	one person (or more than one person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the stock of such corporation;

	☐	one person (or more than one person acting as a group) acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) ownership of the Company’s stock possessing 50% or more of the total voting power of the stock of such corporation;

	☐	a majority of the members of the Board are replaced during any twelve-month period by directors whose appointment or election is not endorsed by a majority of the Board before the date of appointment or election; or

	☐	the sale of all or substantially all of the Company’s assets.

Notwithstanding the foregoing, a “change in control” shall not occur unless such transaction constitutes a change in the ownership of the Company, a change in effective control of the Company, or a change in the ownership of a substantial portion of the Company’s assets under Section 409A.

DIRECTOR COMPENSATION

The following table sets forth certain information concerning the compensation paid to our independent directors for services rendered to us during the fiscal year ended June 30, ~~2021~~2022. Mr. Ehrlich’s compensation is also disclosed under “Summary Compensation Table” above.

Name	~~Fees~~FeesEarned ~~Earned~~orPaid ~~or Paid in Cash~~ inCash($)		~~Stock Awards~~StockAwards		~~Option Awards~~OptionAwards		Total
Schechter Barry	$	50,000	$	—	$	—195,000	$	50245,000
Spektor Zorik	$	50,000	$	—	$	—195,000	$	50245,000
Leo Ehrlich	$	50,000	$	—	$	—195,000	$	50245,000

Narrative to Director Compensation Table

Commencing with the first quarter of fiscal 2021, the Company increased the quarterly cash payment to $12,500 per quarter, which payments ~~will~~are be made to all directors serving on the Company’s Board of Directors, rather than only the independent directors. Directors are reimbursed for out-of-pocket expenses incurred as a result of their participation on our Board and committees.

AsOn ofOctober ~~June 30~~10, 2021, ~~each~~the ofCompensation ~~Dr.~~Committee ~~Schechter~~approved ~~and~~the ~~Dr.~~issuance ~~Spektor~~of ~~held~~1 million stock options to purchase ~~500,000~~ shares of the Company’s ~~Class~~common Astock each to 2 independent directors of the Company, which are exercisable for 10 years at $0.24 per share of common stock. These stock options with 1 year vesting period were valued at approximately $195,000, based on the closing bid price as quoted on the OTC on October 10, 2021 at $0.24 per share.

66As ~~Table~~of June 30, 2022, each of ~~Contents~~Dr. Schechter and Dr. Spektor held options to purchase 1,500,000 shares of the Company’s Class A common stock.

Table of Contents

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table sets forth information known to us with respect to the beneficial ownership of our common stock as of September 22, ~~2021~~2022, for: (i) each person known by us to beneficially own more than 5% of our voting securities, (ii) each named executive officer, (iii) each of our directors, and (iv) all of our current executive officers and directors as a group. The address of each of the ~~persons~~officers and directors set forth below is in care of Innovation Pharmaceuticals Inc., 301 Edgewater Place - Suite 100, Wakefield, MA 01880.

Name of Beneficial Owner	Shares Beneficially Owned(1)								% of
	Class A				Class B				Total Voting
	Shares		%		Shares		%		Power(2)
Stockholders
Kips Bay Select LP (3)		45,032,659		9.2		—		—		7.0
Officers and Directors
Leo Ehrlich(3)		7,819,786	*			15,641,463		100		27.4
Leo Ehrlich(4)		4,760,758		1.0		15,641,463		100		24.9
Barry Schechter(4)		1,250,000	*			—		—
Barry Schechter(5)		2,250,000	*			—		—
Zorik Spektor(4)		1,025,000	*			—		—
Zorik Spektor(5)		2,025,000	*			—		—
Jane Harness(5)		555,750	*			—		—
Jane Harness(6)		1,551,691	*			—		—
All current executive officers and directors as a group (4 persons)(6)		10,650,536		24.4		15,641,463		100		27.8
All current executive officers and directors as a group (4 persons)(7)		10,587,449		2.1		15,641,463		100		25.6

____________

*	Denotes less than 1%.
(1)	“Beneficial owner” means having or sharing, directly or indirectly (i) voting power, which includes the power to vote or to direct the voting, or (ii) investment power, which includes the power to dispose or to direct the disposition, of shares of the common stock of an issuer. The definition of beneficial ownership includes shares underlying options or warrants to purchase common stock, or other securities or convertible debt convertible into common stock, that are exercisable or convertible or that will become exercisable or convertible within 60 days. Unless otherwise indicated, the beneficial owner has sole voting and investment power. For each stockholder, the calculation of percentage of beneficial ownership is based upon ~~437~~488,~~096~~225,~~222~~673 shares of Class A common stock and 15,641,463 shares of Class B common stock outstanding as of September 22, ~~2021~~2022, and shares of common stock subject to options, warrants and/or conversion rights held by the stockholder that are currently exercisable or are exercisable within 60 days of September 22, ~~2021~~2022, which are deemed to be outstanding and to be beneficially owned by the stockholder holding such options, warrants or conversion rights. The percentage ownership of any stockholder is determined by assuming that the stockholder has exercised all options, warrants and conversion rights to obtain additional securities and that no other stockholder has exercised such rights.
(2)	Percentage total voting power represents voting power with respect to all shares of our Class A common stock and Class B common stock, voting together as a single class. Each holder of Class B common stock is entitled to ten votes per share of Class B common stock, and each holder of Class A common stock is entitled to one vote per share of Class A common stock on all matters submitted to our stockholders for a vote. The Class A common stock and Class B common stock vote together as a single class on all matters submitted to a vote of our stockholders, except as may otherwise be required by law. The Class B common stock is convertible at any time by the holder into shares of Class A common stock on a share-for-share basis.
(3)	~~Includes~~Based ~~(i)~~on ~~2,752,310~~information ~~shares~~contained ofin ~~Class~~a Schedule 13G/A ~~common~~filed ~~stock held~~ by ~~Mr.~~Kips ~~Ehrlich’s~~Bay ~~spouse,~~Select ~~(ii)~~LP ~~2,567,476~~with ~~shares of Class A common stock into which a convertible loan and accrued interest in~~ the ~~amount~~SEC ofon ~~$1.3~~July ~~million may be converted at $0.50 per share~~5, ~~(iii) vested options to purchase 2~~2022,~~000,000~~ representing shares of Class A common stock ~~granted~~beneficially toowned ~~Mr.~~as ~~Ehrlich under the 2010 Equity Incentive Plan, (iv) vested options to purchase 500,000 shares~~ of ~~Class~~July ~~A common stock granted to Mr. Ehrlich under the 2016 Equity Incentive Plan~~5, ~~and (v) 15,641,463 shares of Class B common stock held directly by Mr~~2022. ~~Ehrlich.~~The ~~Each~~address ~~share~~ of ~~Class~~Kips ABay ~~common~~Select ~~stock~~LP ~~carries~~is ~~one~~350 ~~vote~~Lincoln ~~and each share of Class B common stock carries ten votes on all matters before the Company’s stockholders~~Rd., ~~Class~~Miami, BFlorida ~~common stock is convertible into shares of Class A common stock at the holder’s election~~33139.
(4)	For ~~each~~Leo Ehrlich, includes (i) 2,752,310 shares of ~~Messrs~~Class A common stock held by Mr. ~~Schechter~~Ehrlich’s spouse, (ii) 508,448 shares of Class A common stock into which a convertible loan and ~~Spektor~~accrued interest in the amount of $254,224 ~~includes~~may be converted at $0.50 per share, (iii) vested options to purchase 500,000 shares of Class A common stock granted to Mr. Ehrlich under the 2016 Equity Incentive Plan, (iv) 1,000,000 shares of Class A common stock issuable upon the exercise of stock options that are currently exercisable or are exercisable within 60 days of September 22, ~~2021~~2022, and (v) 15,641,463 shares of Class B common stock held directly by Mr. Ehrlich. Each share of Class A common stock carries one vote and each share of Class B common stock carries ten votes on all matters before the Company’s stockholders. Class B common stock is convertible into shares of Class A common stock at the holder’s election.
(5)	Includes 518,962 shares of Class A common stock issuable upon the exercise of stock options that are currently exercisable or are exercisable within 60 days of September 22, 2021.
(6)	Includes 6,586,438 shares of Class A common stock, in each case that are currently exercisable or are exercisable within 60 days of September 22, 2021.

6751 Table of Contents

(5)	For each of Messrs. Schechter and Spektor, includes 1,500,000 shares of Class A common stock issuable upon the exercise of stock options that are currently exercisable or are exercisable within 60 days of September 22, 2022.

(6)	For Jane Harness, includes 1,307,274 shares of Class A common stock issuable upon the exercise of stock options that are currently exercisable or are exercisable within 60 days of September 22, 2022 and 244,417 shares of Class A common stock, in each case that are currently exercisable or are exercisable within 60 days of September 22, 2022.

(7)	Includes 6,354,652 shares of Class A common stock, in each case that are currently exercisable or are exercisable within 60 days of September 22, 2022.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

The following table sets forth certain information about the securities authorized for issuance under our equity incentive plans as of June 30, ~~2021~~2022.

Plan Category

Number of securities to be issued upon exercise of outstanding options, warrants and rights (a)

Weighted-average exercise price of outstanding options, warrants and rights (b)

Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c)

Equity compensation plans approved by stockholders (1)

290,~~210,~~000

01.5424

1921,~~790~~910,000

Equity compensation plans not approved by stockholders (2)

48,~~569~~178,~~935~~269

0.2624

106,~~554~~946,~~882~~848

Total

68,~~779~~268,~~935~~269

0.3525

3028,~~344~~856,~~882~~548

__________________

(1)	Consists of the Company’s 2010 Equity Incentive Plan.

(2)	Consists of the Company’s 2016 Equity Incentive Plan.

Related Party Transactions

The Audit Committee’s charter requires it to approve or ratify certain transactions involving the Company and “related persons,” as defined under the relevant SEC rules. Any transaction with a related person, other than transactions available to all employees generally or involving aggregate amounts of less than $120,000, must be approved or ratified by the Audit Committee. The policy applies to all executive officers, directors and their family members and entities in which any of these individuals has a substantial ownership interest or control. None of such related persons has been involved in any transactions with us since the beginning of fiscal ~~2020~~2021 which are required to be disclosed pursuant to Item 404 of SEC Regulation S-K. For information about transactions with related persons that were entered into before fiscal 2021, see Notes 911 and 1012 in the accompanying notes to the financial statements.

6852 Table of Contents

Independent Directors

In considering and making decisions as to the independence of each of the directors of the Company, the Board considered transactions and relationships between the Company (and its subsidiaries) and each director (and each member of such director’s immediate family and any entity with which the director or family member has an affiliation such that the director or family member may have a material indirect interest in a transaction or relationship with such entity). The Board has determined that the following members of the Board are independent as defined in applicable SEC and Nasdaq rules and regulations, and that each constitutes an “Independent Director” as defined in Nasdaq Listing Rule 5605: Dr. Barry Schechter and Dr. Zorik Spektor.

ITEM 14. PRINCIPAL ACCOUNTANTS FEES AND SERVICES

The following table sets forth the aggregate fees for professional audit services rendered by Heaton & Company, PLLC (d/b/a Pinnacle Accountancy Group of Utah) (“Pinnacle”) for the audit of the Company’s annual financial statements for the fiscal ~~year~~years ended June 30, ~~2021~~2022 and ~~2020~~2021, and fees billed for other services provided by Pinnacle in the fiscal ~~year~~years ended June 30, ~~2021~~2022 and ~~2020~~2021. The Board of Directors has approved all of the following fees.

	2021		2020
	2022		2021
Audit Fees	$	6779,000	$	5667,000
Audit Related Fees		—		—
Tax Fees		—		—
All Other Fees		—		—
Total	$	6779,000	$	5667,000

(1) Audit Fees consist of the aggregate fees billed for professional services rendered for the audit of our annual financial statements and the reviews of the financial statements included in our Forms 10-Q and for any other services that were normally provided by Pinnacle in connection with our statutory and regulatory filings or engagements.

Our Audit Committee has considered whether the provision of the non-audit services described above is compatible with maintaining auditor independence and determined that such services are appropriate. Before auditors are engaged to provide us audit or non-audit services, such engagement is (without exception, required to be) approved by the Audit Committee of our Board.

Pre-Approval Policies and Procedures

Under the Sarbanes-Oxley Act of 2002, all audit and non-audit services performed by our auditors must be approved in advance by our Board to assure that such services do not impair the auditors’ independence from us. In accordance with its policies and procedures, our Board pre-approved the audit service performed by Pinnacle for our financial statements as of and for the year ended June 30, ~~2021~~2022.

6953 Table of Contents

PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENTS

	(a)	Financial statements

		See Index to financial statements and Supplemental Data under Part II, Item 8 of this Annual Report on Form 10-K.

	(b)	Exhibits

Exhibit No.	Title	Method of Filing
3.1	Amended and Restated Articles of Incorporation of Innovation Pharmaceuticals Inc.	Exhibit 3.1 to the Form 10-K for the year ended June 30, 2019 filed on September 30, 2019 (File No. 001-37357).
3.2	Amended and Restated Bylaws of Innovation Pharmaceuticals Inc.	Exhibit 3.2 to the Form 10-K for the year ended June 30, 2017 filed on September 11, 2017 (File No. 001-37357).
3.3	Certificate of Designation of Preferences, Rights and Limitations of Series B-2 5% Convertible Preferred Stock	Exhibit 3.1 to the Current Report on Form 8-K of the Company filed on December 10, 2020 (File No. 001-37357).
4.1	Description of Class A common stock	Exhibit 4.1 to the Form 10-K for the year ended June 30, 2019 filed on September 30, 2019 (File No. 001-37357).
4.2	Registration Rights Agreement, dated as of July 31, 2020, between the Company and Aspire Capital Fund, LLC	Exhibit 4.1 to the Current Report on Form 8-K of the Company filed on August 4, 2020 (File No. 001-37357).
4.3	Form of Warrant to Purchase Series B-2 Preferred Stock	Exhibit 4.1 to the Current Report on Form 8-K of the Company filed on December 10, 2020 (File No. 001-37357).
10.1	Patent License Agreement, dated January 3, 2003, between PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) and the University of Pennsylvania, Assigned by U.S. Court to the Company	Exhibit 10.20 to the Form 10-K for the year ended June 30, 2013 filed on September 30, 2013 (File No. 001-37357).
10.2	Letter Agreement, dated December 23, 2003, amending the Patent License Agreement, dated January 3, 2003, between PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) and the University of Pennsylvania, Assigned by U.S. Court to the Company	Exhibit 10.21 to the Form 10-K for the year ended June 30, 2013 filed on September 30, 2013 (File No. 001-37357).
10.3	Software License Agreement, dated May 30, 2003, between PolyMedix Pharmaceuticals, Inc. (formerly known as PolyMedix, Inc.) and the University of Pennsylvania, Assigned by U.S. Court to the Company	Exhibit 10.22 to the Form 10-K for the year ended June 30, 2013 filed on September 30, 2013 (File No. 001-37357).
10.4	~~Material~~Exclusive ~~Transfer~~License Agreement, ~~With~~dated ~~Beth~~July ~~Israel~~18, ~~Deaconess~~2019, between the Company and Alfasigma S.p.A.	Exhibit 10.381 to the Current Report on Form 108-QK ~~for~~of the ~~quarterly~~Company ~~period ended March 31, 2014~~ filed on ~~May~~July 1222, ~~2014~~2019 (File No. 001-37357).
10.5	Series A Preferred Share Purchase Agreement, dated ~~August~~June 289, ~~2014~~2022, between ~~the~~BT ~~Company~~BeaMedical ~~and~~Technologies ~~Aruda,~~Ltd. ~~Inc~~(formerly known as Squalus Medical Ltd.) and the Company	Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on ~~September~~June 215, ~~2014~~2022 (File No. 001-37357).
10.2	Amendment among the Company, Wayne Aruda and Aruda Inc.	Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on September 2, 2014 (File No. 001-37357).
10.7	Exclusive License Agreement, dated July 18, 2019, between the Company and Alfasigma S.p.A.	Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on July 22, 2019 (File No. 001-37357).
10.8	Common Stock Purchase Agreement, dated as of July 31, 2020, between the Company and Aspire Capital Fund, LLC	Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on August 4, 2020 (File No. 001-37357).

70 Table of Contents

10.6	Demand Unsecured Note between the Company and Leo Ehrlich dated August 25, 2010	Exhibit 10.27 to the Form 10-K for the year ended June 30, 2010 filed on March 8, 2011 (File No. 001-37357).
10.7*	Form of executive employment agreement	Exhibit 10.1 to the Form 10-Q of the Company for the quarterly period ended September 30, 2016 filed on November 9, 2016 (File No. 001-37357).
10.8*	Innovation Pharmaceuticals Inc. 2010 Equity Incentive Plan	Exhibit 99-3 to the Current Report on Form 8-K/A of the Company filed on February 22, 2011 (File No. 001-37357).
10.9*	Form of Non-qualified Stock Option Agreement for the Innovation Pharmaceuticals Inc. 2010 Equity Incentive Plan	Exhibit 10.16 to the Form 10-K for the year ended June 30, 2017 filed on September 11, 2017 (File No. 001-37357).
10.10*	Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.11*	Amendments to the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan, as amended	Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on October 14, 2021 (File No. 001-37357).

10.9	Demand Unsecured Note between the Company and Leo Ehrlich dated August 25, 2010	Exhibit 10.27 to the Form 10-K for the year ended June 30, 2010 filed on March 8, 2011(File No. 001-37357).
10.10*	Form of executive employment agreement	Exhibit 10.1 to the Form 10-Q of the Company for the quarterly period ended September 30, 2016 filed on November 9, 2016 (File No. 001-37357).
10.11*	Innovation Pharmaceuticals Inc. 2010 Equity Incentive Plan	Exhibit 99-3 to the Current Report on Form 8-K/A of the Company filed on February 22, 2011 (File No. 001-37357).
10.12*	Form of Non-qualified Stock Option Agreement for the Innovation Pharmaceuticals Inc. 2010 Equity Incentive Plan	Exhibit 10.16 to the Form 10-K for the year ended June 30, 2017 filed on September 11, 2017 (File No. 001-37357).
10.13*	Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.14*	Form of Incentive Stock Option Agreement for Employees for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.3 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.15*	Form of Non-qualified Stock Option Agreement for Employees for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.4 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.16*	Form of Non-qualified Stock Option Agreement for Non-Employee Directors for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.5 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.17*	Form of Restricted Stock Award Agreement for Employees for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.18*	Form of Restricted Stock Award Agreement for Non-Employee Directors for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.7 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.19	Securities Purchase Agreement, dated December 9, 2020, between the Company and the investor party thereto	Exhibit 10.1 to the Current Report on Form 8-K of the Company filed on December 10, 2020 (File No. 001-37357).
21.1	Subsidiaries of Innovation Pharmaceuticals Inc.	Exhibit 21.1 to the Form 10-K for the year ended June 30, 2019 filed on September 30, 2019 (File No. 001-37357).
23.1	Consent of Independent Registered Public Accounting Firm	Filed herewith
31.1	Chief Executive Officer and Chief Financial Officer Certification required under Section 302 of the Sarbanes Oxley Act of 2002	Filed herewith
32.1	Chief Executive Officer and Chief Financial Officer Certification required under Section 906 of the Sarbanes Oxley Act of 2002	Furnished herewith
101	The following materials from the Company’s Annual Report on Form 10-K for the year ended June 30, 2021 formatted in Extensible Business Reporting Language (XBRL): (i) the Statements of Income, (ii) the Statements of Comprehensive Income, (iii) the Balance Sheets, (iv) the Statements of Cash Flows, (v) the Statements of Equity and (vi) related notes	Filed herewith

Table of Contents

10.12*	Form of Incentive Stock Option Agreement for Employees for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.3 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.13*	Form of Non-qualified Stock Option Agreement for Employees for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.4 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.14*	Form of Non-qualified Stock Option Agreement for Non-Employee Directors for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.5 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.15*	Form of Restricted Stock Award Agreement for Employees for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.2 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
10.16*	Form of Restricted Stock Award Agreement for Non-Employee Directors for the Innovation Pharmaceuticals Inc. 2016 Equity Incentive Plan	Exhibit 10.7 to the Current Report on Form 8-K of the Company filed on July 1, 2016 (File No. 001-37357).
21.1	Subsidiaries of Innovation Pharmaceuticals Inc.	Exhibit 21.1 to the Form 10-K for the year ended June 30, 2019 filed on September 30, 2019 (File No. 001-37357).
23.1	Consent of Independent Registered Public Accounting Firm	Filed herewith
31.1	Chief Executive Officer and Chief Financial Officer Certification required under Section 302 of the Sarbanes Oxley Act of 2002	Filed herewith
32.1	Chief Executive Officer and Chief Financial Officer Certification required under Section 906 of the Sarbanes Oxley Act of 2002	Furnished herewith
101	The following materials from the Company’s Annual Report on Form 10-K for the year ended June 30, 2022 formatted in Extensible Business Reporting Language (XBRL): (i) the Statements of Income, (ii) the Statements of Comprehensive Income, (iii) the Balance Sheets, (iv) the Statements of Cash Flows, (v) the Statements of Equity and (vi) related notes	Filed herewith
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).	Filed herewith

____________

* Identifies a management contract or compensation plan or arrangement.

ITEM 16. FORM 10-K SUMMARY

Not applicable.

7155 Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Innovation Pharmaceuticals Inc.
	(Registrant)
Date: September 27, 2021	By:	/s/ Leo Ehrlich
Date: September 28, 2022	By:	/s/ Leo Ehrlich
	Name:	Leo Ehrlich
	Title:	Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer, and Secretary

72 Table of Contents

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Leo Ehrlich, his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Leo Ehrlich	Chief Executive Officer, Chief Financial Officer,	September 2728, ~~2021~~2022
Leo Ehrlich	Principal Accounting Officer, Secretary and Director
/s/ Barry Schechter	Director	September 2728, ~~2021~~2022
Barry Schechter
/s/ Zorik Spektor	Director	September 2728, ~~2021~~2022
Zorik Spektor

7356

Filing Compare · Innovation Pharmaceuticals Inc.